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ABSTRACT 
MASS SPECTROMETRY-BASED QUANTITATIVE PROTEOMIC 
ANALYSIS OF BIOLOGICAL FLUIDS 
 
PATIENCE AKOSUA AFEDI 
2019 
Proteomics is a high-throughput approach to study protein expression, structure, function, 
interaction, post-translational modifications, and localization in a cell or tissue. Proteomic 
shotgun approach was used to analyze changes in proteins in bovine follicular fluid (FF) 
and plasma (PL) from cows with high estradiol (HE2) or low E2 (LE2) during the pre-
ovulatory period. FF creates a unique microenvironment in follicles necessary for follicle 
growth and oocyte maturation, and pre-ovulatory concentrations of E2 have been 
reported to impact several processes involved with fertility.  Initial steps in the analysis 
involved development of an immunodepletion protocol for high abundant proteins 
(HAPs) in bovine PL, FF, epididymis sperm and ejaculated sperm. The determined 
depletion rates for the HAPs albumin, IgG, and IgA ranged from 98.7 to 99.9%. Similar 
depletion rate was observed for alpha-1-antitrypsin based on its gel band. Peptides were 
labeled with iTRAQ reagents and quantified using 2-dimentional liquid chromatography 
(LC) electrospray (ES)-based mass spectrometry. E2 was associated with protein changes 
in PL and FF. Protein expression changes between FF HE2 and FF LE2 were higher than 
PL HE2 and PL LE2. There were 15 up-regulated proteins and ten down-regulated 
xv 
 
proteins in FF HE2 compared to FF LE2. Seven proteins were up-regulated and nine 
proteins down-regulated in PL HE2 compared to PL LE2. Proteins were more 
predominant in PL than in FF but the extent of protein changes with HE2 was greater in 
FF than in PL. Several of the differentially expressed proteins function in follicle 
development and were mainly categorized under cellular process and metabolic process. 
Pathway analysis identified the up and down-regulated proteins were predominantly 
associated with the complement and coagulation cascades which support the view that 
folliculogenesis and ovulation are hemorrhagic events. The data demonstrates E2 
regulates a wide range of reproductive associated proteins in bovine PL and FF and forms 
the basis for further investigation of specific processes involved in such regulation. This 
work was also interested in characterization and quantification of atherosclerotic lesions 
in three regions of aortic root of ApoE-/- mice.  
Atherosclerosis is the underlining cause of heart attack and stroke, the two leading cause 
of cardiovascular death worldwide. The three regions of the aortic root examined were 
the ascending aorta region (AAR), region showing the orifices of the coronary arteries 
marking the start of the ascending arch (OCAR) and aortic sinus region (ASR) in ApoE-/- 
male and female mice at different ages. 67 ApoE-/- and 27 wild type C57BL/6J mice 
(controls) were fed with a high fat diet (HFD) until age 8, 12, 18, or 24 weeks. Through 
systematic classification and quantification of lesions in each region and statistically data 
analysis, we found that the complexity and total atherosclerotic lesion areas in ApoE-/- 
mice was location and age dependent. It was slowest in the AAR with lesions progressing 
from dominant type I at 8 weeks, type II at 12 weeks, types III at 18 and types III and IV 
at 24 weeks of age. Lesion development was comparable in the OCAR and ASR regions; 
xvi 
 
types II and III lesions dominated in mice at 8 and 12 weeks of age respectively while 
types IV and types IV and V dominated at 18 and 24 weeks of age, respectively. Average 
percentage of atherosclerotic lesions typically increased from the AAR to the OCAR to 
the ASR at a specific age, and from 8 to 24 weeks of ApoE-/- mice at each region, 
correlating with the histological data. These findings would be beneficial in experimental 
design and targeting of lesion types in aortic roots of the popular ApoE-/- murine 
atherosclerosis model.  
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CHAPTER 1 
1 LITERATURE REVIEW 
1.1 Mass-spectrometry Based Proteomics 
Proteomics is a high-throughput approach to study protein expression, structure, 
function, interaction, post-translational modifications, and localization in a cell or tissue1. 
Proteomic field involves collection of varied disciplines including molecular biology, 
biochemistry, bioinformatics, cell imaging by light and electron microscopy, array and 
chip experiments, and genetic readout experiments1, 2. This makes proteomics a versatile 
tool for studying numerous biological systems. The ability of proteomic to analyze 
thousands of proteins and post-translational modifications (PTMs) in a single experiment 
with  good quality makes it advantageous over traditional methods such as western blots 
which often analyze one protein at a time3. 
Mass spectrometry is now the de facto method for analyzing proteomic samples, 
contributed greatly by advancement in mass spectrometry instrumentation including 
advancement in LC systems (e.g. ultra-high-pressure reversed-phase systems) and 
development of commercial and public software tools able to identify and quantify 
proteins from the numerous data generated from the MS and MS/MS analysis. 
Advancement in current mass spectrometry for proteomics [(e.g. quadrupole time-of-
flight (QTOF), linear trap quadroupole (LTQ) and Orbitrap technology)] include 
improved sensitivity (ten to 50 times), data acquisition and speed (five to ten times), and 
number of proteins identified and quantified from a proteome (5,000–10,000 proteins)4.  
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Because mass spectrometry is central to proteomics and is used in this dissertation, a 
theoretical background to the technology and principles is discussed below. 
1.2 Mass Spectrometer 
Mass spectrometric measurements are carried out in the gas phase on ionized 
analytes. The basic components of a mass spectrometer (Figure 1.1) are an ion source, a 
mass analyzer that measures the mass-to-charge ratio (m/z) of the ionized analytes, and a 
detector that registers the number of ions at each m/z value and displays the results in a 
chart form called the mass spectrum. 
 
 
Figure 1.1. The basic components of a mass spectrometer. Shown in Banerjee and 
Mazumdar3. The ion source ionizes the analytes, the mass analyzer measures the mass-to-
charge ratio (m/z) of the ionized analytes, and a detector registers the number of ions at 
each m/z value, displayed in the mass spectrum. 
 
1.2.1 Ionization Techniques   
Electrospray ionization (ESI) and matrix-assisted laser desorption/ionization 
(MALDI) are the two techniques most commonly used to volatize and ionize the proteins 
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or peptides for mass spectrometric analysis. MALDI method involves subliming and 
ionizing the analyte out of a dry crystalline matrix via laser pulses. ESI ionizes analytes 
out of a solution. MALDI is relatively used to analyze simple peptide mixtures compared 
to ESI method which is preferred for complex matrices2.  ESI technique is used in this 
dissertation and is thus further discussed. 
ESI is a soft ionization process, i.e. very little residual energy is retained by the 
analyte which generally results in no fragmentation of the analyte or breakage of very 
weak interactions like electrostatic interactions, van der Waals interactions, and 
hydrophobic interactions upon the ionization process. ESI also produces multiple charged 
ions thereby giving ions with m/z values within the mass range of all common mass 
analyzers. These factors make ESI a powerful and reliable tool for ionizing non-volatile 
thermally labile large-molecular weight biomolecules (105 Da), such as proteins in the 
gaseous states and their subsequent mass spectrometric analysis for rapid identification 
and structural characterization on the basis of molecular mass of the analyte. Although 
ESI is primarily used for biomolecules, its application has been extended to a broad range 
of analytes including polar organic, inorganic, and metal-organic complexes3.  The ESI 
method is robust and sensitive and can detect peptides at femto levels in microliters 
volumes. Because ESI ionizes analytes out of a solution, it is readily coupled to liquid-
based separation tools such as chromatography techniques, which allows for 
prefractionation of the peptides in complex mixtures thereby reducing the number of 
different precursors that enter the mass spectrometer at a time. 
Under ESI operation, a dilute solution of the analyte is drawn to the tip of a 
capillary tube where a high voltage (2-6 kV) is applied. The applied voltage creates a 
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strong electric field which causes the dispersion of the sample solution into an aerosol of 
highly charged electrospray (ES) droplets with the same polarity as the applied voltage. A 
coaxial nebulizer gas (dry N2) flows around the capillary and enhances the nebulization, 
directs the emerging charged droplets towards the mass spectrometer and helps in the 
solvent evaporation of the charge droplets. The charged droplets diminishes in size by 
solvent evaporation as it moves towards the mass spectrometer until it reaches the point 
(Rayleigh limit) where the surface tension can no longer sustain the Coulomb force of 
repulsion and results in disintegration into much smaller offspring droplets (Coulomb 
fission). Solvent evaporation and Coulomb fission repeats until nanodroplets are obtained 
from which gas-phased charge analyte molecules is formed3. 
Different models have been proposed for the mechanism for forming the gas-
phase ions of the analyte from the highly charge droplets. According to the Charge 
Residue Model (CRM), this is proposed for large macromolecules like proteins, series of 
solvent evaporation and Coulomb fission result in extremely small charged droplet that 
contains only one analyte molecule. Desolvation of this droplet causes its charges (on the 
surface) to land on the analyte. Based on the Ion Evaporation Model (IEM), series of 
solvent evaporation and Coulomb fission decrease the radii of the charged droplets to a 
size when the electric field due to the charges at the surface of the droplet is strong 
enough to cause direct emission of the solvated ion. Thus formation of extremely small 
droplets is not required. Applied positive potential or positive-ion mode results in 
positively charged ions and applied negative potential or negative-ion mode results in 
negatively charge ions3.  
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Figure 1.2. Schematic representation of the electrospray ionization (ESI) process. Shown 
in Banerjee and Mazumdar3. ESI is a soft ionization process often used to ionize proteins 
for mass spectrometry analysis. 
 
To reduce flow rate which subsequently reduce space charge effect and increases 
ionization efficiency, small capillary electrospray emitter tips are employed (nano-
electrospray). Nano-electrospray is able to achieve a constant signal for 10-30 minutes 
for a 1 μl sample. The nano-electrospray is more tolerable to high aqueous solvents and 
salt contamination compared to conventional electrospray. Because less sample volume is 
used in nano-electrospray, sample lasts longer enabling multiple experiments to be 
performed3.  
1.2.2 Mass Analyzers 
The mass analyzer is central to the mass spectrometer. There are four basic types 
of mass analyzers currently used in proteomics research. These are the ion trap, time-of-
flight (TOF), quadrupole, and fourier transform ion cyclotron (FT-MS) which is currently 
being replaced by the orbitrap analyzer. These vary in design and in key parameters that 
characterize a mass analyzer, namely sensitivity, resolution, mass accuracy, and the 
ability to generate information-rich ion mass spectra from peptide fragments. Mass 
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analyzers can be stand alone or, in some cases, put together in tandem to take advantage 
of the strengths of each. This dissertation used the Finnigan Linear Trap Quadropole 
(LTQ) (Thermo Fisher Scientific). It consists of a 2-dimentional (2-D) quadrupole ion 
trap analyzer.  
Ion trap analyzers are typically composed of four rod-shaped electrodes, to which 
DC and AC are applied to produce electric fields that confine ions of interest in space 
prior to subsequent MS or MS/MS analysis. AC of same amplitude but opposite sign (i.e. 
positive and negative polarity) within the radio frequency (RF) range is applied to pairs 
of electrodes (This is referred to as the ‘main RF’) helps to confine ions radially and 
induce ion motion. The applied DC helps to confine ions axially. Ions of interest are 
isolated (i.e. trapped) and unwanted ions are simultaneously ejected via resonance 
ejection. Simultaneous resonance ejection is achieved by applying a superimposed AC 
wave containing secular frequency values (q) matching each of the unwanted ion’s 
secular motion to the exit rod5. In two dimensional (2-D) trap, also called linear ion tap 
(LIT) (Figure 1.3), the forces act on the ions only in the x and y dimensions. This allows 
them to spread out axially and increases the ion capacity compared to conventional three 
dimensional (3-D) traps. Therefore LIT has increased resolution, sensitivity, and mass 
accuracy than the 3-D trap and is more commonly used2, 6.  Accordingly, the Finnigan 
LTQ mass spectrometer is robust, has high sensitivity, and provides rapid and 
reproducible mass spectrometric analysis of complex samples.  
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Figure 1.3. Basic design of the two-dimensional quadrupole ion trap. Shown in 
Schwartzet et al.6 The Finnigan LTQ mass spectrometer used in this dissertation consists 
of this type of analyzer. 
 
1.2.3 Fragmentation Techniques for Proteomics 
There are a number of techniques used to generate the fragment ions of precursor 
ions. These include collision-induced dissociation (CID), electron-capture dissociation 
(ECD), electron-transfer dissociation (ETD), surface-induced dissociation (SID), and 
infrared multiphoton dissociation (IRMPD). CID is the most widely used method to 
generate fragment ion. In CID, the gaseous precursor ion is allowed to collide with an 
inert and neutral target gas (e.g. N2, He, Ar) in the collision cell. Upon the collision, the 
precursor ion gains some of the kinetic energy which is converted into internal energy. 
Thus, an unstable excited state precursor ion is produced which then decompose into the 
product ions. CID mainly forms N-terminal a- and b-fragments, and C-terminal y-
fragment. Among the ion types, b and y are the most common, formed from the breakage 
of the amide bonds of the peptide backbone3.  Figure 1.4 shows formation of b- and y- 
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ions. a-ion can be formed from neutral loss of carbon monoxide from b-ion. CID was 
used in the identification of proteins in high abundant proteins (HAPs) and low abundant 
proteins (LAPs)/depleted fractions in plasma and FF in this dissertation.  
 
Figure 1.4. Formation of fragment ions from a peptide backbone. b- and y-ions are 
commonly formed with CID and are formed via breakage of the peptide bond. a-ion can 
be formed from neutral loss of carbon monoxide from b-ion. 
(http://www.alchemistmatt.com/mwthelp/peptidefragmodelling.htm). 
 
 1.2.3.1 Pulsed Q Collision-Induced Dissociation (PQD) 
Pulsed Q Collision-Induced Dissociation (PQD) was developed by Thermo Fisher 
Scientific and implemented exclusively for their LIT mass spectrometers. PQD involves 
activating the precursor ion at a high activation (Q) value (0.6-0.8 eV) and using a short 
(~100 μs), high amplitude resonance excitation pulse. In this step, the ions with m/z 
resonant to this excitation pulse absorb energy and become kinetically excited. Next, ions 
are held at the high Q value for a short period (delay time ~ 100 μs), which is long 
enough for the kinetic energy of the ions to be converted into internal energy through 
collisions, but not long enough for significant dissociation to occur. Subsequently, the 
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precursor ions’ Q value is pulsed to a low value by rapidly dropping the RF amplitude 
and then allowing the precursor ions to undergo fragmentation at this low Q value7. 
PQD generates spectra qualitatively similar to CID but additionally allows the 
observation of low m/z fragments that are usually excluded from CID spectra due to the 
“1/3 rule”. PQD therefore eliminates the need for MS3 which is often required with CID 
in ion trap instruments in order to detect low m/z fragments7, 8.  Because of its ability to 
detect product ions of low m/z, it has been applied successfully to detect the signature 
low-mass reporter ions (ranges from 114.1 to 121.1) of Isobaric Tag for Relative and 
Absolute Quantification (iTRAQ) labels for the quantification of peptides9. PQD was also 
successfully employed with iTRAQ labeling in this dissertation.  
1.2.4 Tandem Mass Spectrometry 
Tandem mass spectrometry (MS/MS) is a method where the gaseous ions are 
subjected to two or more sequential stages of mass analysis (which may be separated 
spatially or temporally) according to quotient mass/charge3. In MS/MS analysis, a 
precursor ion (parent ion) is selected by a mass analyser (Q1) and then focused into a 
collision cell (q2) where it undergoes gas-phased reactions to generate different fragment 
ions (daughter/product ions) of different masses. Another analyser (Q3) scans the masses 
of the product ions and generates the product ion spectrum. The MS/MS technique is 
selective, accurate, reproducible, and enhances the lower limit of detection for peptides 
by up to 100-fold compared to unbiased MS analysis. It also has multiplex capability in 
that it can analyze and quantitate hundreds of proteins per run, thereby increasing the 
throughput.  
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1.2.5 Data Dependent Acquisition and Data Independent Acquisition 
LC-MS/MS experiments in Data Dependent Acquisition (DDA) mode10, 11  is the 
standard method for proteomic profiling, biomarker discovery, and relative quantification 
of proteins through the use of stable-isotope labels. DDA is a method of choice due to its 
flexibility, breadth of detection, and the simplicity of its setup and analysis.  In DDA, the 
instrument cycles through first a short MS1 survey scan of currently eluting peptides 
which serves to monitor peptides intensities and identifies the most intense ions and 
potential sites to fragment. In the sequential MS2 scans, the most abundant precursor ions 
are individually isolated and fragmented in order of decreasing precursor ion intensity. 
The number of MS2 scans (or number of the top precursors) can be predefined by the 
user up to ten MS2 scans. Both MS scan and MS2 scans can occur in a duty cycle of 
approximately 1s up to 2 s with 10 MS2 scans. DDA can be limited in reproducibility and 
precision if too many peptides co-elute and appear in a single MS scan and only the most 
abundant peptides are selected thereby missing the rest. Also, it can prevent the 
measurements of low abundant proteins. Therefore, prior protein and peptide 
fractionations can be critical to successful application of DDA. Data generated in this 
dissertation used DDA and the optimized DDA parameters12 used are stated at the 
relevant sections.  
Data Independent Acquisition (DIA) involves repeatedly selecting all peptides 
within a large predefined mass ranges for MS2 scans. This generates highly complex 
MS2 spectra which can be analyzed aided by spectral libraries derived from prior DIA 
experiments or auxiliary DDA data. The complexity of the DIA MS2 data makes it 
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difficult to analyze and this is currently the main disadvantage of using this method. 
Recently however, DIA is gaining more attention with the development of bioinformatics 
softwares such as DIA-Umpire, OpenSWATH, and SWATHProphet, able to analyze 
DIA data10.  DIA is also limited in reproducibility and measurement of low abundant 
proteins as their signals can be dwarfed by more abundant proteins.  
1.3 Shotgun/Bottom-up Proteomic Workflow 
Advances in all areas of LCMS analysis including LC instrumentation and 
bioinformatics for handling MS/MS generated data, generation of complete gene 
sequences for a wide variety of organisms, and robust sample preparation and 
quantification techniques are increasingly making proteomics a reliable tool for 
investigating the proteome13. Proteomic workflows typically follow either the ‘bottom-up 
approach’ or top-down approach14. In bottom-up, the analysis is performed on proteolytic 
peptides of the protein while in top-down, the intact protein is analyzed.  When bottom-
up analysis is performed on a mixture of proteins it is called shotgun proteomics. Shotgun 
proteomics is superior for the analysis of complex matrices. In this dissertation, the 
shotgun proteomics approach was optimized and the main steps in our in-house workflow 
are shown in Figure 1.5. 
1.3.1 Protein Prefractionation 
Biological samples are complex matrices that contain wide dynamic range in 
protein concentrations. The dynamic range in protein concentrations in plasma is said to 
span 10 to 12 orders of magnitude15, 16.  Albumin and IgG, the top two high-abundant 
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proteins (HAPs) in plasma constitute about 60% of the total plasma proteome17, 18 and the 
top 12 abundant proteins make-up ~95% of the total protein mass15, 19. Proteomic analysis 
of complex biological samples is therefore limited in the limit of detection (LOD), limit 
of quantification (LOQ), and the linear range of response. Shotgun workflows can 
incorporate prefractionation methods for separation of proteins mixture to reduce these 
limitations. Available prefractionation methods include 1- and 2-dimensional 
polyacrylamide gel-electrophoresis, depletion, and isoelectric focusing (IEF)14.  
Depletion is done to separate the HAPs from the low-abundant proteins (LAPs). Removal 
of the HAPs enhance the detection of LAPs which otherwise are masked by the HAPs. 
Immunodepletion involves the use of antibodies in the separation. Our lab optimized 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and 
immunodepletion for the separation of protein mixtures in bovine plasma (PL), follicular 
fluid (FF), ejaculated sperm, and epididymal sperm samples. Detailed description of the 
depletion protocol development and optimization is discussed in chapter 2. 
SDS-PAGE is a common, simple, rapid, and sensitive fractionation method to 
separate intact proteins20.  The sodium dodecyl sulfate (SDS) denatures and disrupts the 
structure of proteins and confer uniform negative charge to the proteins such that the 
proteins separate primarily based on molecular weight. Separated protein gel bands can 
be detected by Coomassie Brilliant Blue or silver staining but the former is preferred for 
shotgun proteomics due to better linearity of signal and amenability to LC-MS/MS14.  For 
LC-MS/MS, gel bands are excised and digested by the in-gel trypsin digestion method21 
prior to analysis. In this dissertation, SDS-PAGE was used to separate crude, bound, and 
depleted fractions of PL, FF, and epididymal and ejaculated sperm samples. 
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Figure 1.5. Shotgun proteomic workflow used in-house. 
 
1.3.2 Proteolytic Digestion 
Proteolytic digestion of intact proteins generates peptides with masses able to be 
analyzed by mass spectrometry. Trypsin has become the gold standard for protein 
digestion to peptides for shotgun proteomics13, 14 and is used in this dissertation. Trypsin 
cleaves the carboxyl side of arginine and lysine. This sequence specific information is 
utilized in the identification of peptides and proteins during database search on LC-
MS/MS data. Apart from its high specificity, trypsin is also preferred because it generates 
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suitable size peptides (10-15 amino acids residue long) and produces double charged 
precursor ions which fragment efficiently in CID12.   
1.3.3 Peptide Fractionation 
The mixture of peptides from proteolytic digests of protein mixture is often too 
complex for current mass spectrometers to deal with all at once despite the recent 
progress in mass spectrometry. An optimized peptide fractionation method prior to MS 
analysis therefore becomes necessary to increase peak capacity (i.e. the number of peaks 
that can be resolved in a unit resolution) and to assure that the number of peptides that 
simultaneously enter the mass spectrometer stays within analyzable limits. This will 
enable more proteins to be identified and quantified22. Among peptide fractionation 
methods, liquid chromatography (LC) is often a method of choice because differences in 
charge and hydrophobicity of peptides can be exploited to assure high resolution of 
peptides. Adequate resolution of peptides of similar masses is crucial for obtaining 
distinct no-mixed fragmentation spectra. LC is also commonly used because of its 
amenability to mass spectrometry, high throughput, and sensitivity. Coupling nano-
electrospray to reverse-phase nanoflow liquid chromatography (RPnLC) has been shown 
to give the largest gain in sensitivity from peptide separation14, 22. Typically, one or more 
chromatographic techniques, such as strong cation exchange (SCX) or hydrophilic 
interaction chromatography (HILIC), are coupled to RPnLC to further enhance peptide 
separations. Multidimensional liquid chromatography techniques are now routinely being 
coupled to tandem mass spectrometry to provide a robust method to identify proteins in 
complex mixtures.  
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Strong-cation exchange-reversed phase (SCX-RP), HILIC-RP, and RP-RP 2D 
systems have been shown to provide suitable orthogonality, i.e. the separation properties 
in first dimension do not affect that in the second dimension22.  Orthogonality is crucial 
for maximizing peak capacity. The SCX-RP has become a popular method in shotgun 
proteomics, known as multidimensional protein identification technology (MudPIT)23, 
due to high sensitivity resulting from the high capacity of strong cation-exchange (SCX) 
resin and the high resolution of SCX and RP24. In SCX, peptides are displaced from the 
SCX resin by increasing salt concentration. Each collected fraction is then loaded onto a 
RP column where it is separated using an organic gradient. The SCX separation can be 
done offline or online in which case the eluted fraction is loaded directly onto the RP 
column. SCX-RP was successfully used in this dissertation.  
1.3.4 Protein identification  
Proteins identification with mass spectroscopy is commonly by database search 
via a number of approaches. Peptide mass fingerprint or peptide mass map analysis 
approaches25  involve determining the masses of experimental peptides derived from 
proteolytic digests of the proteins. Proteins are then identified based on comparison of the 
experimental masses with theoretical masses of peptides produced in silico by digestion 
of sequences in a target database by the same digestion enzyme as used in the 
experiment. Because peptide mass fingerprinting basically requires purified target 
protein, prior fractionation of proteins is necessary and often 1D and 2-D gel 
electrophoresis is used.  
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Protein identification using MS/MS data offer greater degree of specificity than 
peptide mass fingerprinting as it combines fragment ion patterns with peptide masses. 
This approach is more suitable for analysis of complex mixtures and is steadily replacing 
peptide mass fingerprinting. It involves scanning the product ion spectra against 
comprehensive protein sequence databases using one of a number of different algorithms.  
The ‘peptide sequence tag’ approach extracts a short, unambiguous amino acid sequence 
from the peak pattern that, when combined with the mass information, is a specific probe 
to determine the origin of the peptide. A common approach is to calculate a score based 
on comparison of calculated fragments from peptides sequences in the database with 
observed peaks. The calculated score reflects the statistical significance of the match 
between the spectrum and the sequences contained in a database. In another approach 
called the cross-correlation method, the search algorithm uses peptide sequences in the 
database to construct theoretical mass spectra and the overlap or ‘cross-correlation’ 
(known as xcorr) of these predicted spectra with the measured mass spectra determines 
the best match2, 13. The xcorr value is thus a statistical measure of the extent of correlation 
between measured and theoretical fragment spectra and shows the peptide sequence with 
the best match or score. 
The cross-correlation approach is used in one of the most popular peak-finding 
search engine, SEQUESTTM (Thermo-Fisher Scientific). This work utilized SEQUEST 
embedded in Proteome Discoverer (Thermo-Fisher Scientific) and searched the bovine 
protein FASTA database. The Proteome Discoverer application extracts relevant MS/MS 
spectra from the raw file and determines the precursor charge state and the quality of the 
fragmentation spectrum. SEQUEST searches the raw data and generates a peak list and 
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relative abundances. The peaks represent the fragments of peptides for a given mass and 
charge. SEQUEST then used the cross-correlation scoring system and assigns xcorr 
values for peptide candidates. To help increase confidence and validate protein 
identifications, the Proteome Discoverer application also uses a probability-based scoring 
system to independently rate the relevance of the best matches identified by the 
SEQUEST algorithm. The output of this is the false discovery rates (FDRs) or false 
positive rates values. FDR value estimates the number of false positive identifications 
among all identifications found by a peptide identification search. Determination of FDR 
involves searching spectra against a database of decoy (fake) peptides, typically derived 
from digesting in silico the inverted or scrambled sequences of expected proteins.  
As discussed above, the bulk of proteomic data is generated by database search 
using search algorithms. All search engines allow for the setting of a number of variables 
such as molecular mass range, polarity, precursor mass tolerance, fragment mass 
tolerance, scan type, activation type, proteolytic enzyme used and the maximum allowed 
missed cleavage sites by the enzyme, number of charges, maximum number of peptides 
considered for a peptide match, maximum protein references per peptide, type of 
fragment ion (e.g. b- and y- ions), and possible modifications (either static or dynamic) to 
certain residues such as alkylation of cysteine, oxidation of methionine or 
phosphorylation of residues including serine, threonine and tyrosine. Search parameters 
for database search should be chosen carefully and some parameters such as precursor 
and fragment mass tolerance may need to be optimized to generate relevant data. 
Summary of search parameters used in this dissertation are stated at the relevant sections. 
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 1.3.5 Quantitative Proteomics 
Protein quantitative data is important for modeling the cellular and metabolic 
response of an organism and also help in the designing of inhibitors for specific target in 
disease conditions26. Methods for protein quantification by mass spectrometry can be 
grouped into two: label-free methods and stable isotope labeling methods. In either 
quantitation approach, protein quantity can be estimated by measuring of peptide 
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Label-free methods for quantitation are often used when the introduction of stable 
isotopes is impractical (e.g., in many animal studies) or the cost is prohibitive. In label-
free quantitation workflows11, 27 usually the peptide ion peaks or peptide fragment ion(s) 
are integrated and used as a measure of quantity. The absolute quantity can be calculated 
using a standard curve. Quantitation using fragment ions (as in multiple reaction 
monitoring; MRM) is more specific as it requires the masses of the precursor ion and the 
fragment ions to be close to the predicted masses. Also, because peptides fragment in a 
sequence specific manner, it requires that the relative intensities of the fragment ions do 
not deviate from the expected intensities which increase specificity. 
Other label free quantitation methods not based on peak integration involves 
searching the fragment mass spectra against a protein-sequence collection and 
quantitation is subsequently attained using a number of approaches. These include i) 
Spectra counting where the number of different fragment spectra that identifies peptides 
derived from a given protein is used as a measure of protein quantity. This method is 
based on the rationale that peptides from more abundant proteins will be more selected 
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for fragmentation and will thus produce a higher number of MS/MS spectra. ii) Calculate 
exponentially modified protein abundance index (emPAI), a measure based on the 
number of identified peptides of a protein. emPAI is based on the fact that generally more 
peptides are detected for larger proteins and is directly proportional to the protein content 
in the sample. Label-free quantitation not based on peak integration is generally less 
accurate when a small fraction of fragment spectra or peptide is observed for a given 
protein11, 27.  
 To compare samples quantitatively in label-free proteomic workflows, LC-
MS/MS analysis is performed on each sample separately and the calculated peptides and 
proteins quantities in the different samples are compared. Label-free methods are 
therefore susceptible to variations in time-instrument response due to the lack of 
multiplexity. High reproducibility in sample preparation, high reproducibility of 
chromatographic separation, the exact alignment of chromatograms from different 
samples, the use of high-scanning rate, high resolution power of the MS, and highly 
accurate mass measurement are thus prerequisite for statistical significant results11. The 
high-reproducibility requirements in label-free quantitation can put restraints on 
prefractionation. Also, analysis time can be greatly increased when the number of 
samples to be analyzed is large due to the lack of multiplexity. 
Labeling methods involving the use of stable isotopes can be classified into two 
main groups: chemical labeling and metabolic labeling. Labeling strategies are based on 
the fact that both labeled and unlabeled peptides exhibit the same chromatographic and 
ionization properties but can be distinguished from each other by a signature mass-shift11.  
20 
 
Introduction of labels can help optimize reproducibility of the proteomic workflow. In 
metabolic labeling, the label is introduced to the whole-cell organism through the growth 
medium. Metabolic labeling therefore provides the earliest possible introduction of 
stable-isotope labels into the sample but is not always feasible and can be costly and 
time-consuming particularly when applied to the study of complex organisms. Available 
metabolic labeling approaches include Stable Isotopic Labeling with Amino Acids in Cell 
Culture (SILAC) and 14N/15N Labeling22. 
 In chemical labeling, proteins or peptides are tagged with the label through a 
chemical reaction. Available chemical labeling approaches include Isotope-Coded 
Affinity Tags (ICAT), Tandem Mass Tag (TMT), Isotope-Coded Protein Labelling 
(ICPL), and Isobaric Tags for Relative and Absolute Quantification (iTRAQ). The 
different chemical-labeling approaches differ in the site of reaction, the mechanism of 
reaction and the method of quantitation under the mass spectrometer platform11, 22. TMT 
share similar characteristics with iTRAQ but the number of identified peptides and 
proteins are higher with iTRAQ (4-plex or 8-plex) than TMT 6-plex28, 29.  The iTRAQ 
technology was used in this dissertation and is thus further discussed. 
1.3.5.1  iTRAQ Labeling 
iTRAQ is a popular chemical-labeling technique that allows four to eight samples 
to be multiplexed in a single run. The iTRAQ technique is a form of isotope labeling in 
which the tags are isobaric in nature. The tags contain a peptide reactive group N- 
hydroxysuccinimide (NHS) ester derivative, a balancer group (carbonyl group), and a 
reporter group (based on N-methylpiperazine). For 4-plex reagent, the reporter groups of 
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masses 114.1, 115.1, 116.1 and117.1 Da are balanced by corresponding 28, 29, 30 and 31 
balancer group to give a total constant mass of 145.1 Da (Figure 1.6). 8-plex reagent has 
four additional reporter groups of masses 113.1, 118.1, 119.1, and 121.1 and 
corresponding balance masses of  all eight reporter masses range is 192-184 Da, giving a 
total constant mass of 305.1Da26, 30. The different masses of the reporter groups and 
balancer group are achieved by using combinations of 13C, 14N and 18O isotopes. The 
iTRAQ derivatization is achieved by reaction of the NHS ester derivative with the N-
terminus and ɛ-amino group of the lysine side-chains to form an amide bond. This makes 
it possible to label all peptides in a sample.  
The iTRAQ protocol often involves reducing, alkylating, and digesting proteins in 
individual samples prior to iTRAQ labeling. Reduction and alkylation blocks any 
possible reaction of the reagent with cysteine residues. Digested peptides of a sample are 
then labeled with an iTRAQ reagent at room temperature and the individual-labeled 
samples are mixed together in 1:1 ratio. Often iTRAQ-labeled peptides are separated by 
performing strong cation exchange (SCX) followed by reverse-phase liquid 
chromatography.  
Quantitation with iTRAQ has several advantages over other chemical labeling 
techniques. Because the tags are isobaric, individual differentially labeled peptides at a 
given m/z elute as a single combined peak in MS, which greatly enhance the signal. This 
is an important contrast to non-isobaric labeling techniques such as ICAT in which the  
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Figure 1.6. Multiplex quantitation using 4-plex iTRAQ reagent. Shown in Ross et al31. 
(A) Structure of 4-plex iTRAQ reagent; (B) Combination of isotopic enrichments used to 
achieve constant mass (145.1 Da) for each of the four reagents; (C) Illustration of using 
4-plex reagents in an LC-MS/MS experiment. 
 
MS (precursor) signal is split due to mass shift and results in decreased signal.  Also, 
there is less complexity of the MS spectra, a benefit arising from the same mass of 
labeled peptides. At the MS/MS stage, balancer group is loss via neutral loss and the 
reporter ion which retains a charge is released and observed in the low mass region of the 
MS/MS spectrum. All other fragment ions remain isobaric, and their individual signal 
intensities are additive which also increases sensitivity at the MS/MS level26, 30.  Figure 
23 
 
1.7 is an example of the reporter region in MS/MS spectrum observed for a peptide from 
a protein digest in our lab. 
Because of the multiplexing nature of the iTRAQ tags, variation in time 
instrument response is eliminated. Additional benefit of iTRAQ technology is that 
proteins can be identified by their signature peptides and fragment ions via database 
search using appropriate algorithm in a parallel workflow. The quantification and 
identification data are emerged using appropriate algorithm e.g. Proteome Discover, 
ProteinPilot, and i-Tracker26. Protein-identification search parameters for iTRAQ labeled 
peptides include indicating iTRAQ as a fixed modification at the N-terminal and ɛ-amino 
group of lysine residues and iTRAQ as a variable modification at tyrosine residues.  
The peak intensities or areas of the reporter ions of different masses are used to 
calculate the relative quantities of peptides of proteins. More than one spectrum can be 
obtained for a single peptide due to the peptide having more charge states and 
corresponding different m/z and retention times. Additionally, this could be because the 
peptide has better ionization efficiency and is more abundant. Therefore more than one 
peptide ratio and error can be calculated for a single peptide. Spectra ratios are calculated 
often using the lowest reporter ion as the reference (114.1 in 4plex or 113.1 in 8 plex 
experiment). Spectra ratios corresponding to the same peptide are merged by i) taking the 
average of all the representing spectra ratios or the median to represent the peptide or ii) 
scoring the spectra and the spectrum that most defines a given peptide is chosen to 
represent the peptide. The average (or weighted average) or median of the calculated 
peptide ratios of an identified protein is taken to represent the relative quantity of that 
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protein. Absolute quantification with iTRAQ can be achieved by labeling a reference 
peptide belonging to the protein with one of the iTRAQ reagent and upon mixing with 
the other iTRAQ labeled samples and subsequent MS analysis, the intensity or area of the 
reporter ion of the reference peptide is used to calculate the absolute value. 
 
 
 
 
 
 
 
 
 
 
 
1.4 Applications of Proteomics in Reproduction Research in Bovine 
Mass spectrometry-based proteomics is continuing to provide insights into several 
biological systems in human and several species. An important area of its application is 
B A 
Figure 1.7. Exemplary MS/MS spectrum of an electrospray ionized peptide 
fragmented by pulsed q collision induced dissociation (PQD) in Finnigan LTQ. 
iTRAQ reporter ions (arrows) in low mass region in A is zoomed in and shown in 
B. Reporter ions 114, 115, 116 and 117 are observed.    
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molecular research in reproduction. The potential benefits from this area of research are 
enormous and include uncovering and broadening the understanding of a variety of 
molecular events in reproductive important tissues such as testis, ovary, endometrium, 
oviduct, and placenta as well as gametes and embryos; improved understanding of the 
effects of reproductive toxicants particularly disease states (e.g. polycystic ovary 
syndrome (PCOS), infertility, subfertility, endometrial disorders, and miscarriage) or 
hormones and cytokines; and identification of potential protein biomarkers and/or 
treatment targets for successful reproduction and fertility interventions32, 33. While 
significant proteomic research has been dedicated to human reproduction and fertility33, 
very few have focused on that of other species including bovine. A significant contributor 
to this drawback is the lack of available comprehensive sequence database for protein 
identification in these species.  Also, in bovine, established traditional methods for 
assessing and improving reproduction and fertility remain the standard practices among 
farmers.  
Cow-reproductive performance (fertility) is very important as it defines the 
attained biological and economic benefits. Traditionally, cow productivity, i.e. the 
number of calves produced per lifetime or per unit land area is estimated by a number of 
factors including age at first calving, calving (fertility rate), calving interval,  number of 
services per conception (NSC), age at puberty, and nutrition34. First calving marks the 
beginning of a cow's productive life and age at first calving is closely related to 
generation interval (the average age of parents at birth of their offspring that in turn will 
produce the next generation of breeding animals). Late first calving has been associated 
with increasing longer calving intervals. Also, NSC has also been reported to increase in 
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increasing age at first calving.  In general, earlier first calving increases lifetime 
productivity of cows. The commonest estimate of fertility rate is the percentage of mated 
or inseminated cows that become pregnant (pregnancy rate) or finally calve (calving 
rate). Fertility rates can also be estimated prior to calving as the percentage non-return 
rate. This is the number of cows bred that do not come back in heat and are thus assumed 
to have conceived. Differences in calving rate between years have been associated with 
the quality and quantity of available forage. Calving interval is probably the best index of 
a cattle herd's reproductive efficiency.  Calving interval is the amount of time (days or 
months) between the birth of a calf and the birth of a subsequent calf, both from the same 
cow. Calving interval is estimated to be affected by factors such as genetics, age, sex of 
the calf, suckling duration, and feeding after calving. Calving interval decreases with 
shorter suckling duration, high feeding after calving, and having female calves instead of 
males at calving. The shorter calving interval with female calves is attributed to shorter 
suckling duration with females than males. Shortest calving interval is observed with 
cows of intermediate age (6-9 years) compared to young age (3-6 years) and old age (12-
16 years). Effective recognition, measurements and management of the reproductive 
estimates is essential to the productivity of the cow. Artificial insemination (AI) is a 
common practice also used to increase pregnancy rate and cow productivity. In this 
respect, accurate detection of oestrus is essential for achieving high pregnancy rate.  
Although these traditional reproductive estimates are still being practiced, it is 
increasing being recognized that the application of proteomics can provide parallel 
information that will enhance reproduction in cattle. Proteomic application potential 
benefits include identification of biomarkers (i) predictive of early pregnancy detection, 
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fetus, and maternal survival35, 36;  (ii) for evaluation and selection of quality sperm, 
oocyte, and embryo37, 38; (iii) monitoring of genetic/physiological and environmental 
causal diseases affecting reproduction; and (iv) suitable for use as treatment targets for 
successful artificial insemination, pregnancy, and offspring.  Accordingly, a number of 
studies have been conducted39-43.  
Folliculogenesis is the process in which recruited primordial follicle grows and 
undergoes stages from primary, secondary, tertiary (pre antral follicle and mid-antral 
follicle), dominant  to ovulatory follicle with the potential to ovulate its oocyte to be 
fertilized or die by atresia44. Follicular fluid (FF) accumulates into the follicle antrum 
starting with the early stage of follicle development and becomes the natural environment 
of the developing oocyte (Figure 1.8). FF consists of a wide variety of dynamically 
changing proteins responsible for growth and development that ultimately affect the 
quality and fertilization potential of the oocyte. Therefore, FF is a useful substrate for 
proteomic reproduction and fertility research. Moreover, FF is an easily accessible 
biological fluid as it is aspirated in abundance from follicles33.  
Ferrazza et al.40 recently investigated protein expression profile of bovine FF at 
key stages of follicular development. The group identified a total of 143 proteins, twenty-
two of which were differentially expressed between stages indicating intrafollicular 
changes over development. The group also found that the complement and coagulation 
systems, acute-phase response signaling, liver/retinoid X receptor activation, and 
biosynthesis of nitric oxide and reactive oxygen were the most significant pathways 
associated with the proteins. Another group investigated the effect of bovine FF proteins 
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and their acidic and basic groups as maturation media supplements for in vitro embryo 
development. They found oocyte maturation rate, the development to the blastocyst stage 
rate, and blastocyst cell number were not significantly differing in 10% bovine FF 
supplemented in vitro maturation (IVM) medium and controls (supplemented with fetal 
bovine serum and hormones). However, inteferon tau (INFτ) and insulin-like growth 
factor-2-receptor (IGF-2r) expression levels in the 10% bFF were significantly higher 
than in the control. Supplementing the IVM medium with basic bovine FF protein 
fraction resulted in significantly higher oocyte maturation rate and blastocyst cell number 
and greater expression levels for almost all developmentally important genes, especially 
INFτ and HSP70 when compared to supplementing with acidic fraction. INFτ is the 
primary factor responsible for maternal recognition of bovine pregnancy45. Binding of 
IGF-2r to the growth factor enable pathway for the growth factor regulation of fetal 
growth46, 47.  The upregulation of both proteins shows the importance of FF proteins in 
the establishment of pregnancy and fetal growth. Proteomic approach was also used to 
identify eight differentially expressed proteins in FF from preovulatory follicles of less 
fertile cows that are important to follicular function48. 
These studies show the potential of proteomic analysis of FF to provide better 
insights into key factors involved in folliculogenesis, establishment of pregnancy, embryo 
development, and the identification of therapeutic targets in bovine. The applications of 
the outcomes of such research stand to improve the productivity of the cow. In this 
dissertation, proteomic analysis of bovine FF and plasma (PL) was performed and the 
effect of high and low estradiol (E2) on protein expressions during the preovulatory stage 
was investigated.  Detail of this work is discussed in Chapter 3. 
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Figure 1.8. Schematic picture of an ovarian antral follicle in mono-ovulant species. 
Shown in Fahiminiya et al49  
 
1.5 Atherosclerosis 
Atherosclerosis is a multifactorial progressive disease characterized by the 
narrowing and hardening of arteries caused mainly by build-up of cholesterol, lipids, 
cellular debris, and calcium to form plaque in the intima of large- and medium-sized 
arteries50. The plaque formation and subsequent narrowing and hardening of the arteries 
result in chronic luminal obstruction, abnormalities of blood flow, and diminished oxygen 
supply to target organs51. Complications of atherosclerosis lead to coronary artery disease 
(CAD; heart attack), cerebrovascular disease (CeVD; stroke), and diseases of the aorta and 
arteries, including peripheral vascular diseases (PVD) and hypertension. Globally, CAD 
and CeVD are the leading causes of cardiovascular deaths50. Risk factors for 
atherosclerosis include diabetes mellitus, obesity, hypertension, tobacco use, harmful use 
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of alcohol, high levels of low density lipoprotein (LDL) cholesterol, low level of high 
density lipoprotein (HDL) cholesterol, advancing age, male gender, unhealthy diet (rich in 
salt, fat and calories), psychological factors, physical inactivity, poverty, low education 
status, and family history of premature CAD50, 52.  
Atherosclerosis is viewed as an inflammatory disease53, 54 with initial events 
involving dysfunction of the endothelium (lining of the artery)55, 56. Endothelia injury is 
initiated by a variety of events/substances including dyslipidemia (particularly high levels 
of LDL cholesterol), hypertension, infection, presence of free radicals, and low shear stress. 
The damaged endothelium allows migration of lymphocytes, monocyte, and lipids, 
particularly LDL cholesterol, into the arterial intima. Dysfunction of the endothelium also 
promotes expression of cellular adhesion molecules ICAMs (e.g. ICAM-1), vascular cell 
adhesion molecules (VCAMs) (e.g. VCAM-1), chemokines, and selectins such as P- and 
E selectin. These processes are partially mediated by nuclear factor κB (NF-κB), one of the 
transcriptional controllers in vascular inflammation and an integrator in atherogenesis55-57.  
Leucocytes and monocytes adhere to the endothelium via VCAM-1 binding and enter the 
intima by diapedesis between endothelial cells at their junctions. This process is mediated 
through chemokines, such as monocyte chemoattractant protein 1 (MCP-1) and IL-8 as 
leukocyte chemoattractant. LDL cholesterol, upon migration into the arterial intima 
undergoes oxidation to become oxidized LDL (OxLDL) which are subsequently engulfed 
by monocyte-derived macrophages via receptors such as scavenger receptor A (SR-A) and 
CD36. A lipid laden macrophage is called a foam cell and is the first type of atherosclerotic 
lesion55 (Figure 1.9). The monocytes/macrophages promote the local inflammatory 
response secreting cytokines, degrading enzymes [(matrix metalloproteinases (MMPs)] as 
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well as growth factors that stimulate smooth-muscle cell (SMC) migration from the media 
(deeper layer of the artery) into the site of plaque formation and SMC proliferation. As the 
atherosclerosis development continues, a fibrous cap consisting of smooth muscle cells and 
collagen forms. Also, the necrotic lipid core is formed when macrophages involved in the 
initial reaction begin to die and accumulate and a fibrous cap is formed around the lesion 
location. The atherosclerotic lesion (atheromatous plaque) enlarges as cells and lipids 
accumulate. The enlarging lesion causes the inner surface of the artery to become irregular 
and also bulges into the arterial lumen resulting in narrowing of the lumen. These make it 
harder for blood to flow through the artery, resulting in the artery becoming less pliable50, 
55.   
The continuous influx of cells into the sub-intimal space elicits chronic 
inflammatory response by the adaptive immune system. Also, the microenvironment of the 
plaque could elicit adaptive immune response which in such case is coordinated by 
lymphocytes rather than macrophages. The selective recruitment and activation of T- 
helper type 1 (Th1) T lymphocytes represents a key point in the transition from stable 
plaque to unstable plaque. In particular, selective recruitment of Th1 T lymphocytes 
promotes plaque destabilization/disruption eliciting vascular inflammation and 
downregulating extracellular matrix production by SMCs. Other contributors to the 
thinning of the fibrous cap resulting in plaque rapture include activated macrophage 
secreted procoagulant proteins and MMPs proteases that can degrade collagen, interferon 
(IFN)-γ that strongly inhibit the proliferation of SMCs and the production of interstitial 
collagens by vascular SMCs, and ligation of CD40 (expressed by macrophages) which 
increases the production of matrix-degrading proteases. Thinning of the fibrous cap and 
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subsequent rapture of the plaque releases lipid fragments and cellular debris into the vessel 
lumen. Of importance is the exposure of procoagulant factors expressed within lesions to 
circulating clotting factors initiating the coagulation cascade responsible for thrombosis. If 
the thrombus develops in a coronary artery it can cause heart attack and if it develops in 
the cerebral (brain) artery, it can cause stroke50, 55.  
Six types of atherosclerotic lesions have been identified, and are differentiated by 
morphological features and clinical significance58-60. Types I to III lesions (early types) are 
usually clinically silent whereas types IV-VI lesions (advanced forms) are often associated 
with the symptoms and complications of the disease61.  Description of these lesions is 
discussed in section 4.4.4 of Chapter 4. 
 
 
 
Figure 1.9. Atherosclerotic plaque development. The numbering and arrows indicate 
events leading to plaque development. 
(http://www.resverlogix.com/product_development/nexvas_platform/nexvas_vascular_inflammation.html) 
Shown in Glaudemans et al, 201055 
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 1.6 The Apolipoprotein E Knock-Out (ApoE-/-) Mouse Model of Atherosclerosis 
Mice are the most popular experimental animals because of their small size, wide 
availability, easy of genetic manipulation, short generation time allowing less time 
duration for research projects and the relatively low cost in feeding and housing 
compared to other experimental animals62, 63. Wild-type mice however have a different 
serum-lipid profile of elevated levels of HDL in contrast to elevated levels of LDL in 
humans which makes it resistant to developing atherosclerosis unless on a high-saturated 
fat and cholesterol diet for prolonged periods. The C57BL/6 wild-type mouse strain was 
found to be the most susceptible on such diet but only developed early types of lesions 
which were not comparable to that found in humans64. This presented a need for a more 
efficient mouse model for studying atherosclerosis.  
Among the available mice-atherosclerosis models, the apolipoprotien E knock-out 
(ApoE-/-) mouse model65, 66 is popular because of its susceptibility to spontaneously 
develop atherosclerotic lesions in a progressive manner and with lesion morphological 
features observed in humans63, 67. The ApoE-/- mouse model is based on the function of 
apolipoprotein E (ApoE) protein. ApoE is a glycoprotein synthesized in the liver, brain, 
and by monocytes and macrophages in vessels. It is a constituent of all lipoproteins 
except low-density lipoprotein (LDL). It mediates the cellular uptake of several different 
lipoproteins, most notably, cholesterol, atherogenic triglycerides, and very low-density 
lipoproteins (VLDL). It also functions in biliary excretion of cholesterol63, 68, 69.  Deletion 
of the apoE gene thus dramatically increases the serum cholesterol levels mostly in the 
form of VLDL remnants and chylomicrons and makes it susceptible to developing 
atherosclerotic lesions. The atherogenic process is accelerated when on a high saturated 
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fat and cholesterol diet65, 66. Because C57BL/6 mouse strain is more susceptible in 
developing atherosclerosis64, 70, it is often the background for ApoE-/- mice71.  
The ApoE-/- atherosclerotic model allows for studies on lesion size and 
composition and the identification of possible therapeutic targets; nutritional 
interventions aimed at the effects of changes in micro- and macronutrients on lesion size 
and on atherosclerotic cells/molecules (e.g. monocytes, macrophages, oxLDL) or 
mechanisms (e.g. LDL oxidation, uptake of oxLDL by macrophages); the effects of 
therapeutic agents on atherosclerotic molecules, lesions, and events; and the genes related 
to atherosclerosis62, 63, 68.  
1.7 Lesion Analysis in Mice 
Atherosclerotic studies in mice often involve estimating the extent of lesions by 
histological methods. Two methods widely used are the en face method72 and the serial 
cross section method73. The en face method involves removing the entire aorta and 
opening it longitudinally to expose the intimal surface by dissecting from the heart to the 
iliac arteries. The primary incision follows the ventral side of the aorta and the inner 
curvature of the aortic arch. A second incision is made along the outer curvature of the 
aortic arch to the subclavian branch to obtain a flat tissue for imaging. Minor branches 
are cut off and the aorta, from the heart to approximately 3mm distal to the iliac 
bifurcation, is pinned out on a black surface using 0.2mm diameter stainless steel pins. 
Staining with, e.g., Sudan IV is performed to enable visualization of lipid-laden lesions 
and measurement of lesion surface areas. Lesion area is usually represented as a percent 
of the total intimal surface that is covered by atherosclerotic lesions. The en face is a 
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rapid method that provides a two-dimensional assessment of lesion size on the entire 
aorta but is limited in the assessment of lesion thickness71, 72. 
The serial cross-sectioning method involves sequential sectioning of the heart and 
the aortic root onto histological slides and subsequent histopathological analysis 
including staining (e.g. oil red O) and image analysis by appropriate software is used to 
examine and quantify lesions. Analysis of the aortic sinus region requires serial 
sectioning 400µm total area starting from the appearance of the aortic sinus cusps and 
spanning distal towards the ostia of the coronary arteries. Histological analysis of the 
aortic root and the ascending aorta requires serial sectioning spanning about 900µm 
stretch of the aortic root60, 73, 74.  The serial cross-sectioning method, although labor and 
time consuming, enables examination of lesion thickness and composition.  
Atherosclerosis studies with the ApoE-/- mouse model have enabled the 
identification of predilection sites (Figure 1.10) of atherosclerosis development in mice67, 
75 which include the aortic root, carotid arteries, lesser curvature of the aortic arch, 
pulmonary artery and the principal branches of the thoracic aorta. These predilection sites 
have been the focus for probing of the disease. Of these, the quantification of the aortic 
root is considered the standard in many laboratories due to the high susceptibility of this 
site to atherosclerosis in mice and lesions develop in mice at earlier age than the other 
predilection sites. Also, the aortic sinus cups serve as an anatomical landmark to keep the 
area under study constant76. This dissertation characterized and quantified lesions in the 
aortic root of ApoE-/- mice at different ages using the serial cross sectioning method and 
this is discussed in detailed in Chapter 4. 
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1.8 Proteomic in Atherosclerosis Biomarker Discovery  
Although clinical assessments remain the primary tool for atherosclerosis and 
associated cardiovascular disease management, they pose limitations particularly in 
predicting individual risk and risk of recurrence77. A biomarker is defined as “a 
characteristic that is objectively measured and evaluated as an indicator of normal 
biological processes or pharmacologic responses to a therapeutic intervention”78. 
Identification and measurements of atherosclerosis biomarkers, which were originally 
introduced to improve existing clinical assessments and to enable the identification 
 
Figure 1.10. Predilection sites of atherosclerosis development on the aorta and 
pulmonary arteries of ApoE-/- mice. Predilection sites are shaded black. 1. Aortic root; 2. 
Lesser curvature of the aortic arch; 3. Principal branches of the thoracic aorta; 4. Carotid 
arteries; 5. Principal branches of the abdominal aorta; 6. Aortic bifurcation; 7. Iliac 
artery; and 8. Pulmonary arteries (From Nakashima et al.,67) 
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of vulnerable patients79 continue to hold great promise. A suitable biomarker would have 
the advantage of identifying high risk individuals, accurately and quickly diagnose 
disease conditions and effectively predict and treat patients with the disease79. 
Mass-spectrometry-based proteomics technologies are powerful tools that can be 
employed in the search for novel biomarkers for atherosclerosis and related diseases due 
to the ability of such technologies to identify thousands of proteins in a single 
experiment. By these methodologies, several biomarker candidates have been identified. 
A comprehensive list compiled by de la Cuesta et al, 201580 include fibrinogen fragment 
D, annexins (e.g. A4, A5, A10), cathepsin D, alpha 2 macroglobulin, S100 proteins, 
myeloperoxidase (MPO), gelatinase, matrix metalloproteinases (e.g. MMP-3, MMP-9), 
vinculin, apo B100, thrombospondin-2 (TSP-2), manganese-dependent superoxide 
dismutase (MnSOD), and caspase-9 as potential markers of atherosclerosis; death-inducer 
obliterator 1 (DIDO 1), fibrinogen, cardiac troponin I and T ( cTnI, cTnT), inosine, alpha 
2 macroglobulin, and serine as potential biomarker for myocardial infarction; haptoglobin 
(hp) and serum amyloid A (SAA) as candidate markers for ischemic stroke; proline, 
arginine, alanine, ornithine, creatinine, and trimethylamine N-oxide (TMAO) as potential 
markers for coronary artery diseases (CAD).  
Many of the candidate biomarkers have however not been incorporated into 
clinical assessments mainly because they fail to meet all the requirements of a true 
biomarker. Protein biomarkers that have been incorporated into clinical assessments such 
as oxidized low-density lipoprotein (oxLDL), C-reactive protein,  fibrinogen, lipoprotein-
associated phospholipase A2 (Lp-PLA2), Lp(a),  osteopontin (OPN), osteoprotegerin 
(OPG), .MMP-3, MMP-9, myeloperoxidase (MPO) , homocysteine, cardiac troponin I 
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and T ( cTnI, cTnT), and tissue factor  (TF)80, 81 have however not been able to predict 
individual risk above that achieved by the traditional risk factors. Therefore, there is still 
an urgent need to find true and useful biomarkers that can identify vulnerable patients and 
guide treatment development81. 
Circulating blood is the most used sample in proteomic atherosclerotic biomarker 
discovery studies probably because of the ease and convenience of sampling82. Other 
proteomic samples include urine83, circulating cells extracted from plasma/serum such as 
monocytes, platelets and leukocytes, plasma extracellular vesicles such as exosomes and 
microvesicles and tissues like carotid artery81, 84, 85.  In using the ApoE-/- mice in 
atherosclerosis studies, blood and urine samples collected can be viable source for 
proteomic work86. Proteomics on blood and tissues from these mice has the benefit of 
providing insights into the molecular mechanisms associated with the disease. The 
availability of tissues from mice for proteomic work is particularly advantageous since 
obtaining similar sufficient tissues from humans is difficult, especially in considering 
control samples for comparative analyses80.  
Although mice can be a good source for proteomic work, their small size can limit 
the amount of samples collected and this should be considered in the experimental design 
of such studies. Potential atherosclerotic biomarkers can be determined by comparing the 
data generated from ApoE-/- samples to that from control group of the study. A correlation 
analysis can also be performed between identified proteins from the proteomic analysis 
and lesion components, morphology or size.   
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The ApoE-/- mouse model is used in this dissertation to study lesion types and 
patterns with factors such as age and also make available blood and tissue samples for 
proteomic analysis for biomarkers of atherosclerosis.  
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CHAPTER 2 
IMMUNODEPLETION OF MULTIPLE HIGH-ABUNDANT PROTEINS 
FROM BOVINE FLUIDS 
2.1 ABSTRACT 
Immunodepletion of high-abundant proteins (HAPs) aids in the identification and 
analysis of low-abundant proteins (LAPs) in complex samples. Currently, 
immunodepletion methods for bovine samples are very limited whereas greater 
availability exists for human and murine animals. In this study, we report the 
simultaneous depletion of HAPs from bovine samples using an immunoaffinity depletion 
cartridge (the multiple affinity removal system; MARS) designed to target six human 
HAPs, while such a depletion kit for bovine samples is not available. Sandwich ELISA 
analysis showed 98.7 to 99.9% depletion of albumin, IgG and IgA from bovine plasma, 
follicular fluid (FF), ejaculated and epididymis sperm types. A similar percentage is 
expected of alpha-1-antitrypsin due to the dramatic removal in its SDS PAGE band 
compared to the crude samples. The method has high reproducibility and can be 
incorporated into proteomic workflows to increase sensitivity of proteomics analysis of 
LAPs in bovine biological fluids. 
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2.2 BACKGROUND AND MOTIVATION 
Proteomics is a high-throughput approach to study protein expression, structure, 
function and post-translational modifications in a cell or tissue. Advancement in 
proteomic sample preparation technologies, mass spectrometry instrumentation and 
bioinformatics87-89 have increased the application of proteomics to understand various 
biological systems. Bovine proteomics i.e. the application of proteomic strategies to 
bovine biological samples is an area of increasing interest90. Bovine proteomics potential 
benefits are extensive and include identification of biomarkers (i) predictive of early 
pregnancy detection, fetus and maternal survival35, 36; (ii) for evaluation of quality sperm, 
oocyte and embryo37, 38; (iii) for assessing the quality and safety of meat, milk and dairy 
products; and (iv) for detection, diagnosis and monitoring of genetic/physiological and 
environmental causal diseases90, 91.  
As is characteristic of biological samples, the complexity and wide dynamic range 
in protein concentrations found in bovine samples present a challenging step in their 
preparation for proteomic analysis92. The wide dynamic range in protein concentrations 
results in high abundant proteins (HAPs; 1-100 mg/mL) masking the identification and 
characterization of low abundant proteins (LAPs, <100 ng/mL). However, biomarkers of 
disease and normal states are most probably of the low abundant types, which make the 
ability to characterize these LAPs imperative in proteomic analysis. 
To bridge the wide concentration range and reduce sample complexity, proteomic 
workflows often incorporate fractionation method(s). Immunodepletion is a popular 
fractionation method due to its simplicity, specificity and reliability. Immunodepletion 
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method involves using antibodies to remove target HAPs with subsequent enhanced 
detection of LAPs.  Immunodepletion of HAPs allows for loading of LAPs at higher 
concentrations for improved visualization by one-dimensional (1-D) or two-dimensional 
(2-D) gel electrophoresis and liquid chromatography (LC) and increase the sensitivity of 
proteomics analyses19. The reliability of the immunodepletion method has led to 
advancement in immunodepletion technologies including commercialized kits for 
humans19 and murine biological samples93, 94. However, a method for immunodepletion 
of HAPs in samples from other species, including bovine, is very limited.  
In the absence of available immunodepletion technology, the majority of 
proteomic analysis of bovine biological samples have used gel-based 2-D gel 
electrophoresis and modified forms of 2-DE such as 2-D fluorescence differential gel 
electrophoresis (2D-DIGE) followed by mass spectrometry analysis36, 43, 95-97. However, 
incorporating immunodepletion of HAPs will enhance the gel-based approach and also 
decrease the number of fractionation steps often employed in shotgun proteomic analysis. 
Faulkner et al18 presented separate depletion methods for albumin and IgG, the two top 
abundant proteins in bovine plasma. However, combinations of depletions each targeting 
an abundant protein increase analysis time and can result in sample loss and 
contamination. Sequential depletions can also result in a decrease in the number of 
uniquely identified peptides98. 
2.3 OBJECTIVE OF STUDY 
The objective of this study was to develop an efficient and reproducible 
immunodepletion method for simultaneous removal of HAPs in bovine fluids. We 
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employed the high capacity multiple affinity removal system (MARS) originally 
designed to target six HAPs- albumin, Ig G, IgA, transferrin, alpha-1-antitrypsin, and 
haptoglobin (hp) in human biological fluids while a similar technology for bovine is not 
available. The six target HAPs represent 85-90% of the total protein mass in human 
serum. The MARS technology has been successfully utilized in many proteomic 
applications of human bio-fluids99-102.  
2.4 MATERIALS AND METHOD 
2.4.1 Chemicals and Reagents 
All chemicals and water were of LC/MS grade. Bio-SafeTM G-250 stain, 
Tris/glycine/SDS buffer, 2-mercaptoethanol (β-ME), laemmli sample buffer and 4-20% 
Criterion™ TGX precast gel were purchased from Bio-Rad Laboratories Inc. (California, 
USA). Formic acid, acetonitrile (ACN), triethylammonium bicarbonate (TEAB), and 
water were obtained from Fischer Scientific (New Jersey, USA). Ammonium bicarbonate 
(ABC) and iodoacetamide were purchased from Acros Organics (New Jersey, USA). 
Dithiothreitol (DTT) and TPCK treated trypsin was purchased from Promega (Wisconsin, 
USA).  
2.4.2 Cows Experimental Design 
All procedures were approved by the South Dakota State University Institutional 
Animal Care and Use Committee. Samples in the present study were collected from a 
previous study to characterize changes in steroidogenic enzymes and FF steroid 
concentrations103.  Briefly, 32 beef cows were synchronized by injecting with GnRH (100 
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mg as 2 mL of Factrel, intramuscularly; Pfizer Animal Health (Madison, NJ, USA) on 
day -7 and prostaglandin F2α (PGF2α) (PG; 25 mg as 5 mL of Lutalyse intramuscularly 
(Zoetis, Florham Park, NJ, USA) on day 0. Estrus was monitored every 3 h from PG on 
day 0 until hour 33 and at slaughter (hour 36 to 42) with the aid of EstroTect (Western 
Point, Inc, Apple Valley, MN, USA) estrus detection aids. Ovaries of all cows were 
examined on day -7, -4, and 0 by transrectal ultrasonography using an Aloka 500V 
ultrasound with a 7.5-MHz linear probe (Aloka,Wallingford, CT, USA)  to assess 
follicular dynamics and ovulatory response. Ten cows that were determined to initiate a 
new follicular wave by day -4 were slaughtered on day 2 (hour 36 to 42) for ovary 
collection. 
2.4.3 Follicular Fluid (FF) and Blood Samples Collection  
Immediately after ovary collection, follicular fluid (FF) was aspirated from 
dominant follicles (DF; >10mm diameter) and the GCs were separated from the FF by 
centrifugation (1,000 x g for 1 min). The FF was place in RNase Free Tubes (USA 
Scientific), snap frozen in liquid nitrogen and stored at -80oC until ready for analysis. 
Blood samples were collected at slaughter to provide better comparison to the FF 
collected at slaughter. To obtain plasma, blood collected at slaughter was placed in 
EDTA vacutainer tubes (Beckman Dickerson) and centrifuged at 1,200 x g for 30 min at 
4°C.  The plasma supernatant was snap frozen in liquid nitrogen and stored at -80oC until 
ready for further analysis. 
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2.4.4  Bulls Experimental Design and Sperms Collection 
All procedures were approved by the South Dakota State University Institutional 
Animal Care and Use Committee.  Ejaculated sperm from bulls (n = 9) were collected by 
electro-ejaculation weekly for three consecutive weeks. Collected ejaculated sperm on 
the second week was centrifuged at 700 x g for 10 minutes to separate the spermatozoa 
from the seminal plasma. The seminal plasma fraction was labeled as ‘ejaculated semen 
plasma’. The remaining spermatozoa fraction was washed with a high ionic solution104 
and vortexed for one minute to remove any proteins attached and then centrifuged at 700 
x g for 10 min.  The supernatant was labeled as ‘ejaculated sperm proteins’.  Following 
third sperm collection, bulls were rested for six weeks to allow epididymal reserves to 
renormalize. At the end of the resting period, bulls were slaughtered and the testes and 
epididymides collected. Collected epididymides were dissected and epididymal fluid and 
sperm collected from the cauda section and processed as described for the ejaculated 
sperm. The epididymal fluid fraction collected after separation from the epididymal 
spermatozoa was labeled as ‘epididymis semen proteins’. The spermatozoa were than 
wash as described above and the liquid fraction from washing off proteins on the 
epididymal spermatozoa was labeled as ‘epididymis sperm proteins’. All samples were 
stored at -80oC.   
2.4.5  Depletion of High Abundant Proteins (HAPs) 
Depletion of the different bovine fluids (PL, FF, epididymis sperm proteins, 
epididymis semen proteins, ejaculated sperm proteins, and ejaculated semen plasma) 
were performed using the High Capacity Multiple Affinity Spin Cartridge (MARS Hu-
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6HC) # 5188-5341 (Agilent Technologies, CA, USA). The MARS Hu-6 system contains 
polyclonal antibodies designed to remove six HAPs- albumin, IgG, IgA, transferrin, α-
antitrypsin, and haptoglobin (Hp) in human biological fluids. The depletion was done 
with vendor provided buffers. Initial depletions investigated 2, 4, 6, 8, 10, and 12 µL of 
bovine plasma and 4, 5, 7, 10, and 12 µL of bovine FF to determine optimal volume for 
depletion. Each plasma and FF sample volume was diluted with 1x buffer A, pH 7.4 (# 
5185-5987, Agilent Technologies, CA, USA) to achieve a final volume of 200 µL.  
Initial quantification of the crude samples showed the sperm samples were 
markedly of lower concentration compared to that of plasma or FF and upon depletion 
resulted in very low yield. Therefore, to ensure enough proteins is obtained in depleted 
samples for downstream analysis depletion volumes were increased to 60 µL for 
ejaculated semen plasma and 154 µL each for ejaculated sperm proteins, epididymis 
semen proteins and epididymis sperm proteins. For 154 µL depletion volume, 46 µL of 
4x buffer A (# 5188-8283, Agilent Technologies, CA, USA) was added to achieve a total 
volume of 200 µL. For depletion volume of 60 µL, 94 µL of water was added after 
addition of 46 µL of the 4x buffer A to obtain a final volume of 200 µL. The 4x dilution 
buffer A was used for the higher depletion volumes of the sperm to ensure similar neutral 
pH achieved with the plasma and FF samples using 1x buffer A.  
Diluted samples were transferred to 0.22µm spin filters (Corning Incorporated, 
NY, USA) and centrifuged at 16 000 x g for one minute. Filtered samples were applied to 
the spin cartridge which was previously equilibrated with 4 mL 1x buffer A. Flow-
through (FT) fraction (i.e. depleted fraction) was collected by centrifuging at 100 x g for 
1.5 minutes. To ensure optimal recovery of FT, the cartridge was washed twice each with 
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400 µL 1x buffer A. Each wash volume was collected by centrifuging for 2.5 minutes at 
100 x g. Collected wash volumes were combined with initial collected FT. Bound 
fraction were eluted using 2 mL of elution buffer B (#5185-5988, Agilent Technologies, 
CA, USA) at a flow rate of about 0.15 mL/min. Non-depleted samples, eluates, FT, and 
buffers were stored on ice throughout the experiment period to ensure protein integrity. 
Collected FT and eluates were stored at -80oC until ready for analysis.   
2.4.6 Coomassie Bradford Assay 
Coomassie (Bradford) assay kit, (#23200, Pierce Biotechnology, IL, USA) was 
used to determine protein concentrations of bound, depleted and non-depleted samples. 
The quantification was done according to manufacturer’s instruction.  Bovine serum 
albumin, 2 mg/mL (#23209, Thermo Scientific, IL, USA) was used as a standard for 
making a calibration curve which covered a concentration range of 0.00-1500 µg/mL. 
2.4.7 Sandwich ELISA Analysis  
BSA, IgG and IgA concentrations in non-depleted and depleted (FT) samples 
were determined using sandwich ELISA assay kits (Bethyl laboratories Inc., TX, USA).  
IgG was analyzed with bovine IgG ELISA quantitation set (Cat. No. E10-118), IgA with 
bovine IgA ELISA quantitation set (Cat. No. E10-131) and albumin with bovine albumin 
ELISA kit (Cat. No. E11-113). Samples were diluted and washed with vendor-provided 
buffers. Specific dilution factors used for the different samples are shown in Table 2. All 
quantifications were performed according to manufacturer protocols. Briefly, 100 µL of 
dilute IgA or IgG Coating Antibody solution was added to each assay well. The wells 
were incubated at room temperature for an hour and washed with 1x Wash Buffer. 200 
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µL Blocking Solution was added to each well and incubated at room temperature for 30 
minutes to block non-specific binding sites. Wells were then washed with 1x Wash 
Buffer. Assay wells for determining BSA concentration were obtained pre-coated with 
anti-bovine albumin antibody. 100 µL of the diluted FT or non-depleted fractions were 
then added to the assay wells with the coated antibodies. After one hour incubation at 
room temperature, unbound proteins were washed with 1x Wash Buffer.  
In determining IgA or IgG concentrations, 100 µL of  horseradish peroxidase 
(HRP) conjugated anti-bovine IgA or IgG Detection Antibody solution was added to each 
well and incubated at room temperature for an hour to bind to the captured IgA or IgG. 
For albumin determination, 100 µL of Albumin Detection Antibody solution and 100 µL 
of HRP solution were added stepwise with incubations at room temperature for an hour 
after the Detection Antibody addition and for 30 minutes after the HRP solution addition. 
Wells were then washed with 1x Wash Buffer. 100 µl of 3,3’,5,5’-Tetramethylbenzidine 
(TMB) Substrate Solution was added to each well and incubated in the dark for 15 
minutes in IgA or IgG measurements or 30 minutes in albumin measurement to initiate a 
calorimetric reaction which was stopped by addition of 100 µL Stop Solution to each 
well. Absorbance was measured at 450 nm by Synergy H1 Hybrid Multi-Mode Reader 
(BioTek, VT, USA). BSA, IgA and IgG concentrations were derived from calibration 
curves of reference standards included in the quantitation kits. 
2.4.8  SDS PAGE  
Depleted and bound proteins were buffer exchanged into 0.05% TEAB using zeba 
spin desalting columns, 7k MWCO (# 89891, Pierce Biotechnology, IL, USA) according 
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to manufacturer protocol. Samples were vacuum dried prior to SDS-PAGE analysis. 
SDS-PAGE was performed under reducing and non-reducing conditions. Under reducing 
conditions, β-ME was diluted 1:20 in laemmli buffer and the resulting solution diluted 
twice with water. 15 µL of the prepared sample buffer was added to each vacuum dried 
sample. Samples were vortexed, centrifuged and then boiled in a water bath for three 
minutes.  Boiled samples were quickly loaded onto a pre-cast gel. Non-reducing 
conditions excluded the addition of the β-ME and heating step. Equal amounts of 9 or 20 
µg of proteins and 5-8 µL of Precision Plus ProteinTM  unstained standard, 10-250 kDa 
(Bio-Rad Laboratories Inc., CA, USA) was used in the gel runs. Gels were 
electrophoresed in Bio-Rad Power PacTM unit using 1x Tris/glycine buffer and at constant 
voltage of 150 for 62 minutes. Gel bands were visualized using Coomassie BioSafe G250 
stain according to manufacturer instructions. Images were acquired using Proteineer SPII 
(Bruker Daltonics) equipped with SP3 Control software. 
2.4.9 In-Gel Tryptic Digestion of Coomassie-Stained Gel Bands 
Identities of protein-gel bands from bound fractions (HAPs fraction) were 
determined using in-gel digestion nano-LC-MS/MS. For in-gel digestion, each gel band 
from the bound protein lane was excised with sanitized cutting blade, transferred onto 
previously sanitized glass plate and then chopped into pieces. Gel pieces were transferred 
to a 0.5mL microcentrifuge tube and washed with 100µL LC/MS-grade water with gentle 
vortexing for five minutes. The water was removed and the gel pieces completely 
destained by washing with several 100µL portions of 25 mM ammonium bicarbonate 
(ABC) in ACN/ water (v/v = 50/50) solution. Destained gel pieces were dehydrated with 
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100 µl ACN for 10 minutes and dried in a speed-vac at 4oC for 5 minutes. Reduction was 
done with 100 µl of 10 mM DTT at 55oC for 30 minutes.  
After removal of reduction solution, alkylation was carried out by addition of 100 
µL of freshly prepared 55 mM iodoacetamide and incubating in a dark room for 45 
minutes. Gel pieces were washed with 100µL 25 mM ABC solution for 10 minutes, 
dehydrated with 100 µL ACN, and dried in speed-vac at 4oC for five minutes. 30 µL of 
freshly prepared cold 20 µg/mL TPCK treated trypsin (P/N 4370282; Ab Sciex Pte Ltd, 
MA, USA) in 25 mM ABC solution was then added to each sample and incubated on ice 
until gel pieces became fully rehydrated and clear. Excess trypsin solution was removed 
and the gel pieces were covered with 30 µL 25 mM ABC solution and incubated for 16 h 
at 37oC. To extract tryptic peptides, 25 µL of 25 mM ABC solution was added and the 
liquid fraction collected. Then 50 µL of ACN was added and incubated for 10 minutes 
with slight shaking and the liquid fraction also collected.  Finally, 30 µL water and 50 µL 
ACN were added stepwise with 10 minutes incubation with shaking in each step and the 
liquid fraction also collected. All extracted liquid fractions were combined, frozen for 15 
minutes and dried in a speed-vac at 4oC. Dried peptides were stored at -80oC. 
2.4.10 Nano-LC-MS/MS  
Dried peptides were purified and concentrated with either Pierce® C18 spin 
columns (Pierce Biotechnology, IL, USA) or ZipTip C18 tips (Millipore, MA, USA) 
based respectively on high intensity or low intensity of coomassie blue stained-gel band 
prior to de-staining. Purification was done according to manufacturer protocols. Purified 
samples were dried in a speed-vac at 4oC and stored at -80oC until analysis. Protein 
51 
 
identification was performed with nano-liquid chromatography tandem mass 
spectrometry (nanoLC-MS/MS) analysis by using Eksigent nanoLC - Thermo LTQ mass 
spectrometer. The dried, purified digest from each interested protein band was brought up 
in water/ACN/formic acid (95%5%/0.1%) and then was loaded on IntegraFrit Sample 
trap (ProteoPep IITM C18, 300 Å, 5µm , 100 μm × 25 mm New Objective, Inc., Woburn, 
MA). The retained peptides were washed isocratically with water premixed with 0.1% 
formic acid pumped from channel 1A to remove any excess reagents. The cleaned 
peptides were resolved on an analytical column (ProteoPepTM II C18, 300 Å, 5µm, 75 μm 
×100 mm, 75 µm tip size, New Objective, Inc., Woburn, MA) with a multistep gradient 
of solvent 2A (water premixed with 0.1% formic acid) and solvent 2B (ACN premixed 
with 0.1% formic acid) at a flow rate of 200 nL/min. A 90-min or a 240-min gradient was 
used for the peptides separation. The 90-min gradient started at 5% solvent B and was 
held for 5 minutes, then linearly increased to 40% solvent B at 55 min and to 95% solvent 
B at 65 min and finally held at 95% solvent B for 5 min before allowing to return to 
initial 5% solvent B at 73 min. Column re-equilibration with initial 5% solvent B was 
done for 17 min. The 240-min gradient started at 5% solvent B and was held for 5 
minutes, then linearly increased to 40% solvent B at 190 min and to 95% solvent B at 205 
min and finally held at 95% solvent B for 15 min before allowing to return to initial 5% 
solvent B at 223 min. Column re-equilibration with initial 5% solvent B was done for 17 
min. 
The LTQ mass spectrometer was operated in the data-dependent mode. The full 
MS spectra were acquired in positive mode within a range of 300-1800 m/z. Top three 
ions with intensities exceeding a preset threshold in full mass scan were chosen for
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Table 2.1. Concentrations of crude bovine fluids and data on yield (flow-through proteins) obtained after 
immunodepletion of abundant proteins 
Sample 
Concentration of 
crude (µg/ml) 
Load 
volume 
(µl) 
Load (µg) Yield (µg)  Yield (%) Yield concentration 
(µg/ml) 
Plasma 63960.2 ± 6523.0 4 255.8 ± 26.1 71.2 ± 11.4 27.9 ± 3.8 17798. ± 2839.4 
Follicular fluid 56445 ± 4196.8 5 287.9 ± 19.9 47.9 ± 11.1 17.3 ± 4.2 9988.6 ± 2119.4 
Epididymis sperm proteins 582.8 ± 64.3 154 89.8 ± 9.9 30.5 ± 4.5 34.1 ± 4.6 200.5 ± 30.8 
Epididymis semen proteins 1857.6 ± 236.7 154 286.1 ± 36.5 109.7 ± 7.33 38.7 ± 3.82 712.6 ± 47.6 
Ejaculated sperm proteins 1744.6 ± 42.35 154 268.7 ± 6.52 134.6 ± 9.4 50.9 ± 3.4 874.2 ±  61.13 
Ejaculated semen plasma 19678.9 ± 2866.7 60 1238.2 ± 156.8 552.2 ± 66.4 44.6 ±  1.5 9202.9  ± 1106.9 
Table 2.2. Dilution factors used in sandwich ELISA assay for measuring BSA, IgG and IgA 
concentrations in non-depleted and flow-through (FT) fractions 
  Dilution factors 
  Albumin IgG IgA 
Sample Non-depleted FT  Non-depleted FT  Non-depleted FT 
Plasma 2.5E+05 4.0E+02 1.0E+05 2.0 7.5E+04 3.0 
Follicular fluid 1.5E+05 2.0E+01 9.0E+04 2.0 1.5E+04 2.0 
Epididymis sperm proteins 3.0E+03 1.0E+02 1.0E+02 2.0 5.0E+01 1.0 
Epididymis semen proteins 1.0E+04 3.0E+02 3.0E+02 8.0 5.0E+01 2.0 
Ejaculated sperm proteins 3.0E+03 5.0E+02 2.0E+02 2.0 1.0E+02 5.0 
Ejaculated semen plasma 1.0E+04 2.0E+01 3.0E+02 2.0 2.0E+02 1.5 
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collision- induced dissociation (CID) in LTQ. The Q activation and time was set 
respectively at 0.25 eV and 30 ms. The maximum ion injection times used were 5.0 x104 
ms for the MS scan and 1.2 x105 for the MS/MS scan. The automatic gain control target 
settings were 3.0 x104 for the MS scan mode and 1.0 x 104 for the MS/MS scan mode. 
The normalized collision energy was 35 eV and the isolation window employed was 2.5 
m/z. The dynamic exclusion settings utilized were repeat count 2, exclusion duration 36 
s, exclusion list size 500, exclusion mass width low 1.0 and exclusion mass width high 
1.5.  
 2.4.11 Protein Identification  
The LC-MS/MS raw data from nanoLC-LTQ were correlated to theoretical 
fragmentation patterns of tryptic peptide sequences from the Fasta databases (Bovine and 
human) using SEQUESTTM (Thermo Fisher). The search parameters included (i) fixed 
cysteine modifications of +57 Da for carbamidomethyl-cysteines, (ii) variable 
modifications allowing +16 Da with methionines for methionine sulfoxide; (iii) restricted 
to trypsin-digested peptides and allowed for two missed cleavages; (iv) precursor mass 
range was 310-5000 Da; (v) precursor mass tolerance of 2.5 Da and fragment mass 
tolerance of ±0.8 Da; (vi) target false discovery rate (FDR) strict was 0.01 and FDR 
relaxed was 0.05; (vii) peptide were identified based on top hit(s) with individual cross 
correlation exceeding a threshold dependent on the precursor charge state. The proteins 
matched with at least two peptides at minimum 95% confidence (false discovery rate 
(FDR) of ≤5%) were considered as positive identification.  
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2.4.12 Reproducibility and Recovery of MARS Hu-6HC on Bovine Fluids 
To determine reproducibility of the MARS Hu-6HC cartridge, the bovine fluids 
were subjected to 3-5 replicate depletions on same day for 2-5 separate days. 
Reproducibility was assessed by coefficient of variations (CVs) of the percent of total 
protein depleted (Table 2.3.) and by SDS PAGE separation of crude, bound and depleted 
fractions (Figure 2.2. and 2.4.). Recovery was determined as protein content in bound 
plus FT fractions expressed as percent of protein content in non-depleted sample (Table 
2.4). Recovery ranged from 73-101%. Recovery of plasma (94%) and FF (101%) were 
higher than that of the sperm samples (73-82%). 
 
Table 2.3. *Total protein depleted with the MARS Hu-6HC cartridge on bovine fluids 
Sample 
Volume 
Depleted 
(µl) 
Total protein depleted on 
same day (%) 
Total protein depleted on 
separate days (%) 
    Mean ± SD    % CV Mean ± SD %CV 
Plasma 4 71.9 ± 4.9 6.8 72.1 ± 3.8 5.2 
Follicular fluid 5 86.0 ± 3.6 4.2 82.6 ± 3.8 4.6 
Epididymis  sperm proteins 154 66.2 ± 2.1 3.2 66. 1 ± 4.6 6.9 
Epididymis semen proteins 154 58.2 ± 2.9 5 61.3 ± 3.8 6.2 
Ejaculated sperm proteins 154 49.7 ± 2.9 5.9 49.8 ± 3.3 6.6 
Ejaculated semen plasma 60 53.6 ± 2.4 4.5 53.7 ± 1.9 3.5 
*Total protein depleted data were obtained from 2-5 separate days of depletions with n= 3-5 
replicates on day depletion. 
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2.5 RESULTS 
2.5.1 Depletion Efficiency of Target Proteins from the Bovine Fluids 
Percent depletion of the bovine samples by using the MARS Hu-6HC cartridge in 
removing the target HAPs was determined by comparing the total protein content in the 
FT (depleted) fraction to that of the non-depleted samples. Total protein depleted from 
each bovine fluid is shown in Table 3. Total protein depleted, expressed as percent 
depletion were comparable for different volumes of plasma or FF investigated: 67.9 ± 3.1 
(4.1%) for 2, 4, 6, 8, 10, 12, and 14 µL of plasma and 83.4 ± 6.0 (7.2%) for 4, 5, 7, 10, 
12, and 14 µL of FF; mean ± SD (%CV) (Figures 1 and 2). Therefore, 4 µL plasma and 5 
µL of FF were used in further investigation to conserve samples. Percent of LAPs (yield) 
from each bovine fluid is shown in Table 1. From two to five separate days of depletion, 
total protein depleted was highest for the FF sample (82.6 ± 3.8%) followed by the 
plasma sample (72.1 ± 3.8%) and then the four sperm- sample types- 66.1 ± 4.6 for 
epididymis sperm proteins, 61.3 ± 3.8% for epididymis semen proteins, 49.8 ± 3.3% for 
ejaculated sperm proteins and 53.7 ± 1.9% for ejaculated semen plasma. Similar values 
were obtained for same day depletions (Table 2.3).  
The effectiveness of depletion of abundant proteins was also assessed by SDS 
PAGE separation of non-depleted, bound and depleted proteins. Figures 2.2, 2.3, and 2.4 
reveal the unmasking and highlighting of LAPs after dramatic removal of HAPs from the 
different bovine fluids. In-gel digestion nano-LC-MS/MS analysis of gel bands from 
bound fractions identified four out of the six target HAPs namely serum bovine albumin 
(BSA), IgG, IgA and α-1-antitrypsin. Gel bands containing these proteins are shown in 
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Figure. 2.2. Transferrin and Hp were not identified in the bound fractions by the nanoLC-
MS/MS method.  
2.5.2 Specific Depletion Efficiency of BSA, IgG and IgA  
Depletion efficiency (i.e. the extent of removal) of BSA, IgG and IgA from the 
different bovine fluids was individually assessed using sandwich ELISA.  Results showed 
depletion of 98.25 to 99.99% BSA, 98.65 to 99.96% IgG and 98.85 to 99.96% IgA from 
all the bovine samples studied (Table 2.5). The observed depletion rates are comparable 
to manufacturer specification of 98.9-99.9% obtained for human biological fluids. 
Depletion efficiency for α-1-antitrypsin was not measured by the ELISA method. 
However, the dramatic removal of its protein gel band (Figure. 2.2) indicates similar 
depletion rate for this protein can be expected.  
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Figure 2.1. Total 
proteins depleted from 
different volumes of 
bovine plasma and 
follicular fluid (FF) 
with the MARS Hu-
6HC cartridge. Total 
protein depleted is 
similar over 2 (n=1), 4 
(n=7 ), 6 (n= 7), 8 
(n=2), 10 (n=5), 12 
(n=2), and 14 (n=8) µL 
of plasma and 4 (n=1), 
5 (n=1), 7 (n=3), 10 
(n=2), 12 (n=2), and 14 
(n=2) µL of FF. 
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2.5.3 Specificity of the Immunodepletion 
To assess the specificity of the depletion method for the target proteins in bovine 
fluids, 1-D SDS PAGE nano-LC-MS/MS analysis was performed on bound fractions. 
Concomitant removal of non-target proteins were observed from all the bovine samples 
depleted. These are summarized in Table 2.6. Non-target proteins from bound fraction of 
the ejaculated sperm types included three major binder of sperm (BSP) proteins namely 
PDC-109, BSP-A3 and BSP-30kD (Figure 2.3). Among the BSP depleted, the highest 
depletion rate was observed for PDC-109 which forms 25-47% of total BSP proteins105.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2. Reproducibility of the MARS Hu-6HC cartridge on different depletion 
volumes of bovine plasma. Lanes: 8D, 10D, 12D and 14D- Depleted fractions 
respectively from depletion of 8, 10, 12 and 14 µL of bovine plasma; B8, B10, B12 
and B14- Bound fractions respectively from depletion of 8, 10, 12 and 14µL of bovine 
plasma; C-Crude bovine plasma; M- Molecular weight marker. Reproducibility of the 
separation show similar depletion efficiencies were obtained for the different volumes 
of plasma depleted. Arrows show gel bands at the respective molecular weights of 
depleted BSA, IgA, IgG, and alpha-1- antitrypsin. 9µg of proteins were loaded on each 
lane of 4-20% Criterion™ TGX precast gel and run under reducing conditions using β-
ME. Bands were visualized with Coomassie blue staining 
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2.5.4 Reproducibility  
The immunodepletion method had good reproducibility for all the bovine samples 
studied.  The coefficient of variations (%CVs) of depletion efficiencies determined on the 
same day or separate days ranged 3.2 to 6.8 and 3.5 to 6.9 %, respectively (Table 2.3). 
The good reproducibility is also supported by the consistent protein band pattern on the 
SDS PAGE gel as is demonstrated in Figure 2.4. 
 
Table 2.4. Recovery with depletion method 
Sample 
Volume 
Depleted (µL) 
Recovery (%) 
    Mean ± SD % CV 
Plasma 4 93.96 ± 11.57 12.31 
Follicular fluid 5 101.35 ± 10.98 10.83 
Epididymis  sperm proteins 154 73.65 ± 7.51  10.2 
Epididymis semen proteins 154 81.77 ± 7.42  9.08 
Ejaculated sperm proteins 154 79.65 ± 3.82  4.8 
Ejaculated semen plasma 60 81.45 ± 3.53 4.33 
Data obtained from 2-5 separate days of depletions with n= 3-5 replicates on day 
depletion 
 
N= 2 replicates on 1-2 separate day 
Table 2.5. Depletion efficiencies of BSA, IgG and IgA obtained with the MARS 
Hu-6HC cartridge on Bovine fluids from Sandwich ELISA Analysis 
 % Depletion Efficiency (Mean ± SD) 
Sample Albumin IgG IgA 
Plasma 98.73 ± 0.29 99.45 ± 0.01 98.85 ± 0.21 
Follicular fluid 99.97 ± 0.02 99.96 ± 0.00 98.85 ± 0.60 
Epididymis sperm proteins 99.92 ± 0.04 99.61 ± 0.24 98.79 ± 0.45 
Epididymis semen plasma 99.98 ± 0.00 99.57 ± 0.21 99.40 ± 0.12 
Ejaculated sperm proteins 99.52 ± 0.20  99.52 ± 0.03 99.63 ± 0.04 
Ejaculated semen plasma 99.45 ± 0.01 98.65 ± 0.06 99.96 ± 0.02 
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2.6  DISCUSSION 
Immunodepletion methods are popular and often the first step fractionation to 
narrow the wide concentration range in biological samples and reduce sample 
complexity. To date, available immunodepletion methods for bovine samples are very 
limited. This study report a method for simultaneous immunodepletion of abundant 
proteins BSA, IgG, IgA and alpha-1-antitrypsin from bovine plasma, FF, epididymis and 
ejaculated sperm types with high depletion rates. Depletion rates for BSA, IgG and IgA 
were confirmed as 98.7 to 99.9% from all the bovine fluids studied using sandwich 
ELISA. The observed depletion rates are comparable to that stated by manufacturer for 
Figure 2.3. Unmasking and highlighting of LAPs after removal of HAPs from bovine 
ejaculated and epididymis sperm types with MARS Hu-6Hc cartridge.  M- Molecular 
weight marker. C- Crude sperm sample; D- Depleted fraction; B- Bound fraction. 1, 2, 
3, and 4 respectively ejaculated sperm proteins, ejaculated semen plasma, epididymis 
sperm proteins and epididymis semen proteins. BSA, IgG and IgA were targeted 
proteins depleted. Seminal plasma proteins- PDC-109, BSP-A3 and BSAP-30 kDa 
were non-specifically depleted from ejaculated sperm sample types. These seminal 
plasma proteins are HAPs found in ejaculated sperm. 20 µg of proteins were loaded on 
each lane of 4-20% Criterion™ TGX precast gel and run under non-reducing 
conditions. Bands were visualized with Coomassie blue staining. 
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these proteins from human fluids which is 98.9-99.9%. The similar depletion rates 
indicate sample variability did not significantly affect the affinity of the MARS 
polyclonal antibodies for the target proteins in the bovine fluids. Greater sequence 
similarities between the target proteins in human and bovine explains the effective 
application of this immunodepletion technology on bovine fluids. A search in UniprotKB 
database (http://www.uniprot.org) showed human serum albumin and alpha-1-antitrypsin 
respectively share greater than 75 and 68% sequence identity with their respective 
proteins in bovine. Sequence identity between human and bovine immunoglobulins light 
chains range is 53-76% whiles the heavy chains range is 33-65%. The high depletion 
rates achieved with the presented method makes it a viable alternative for achieving 
Figure 2.4. Reproducibility of the immunodepletion of bovine plasma and follicular 
fluid (FF) with the MARS Hu-6HC spin cartridge. Three replicates of plasma and 
two replicates of FF depletions were carried out with respectively 4µL and 5µL 
depleted volume in each case. Lanes: M-Molecular weight marker; C-Crude sample; 
D- Depleted fraction; B-Bound fraction. 6 µg of proteins were loaded on each lane 
of 4-20% Criterion™ TGX precast gel and run under non-reducing conditions. 
Bands were visualized with Coomassie blue staining. 
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immunodepletion of these abundant proteins in bovine biological fluids while similar 
technology is currently unavailable 
 
Table 2.6. SEQUEST results showing non-target proteins* in bound fractions of 
bovine plasma, follicular fluid (FF), epididymis, and ejaculated sperms after depletion 
with MARS Hu-6HC cartridge.  
Accession  No of peptides 
identified 
Score Description Protein Familyᵻ 
B8Y9S9 38 528.63 Embryo-specific fibronectin 1 
transcript variant  
 
P07589 27 515.40 Fibronectin  
Q7SIH1 33 395.84 Alpha-2-macroglobulin   
P02784a 8 323.32 Seminal plasma protein PDC-
109 
 
F1MAV0 19 238.79 Fibrinogen beta chain  
A5PJE3 16 229.46 Fibrinogen alpha chain  
G3X7A5 17 179.49 Complement C3   
P12799 8 173.91 Fibrinogen gamma-B chain  
P81019a 3 62.58 Seminal plasma protein BSP-30 
kDa 
 
P01030 2 42.92 Complement C4   
P04557a 2 34.56 Seminal plasma protein A3  
F1MBL6 2 32.17 Uncharacterized protein 
(Fragment)  
P13/P14 kinase family 
F1MI18 2 24.05 Uncharacterized protein  Alpha-2 macroglobin 
family 
E1BIF6 2 19.75 Uncharacterized protein  Ubiquitin associated 
domain 
P23805 4 16.95 Conglutinin   
Q28085 2 15.71 Complement factor H   
G3N0S9 2 11.42 Uncharacterized protein   Sushi CCP/SCR 
domain family 
F1N5M2 2  8.76 Vitamin D-binding protein  
*List excludes trypsin and keratin related proteins 
ᵻ Identified from UniProt KB search with accession number 
aOnly observed in ejaculated sperm types 
 
Contrary to the lack of effect of sample variability on individual target protein 
depletion rate, sample variability seems to affect the total proteins depleted in a sample. 
Total protein depleted was about 50- 83% for the bovine samples investigated. This range 
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was lower than the manufacturer specifications of 85-90% for human serum. But bovine 
FF and plasma were closer to the lower end range; respectively 83% and 71%. The total 
protein depleted is based on the levels of the target proteins in certain samples. Thus, 
differences in the levels of the target proteins in the different bovine fluids and between 
human and bovine would affect the total protein depleted. For instance, albumin, the most 
abundant protein in plasma represents more than 50% of the total protein in human 
plasma15 and about 42% in bovine plasma106. Plasma and FF are closely related in 
composition and majority of proteins in FF are viewed to originate from the blood107-109. 
But albumin is higher in FF compared to serum110, 111 which might explain the highest 
depletion rate attained with the FF. 2-DE analysis of caudal epididymis fluid found 
albumin represented ~21% of all proteins spots detected 42. By contrast, albumin 
concentration is very minimal in ejaculated sperm112. Accordingly, total proteins depleted 
were lower for the sperm sample types compared to the plasma and FF samples.  
The lower total proteins depleted from the bovine fluids are also contributed by 
the lack of depletion of Hp and transferrin which are both target proteins of the MARS 
Hu-6HC cartridge, contributing to the manufacture stated 85-90% . Sequence homology 
could not explain the lack of removal of both proteins as they are highly homologous 
between human and bovine, respectively 69% and 75% sequence identity. High 
specificity of the MARS Hu-6HC cartridge for human transferrin and Hp appears to be 
the primary reason for both proteins not depleted from the bovine fluids. Although Hp 
and transferrin were not depleted, the simultaneous rapid depletion of albumin, IgG, IgA 
and alpha-1-antitrypsin from all the bovine fluids show the effectiveness of application of 
the current immunodepletion method to bovine fluids. Albumin and IgG represents about 
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60% of the bovine plasma proteome. Depletion of both proteins increased the number of 
spots and intensities on a 2-DE map18. The additional depletion of abundant proteins by 
this depletion method is expected to provide more desirable probing of low copied 
proteins in gel-based and gel-free proteomic workflows for bovine fluids analysis. As 
shown in this study, the depletion of the four major proteins unmasked and highlighted 
more protein gel bands in SDS PAGE gels presented. Because the HAPs were removed 
in a single step, sample loss is expected to be minimized. Also, time is reduced.  
To determine reproducibility of the immunodepletion, replicate depletions on 
same day and on separate days were analyzed. The results show the method had high 
reproducibility on the bovine fluids as revealed by the low % CV values of total proteins 
depleted from different and same volumes. Because immunodepletion is often a first step 
fractionation option, a good reproducibility for its application is critical to the accuracy 
and further reproducibility of downstream protein separation, identification, and 
quantification. Low loading volumes of plasma and FF (4 and 5 µL) did not affect the 
reproducibility and this can be beneficial if sample is limiting.  
Concomitant removal of non-target proteins in immunodepletion methods is often 
inevitable99, 100. Non-target proteins removal from the bovine fluids included other HAPs, 
e.g. PDC-109, BSP-A3, BSP-30kD, alpha-2-macroglobulin, complement C3, 
complement C4, and fibrinogen. Non-target proteins removal could result from non-
specific binding to cartridge resin, accidental/specific cross reaction of the antibodies, or 
interactions with the target proteins. The BSP proteins were consistently removed from 
the ejaculated sperm samples. Their dramatic removal is considered beneficial since they 
are major proteins constituting 40-57% of the total protein in the seminal plasma 
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component of ejaculates. PDC-109 alone forms 25-47% of the BSP proteins mass105. 
Thus, depletion of the BSP proteins can additionally enhance the analysis of LAPs in 
these ejaculates. However, caution should be taken when applying this depletion method 
to target these seminal proteins since their removal is non-specific. In such cases, a better 
approach would be to analyze both the bound and unbound fractions to ensure adequate 
estimation of their depletions.  
2.7 CONCLUSION 
Immunodepletion methods for bovine fluids are currently very limited. This study 
describes an immunodepletion method for simultaneous removal of minimum of four 
HAPs in different bovine fluids. The high depletion efficiencies (98.7-99.9%) and 
reproducibility make it practical for its application in bovine proteomic analyses.  
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CHAPTER 3 
iTRAQ-BASED QUANTITATIVE ANALYSIS OF BOVINE PLASMA AND 
FOLLICULAR FLUID 
 3.1 ABSTRACT 
Bovine follicular fluid (FF) creates a unique microenvironment in follicles necessary for 
follicle growth and oocyte maturation, and preovulatory concentrations of estradiol (E2) 
have been reported to impact several processes involved with fertility. The objective of 
this study was to analyze changes in proteins in FF and plasma (PL) from animals with 
high E2 (HE2) or low E2 (LE2) during the pre-ovulatory period. Beef cows were 
synchronized with an injection of GnRH on day -7 and an injection of prostaglandin F2α 
(PGF2α) on day 0. Follicular dynamics and ovulatory response were monitored using 
transrectal ultrasonography. Nine cows were selected and slaughtered, blood samples 
were collected at slaughter and FF was aspirated from dominant follicles (DF; >10 mm). 
Abundant proteins (albumin, IgG, IgA, and alpha-1-antitrypsin) were depleted from both 
PL and FF. Peptides were labeled with iTRAQ reagents and quantified using two-
dimentional liquid chromatography ESI-based mass spectrometry. Estradiol was 
associated with increased protein changes in PL and FF. Protein expression changes 
between FF HE2 and FF LE2 were higher than PL HE2 and PL LE2. There were 15 up-
regulated proteins and 10 down-regulated proteins in FF HE2 compared to FF LE2. 
Seven proteins were up-regulated and nine proteins down-regulated in PL HE2 compared 
to PL LE2. Proteins were more predominant in PL than in FF but the extent of protein 
increase with HE2 was greater in FF than in PL. Several of the differentially expressed 
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proteins function in follicle development and were mainly categorized under cellular 
process and metabolic process. Pathway analysis identified the up- and down-regulated 
proteins were predominantly associated with the complement and coagulation cascades. 
The data demonstrates E2 regulates a wide range of reproductive associated proteins in 
bovine PL and FF, and can provide the basis for further investigation of specific 
processes involved in such regulation.  
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3.2  BACKGROUND AND MOTIVATION 
Follicular fluid (FF) provides a unique microenvironment for developing oocytes. 
It contains substances that primarily originate from circulating blood and from secretions 
by granulosa cells (GCs), theca cells, and the oocyte108. Proteins are a major proportion 
of the FF with total concentrations comparable with that in plasma113; however, the 
composition of the proteins in FF changes with follicle development40, 114 which indicates 
their involvement in the development of the follicle and competent oocyte. Accordingly, 
FF proteins have been implicated in oocyte meiosis, ovulation, formation of the corpus 
luteum, and fertilization108. Thus, FF proteins can reflect the physiological condition of 
the follicle and may serve as biomarkers for follicle growth and maturation. 
Estrogens are an important component of FF. During the steroidogenesis process, 
androgens produced in the theca cells traverse the basement membrane of the 
neighboring GCs where they are converted by cytochrome P450 aromatase (CYP19A1) 
under the influence of follicle stimulating hormone (FSH) to estrogens115, with Estradiol-
17β (E2) being the principal form of estrogen present115, 116. The pre-ovulatory follicle is 
reported to have the highest intra-follicular levels of E2 mainly because of the large 
number of GCs and its capacity for androgen aromatization115.  
 In developing follicles, E2 stimulates proliferation and differentiation of GCs115, 
and promotes growth, gap-junction formation, antrum formation, and inhibition of 
atresia117. Perry et al118 reported that among cows exhibiting standing estrus peak 
concentration of E2 were greater and positively associated with follicle size, but this 
association was not found in cows not exhibiting standing estrus. Cows with increased 
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concentration of circulating E2 had an up-regulation of the steroidogenic pathway during 
the pre-ovulatory period as evidenced by increased concentrations of steroidogenic 
associated enzymes 3β-hydroxysteroid dehydrogenase (3β-HSD), CYP19A1, and 
cytochrome P450 side-chain cleavage enzyme (CYP11A1) and steroidogenic products 
estradiol and androstenedione103.   
An important means by which E2 achieves its regulatory reproductive functions is 
via regulation of proteins and protein receptors involved in the relevant functions. Such 
proteins include insulin-like growth factor 1 (IGF-1) which promotes proliferation of 
GCs and endometrial epithelial cells119, follicle stimulating hormone (FSH) receptors in 
GCs, and LH/human chorionic gonadotropin (hCG) receptors in GCs and thecal 
interstitial tissues when coupled with FSH120. Quantitative shot-gun proteomics, 
incorporating isobaric labeling techniques such as isobaric tags for relative and absolute 
quantitation (iTRAQ) and tandem mass tags (TMT), allow measuring of protein changes 
in time-dependent manner with greater precision and accuracy than label-free methods26. 
This can be applied to determine the influence of E2 on the expression of several proteins 
in a short period. Its application to FF is also beneficial considering the large number and 
diversity of the FF proteome. Ferrazza et al40 recently utilized TMT labels and identified 
22 differentially expressed proteins in bovine FF between different stages of follicle 
development. The group also demonstrated a correlation between some of the 
differentially expressed proteins (includes modified fibrinogen, alpha-2-macroglobulin, 
plasminogen, immunoglobulin M heavy chain, and spondin-1) and concentration of E2 or 
progesterone. 
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3.3 OBJECTIVE OF STUDY 
The objective of this study was to use the iTRAQ proteomic approach to 
quantitatively measure PL and FF proteomes and identify the influence of high and low 
pre-ovulatory circulating concentrations of E2 on PL and FF proteomes.  
3.4  MATERIALS AND METHODS 
3.4.1 Materials and Reagents 
Ammonium bicarbonate (ABC) and iodoacetamide were purchased from Acros 
Organics (New Jersey, USA). Formic acid, acetonitrile (ACN), triethylammonium 
bicarbonate (TEAB) and water were obtained from Fischer Scientific (New Jersey, 
USA). Dithiothreitol (DTT) was purchased from Promega (Wisconsin, USA). ZebaTM 
desalting spin columns from Pierce (Rockford, IL,USA). All chemicals and water were of 
LC/MS grade. 
3.4.2 Estradiol Measurement  
Estradiol (E2) concentrations in PL and FF (PL and FF collected as described in 
Chapter Two) were measured by radioimmunoassays (RIA) according to procedures as 
previously described121 and animals were then classified as either high E2 (peak estradiol 
≥ 6.0 pg/mL; PL:  n = 4, FF:  n = 4) or low E2 (peak estradiol ≤ 4.5 pg/mL; PL: n = 5, 
FF: n = 5) according Jinks et al122.  Concentrations of E2 and changes in the 
steroidogenic pathway have previously been reported by Larimore and coworkers103. 
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3.4.3 Coomassie Bradford Assay Quantitation 
The protein contents in depleted samples were quantified using Coomassie 
(Bradford) assay kit, #23200 (Pierce Biotechnology, IL, USA) according to 
manufacturer’s instruction. Bovine serum albumin (#23209, Thermo Scientific, IL, USA) 
was used as a standard for making a calibration curve. The standard (2 mg/mL) was 
diluted with 50 mM TEAB and the calibration curve covered a concentration range of 
0.00-1500 µg/mL.  
3.4.4 Reduction, Alkylation, Digestion, and iTRAQ Labeling of Proteins 
Fifty µg of each of the four depleted bovine samples (PL and FF) containing high 
or low E2 (i.e. PL HE2, PL  LE2, FF HE2 and FF LE2) were pooled and vacuum dried 
(Labconco, Kansas, MO, USA) at 4 oC. The dried proteins were prepared with 4-plex 
iTRAQ reagents according to manufacturer protocol (Applied Biosystems, Foster City, 
CA, USA). Briefly, the dried proteins were re-suspended in 25µL 1M TEAB solution. 
The proteins were denatured with 1µL 2% SDS solution, reduced with 2µL 50 mM tris-
(2-carboxy) ethylphosphine hydrochloride (TCEP), and alkylated with 1 µL of freshly 
prepared 84 mM iodoacetamide solution and incubated in dark room temperature for 30 
minutes. Each sample (50 µg) was digested overnight at 37 oC with 10 µL of freshly 
prepared 1µg/µL TPCK treated trypsin solution, P/N 4370282 (Ab Sciex Pte Ltd, MA, 
USA). iTRAQ reagents 114, 115, 116 and 117 were each resuspended in 70µL ethanol 
and added individually to the four digested PL and FF  protein samples. The samples 
were incubated at room temperature for 1h and the reaction quenched by adding 100 µL 
of HPLC-grade water and incubating at room temperature for 30 minutes. Each labeled 
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peptide was vacuum dried at 4oC, cleaned with ZebaTM desalting spin columns according 
to vendor instructions (Pierce, Rockford, IL,USA) and then vacuum dried  at 4oC. 
Samples were stored at -80oC until ready for analysis. 
3.4.5 Off-line Strong Cation Exchange (SCX) Separation 
The iTRAQ-labeled peptides were separated using ICAT® Cartridge–Cation 
Exchange, # 4326752 (POROS® 50 HS, 50-µm, 4.0 mm × 15 mm),  Opti-Lynx Quick 
Connect Hardware, # 4326688,  and ICAT® Cation Exchange Buffer Pack, # 4326747 
(Applied Biosystems, Foster City, CA, USA). The iTRAQ-labeled dried peptides were 
each diluted 10-fold with Load Buffer (10mM KH2PO4 in 25% ACN; pH 3) and the four 
samples combined in one new vial.  Equilibration of the SCX cartridge was done with 
1mL of Clean Buffer (10 mM KH2PO4 in 25% ACN / 1M KCl; pH 3) followed by 2mL 
Load Buffer. The mixed iTRAQ labeled peptides were then loaded onto the SCX 
cartridge. Excess iTRAQ reagents and salts in the cartridge were removed by washing the 
cartridge with 1mL of Load Buffer. The bound peptides on the cartridge were eluted by 
sequential injection of 500 µL of a series of salt solutions: 0, 30, 40, 50, 60, 70, 85, 100, 
130, 160, 350, 500, and 1000 mM KCl in Load Buffer. The flow rate of elution was ~1 
drop/second. Each eluted fraction and wash solution was cleaned with ZebaTM desalting 
spin columns according to vendor instructions (Pierce, Rockford, IL,USA). Purified 
peptides were vacuum dried at at 4oC (Labconco, Kansas, MO, USA) and stored at -80oC 
until further analysis. 
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3.4.6  Nano-LC-MS/MS Analysis 
Aliquots of the dried SCX peptide fractions were analyzed using the Thermo- 
Fisher FinniganTM LTQTM mass spectrometer equipped with a  nano-electrospray source 
(New Objective, Woburn, MA, USA) and coupled with a nano-LC separation system 
(Eksigent nanoLC 1D-plus). The LC system is equipped with an autosampler (Spark 
Holland 920 Endurance Autosampler). Each peptide fraction was re-suspended in 10 µL 
of water/ACN/formic acid (95%/5%/0.1%) and then 3 µL loaded onto IntegraFrit Sample 
trap (ProteoPep IITM C18, 300 Å, 5µm , 100 μm × 25 mm New Objective, Inc., Woburn, 
MA). The retained peptides were washed isocratically with water premixed with 0.1% 
formic acid pumped from channel 1A to remove any excess reagents. Peptide separation 
was performed on an IntegraFrit Analytical Column (ProteoPepTM II C18, 300 Å, 5µm, 
75 μm ×100 mm, 75µm tip, New Objective, Inc., Woburn, MA) with a multistep 4-h 
gradient using solvent A (water premixed with 0.1% formic acid) and solvent B 
(acetonitrile premixed with 0.1% formic acid) at a flow rate of 200 nL/min. The gradient 
started at 5% solvent B and was held for 5 minutes, then linearly increased to 50% 
solvent B at 205 min and to 95% solvent B at 213 min and finally held at 95% solvent B 
for 5 min before allowing to return to initial 5% solvent B at 223 min. Column re-
equilibration with initial 5% solvent B was done for 17 min.  
The LTQ mass spectrometer was operated in a data-dependent mode. The full MS 
spectra were acquired in positive mode within a range of 400-1800 m/z. The top four 
most intense ions in the acquired full mass scan were selected for followed pulsed Q 
dissociation (PQD) in LTQ. The Q activation and time was set respectively at 0.7 and 0.1 
ms. The maximum ion injection times used were 50 ms for the MS scan and 120 ms for 
73 
 
the MS/MS scans. The automatic gain control target settings were 3.0 x104 for the MS 
scan mode and 1.0 x 104 for the MS/MS scan mode. One microscan of full MS was 
performed. The normalized collision energy was 29.5% and the isolation window 
employed was 2 m/z. The dynamic exclusion settings utilized were repeat count 2, 
exclusion duration 25 s, exclusion list size 500, exclusion mass width low 0.5 and 
exclusion mass width high 1.5.  
3.4.7 Protein Identification and Quantification 
The LC-MS/MS raw data from nanoLC-LTQ were correlated to theoretical 
fragmentation patterns of tryptic peptide sequences in bovine protein fasta database using 
SEQUESTTM search engine embedded in Proteome Discoverer (version 2.1; Thermo 
Fisher Scientific). The search parameters included were as follows: fixed cysteine 
modifications of +57 Da for carbamidomethyl-cysteines, +144  Da for lysine-iTRAQ 
labeling and N-terminal peptides;  dynamic modifications allowing +16 with methionines 
for methionine sulfoxide and + 144 Da for Y-iTRAQ labeling; restricted to trypsin 
digested peptides and allowed for two missed cleavages; precursor mass range was 350-
5000 Da; peptide mass tolerance of 2.5 Da and fragment mass tolerance of ±0.8 Da; 
target FDR strict was 0.01 and FDR relaxed was 0.05; most confident centroid was 
selected for peak integration method and a 0.25 Da integration window tolerance was 
allowed. The proteins matched with at least one unique peptide at minimum 95% 
confidence (FDR < 5%) were considered positive identifications.  
The relative quantification of proteins in the samples was performed with the 
Proteome Discover (1.2). The quantification utilized the relative peak intensities of the 
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iTRAQ reporter ions derived from MS/MS spectra of all unique peptides that represented 
each protein. iTRAQ ratios of the reporter ions were calculated using reporter ions 
representing any two samples. The final ratios obtained from the relative protein 
quantifications were normalized according to the median protein quantification ratio to 
reduce experimental bias. The protein ratios were the median ratio of the corresponding 
peptide ratios. To determine protein expression levels, a fold change of >2.0 or <0.5 
between any two samples were respectively set for up- and down-regulated proteins. 
Functional analysis was performed for all identified proteins and for up- and down-
regulated proteins. 
 3.4.8 Bioinformatic Analysis of Identified Proteins 
The PANTHER (Protein Analysis Through Evolutionary Relationships) 
classification system123 was used to categorize the up- and down regulated proteins based 
on their molecular function (MF), biological process (BP), and cellular component 
(CC)/localization. Similar PANTHER analysis of all identified proteins in PL and FF are 
shown in Appendix 3.  Pathway analysis was performed using the Database 
for Annotation, Visualization, and Integrated Discovery (DAVID)124. Pathway plot was 
derived using Kyoto Encyclopedia of Genes and Genomes (KEGG)125.  Protein-protein 
intereactiosn were annotated using Search Tool for the Retrieval of Interacting 
Genes/Proteins (STRING)126 database. 
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3.5  RESULTS 
 3.5.1 General information on iTRAQ Analysis 
The overview of our iTRAQ-based SCX nano-LC/MS/MS ESI PQD method for 
analyzing the proteomes in bovine PL and FF is show in Figure 1. A total of 231 proteins 
matched to 793 unique peptides were identified with high confidence (FDR of 5% or 
less) and were subsequently included in further analysis. Details of all 231 identified 
proteins are shown in Appendix Table 1. Approximately 61% (140/231) of proteins were 
Reduction, alkylation, 
digestion 
4-plex mixture 
iTRAQ label 114 
Quantification and 50 
µg protein aliquot 
Plasma LE2 (n=5) Plasma HE2 (n = 4) FF LE2 (n=5) FF HE2 (n = 4) 
Depletion of HAPs Depletion of HAPs Depletion of HAPs Depletion of HAPs 
Quantification and 50 
µg protein aliquot 
Quantification and 50 
µg protein aliquot 
Quantification and 50 µg 
protein aliquot 
Reduction, 
alkylation, digestion 
Reduction, alkylation, 
digestion 
Reduction, alkylation, 
digestion 
iTRAQ label 115 iTRAQ label 116 iTRAQ label 117 
SCX and nanoLC-MS/MS 
Data analysis (Protein identification and quantification) 
Figure 3.1. Overview of workflow for identification and relative quantification of proteins in 
bovine plasma and follicular fluid containing high and low pre-ovulatory levels of E2. 
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identified by one unique peptide and ~39% by at least 2 up to 47 unique peptides (Figure 
3.2.A). About a third of proteins identified by one unique peptide were identified at 99% 
confidence. Analysis of the distribution of the sequence coverage (Figure 3.2.B) of the 
detected peptides of the proteins found ~53% (123/231) of identified proteins had greater 
than 5% coverage. Protein pI values ranged from 4.41 to 11.05 (Figure 3.2.C).  The 
molecular mass of the identified proteins ranged from 10.3 to 3811.5 kDa with majority 
of the proteins (~60%) between 20 to 80 kDa (Figure 3.2.D). Several of the proteins 
identified herein have been previously reported as components of bovine PL and/or FF40, 
127.   
3.5.2 Comparative Analysis of Protein Expression in Plasma and Follicular Fluid 
Paired comparisons were made to determine differences in protein expression 
between any two samples. Figure 3.3 depicts the different paired comparisons and the 
number of up- and down-regulated proteins obtained in each analysis. Up- and down-
regulated proteins were determined using a ratio fold-change of >2.0 or <0.5 between any 
two samples. Comparison between same fluid type (i.e. high and low of PL or FF) 
revealed nine down-regulated and seven up-regulated proteins in PL HE2 compared to 
PL LE2 and 10 down-regulated and 15 up regulated proteins in  FF HE2 compared to  FF 
LE2. Comparison between PL and FF showed more proteins up-regulated in PL 
compared to FF. Each PL and FF pair, (i.e. PL LE2 and FF LE2; PL HE2 and FF HE2) 
revealed 51 up-regulated proteins in PL. 21 proteins were down-regulated in  PL LE2 
compared to FF LE2 whereas 27 proteins were down-regulated in the  PL HE2 compared 
to the FF HE2. 39 up-regulated proteins and 11 down-regulated proteins were commonly 
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identified from both PL and FF paired analyses. Overlaps of numbers of proteins from 
the different paired comparisons are depicted in Figure 3.4 and the protein details in each 
pair are reported in Table 3.1. 
The fold change, i.e. iTRAQ ratio value of a protein, is indicative of the extent of 
up- or down-regulation of the protein in a sample. iTRAQ ratios of up- and down-
regulated proteins in PL compared to FF ranged from 2.017 to 27.247 and 0.036 and 
0.499 respectively. NADH dehydrogenase (ubiquinone) 1 beta subcomplex subunit 11 
mitochondrial (NDUFB11), dpy-19 like 4 (DPY19L4), apolipoprotein B (APOB), 
cytohesin 1 (CYTH1), delta-like protein (JAG1), and gametocyte-specific factor 1-like 
(GTSF1L) were among the top up-regulated proteins whereas versican core protein 
(VCAN), inhibin alpha chain (INHA), serglycin (SRGN),  protein tyrosine phosphatase 
receptor type R protein (PTPRR), and dynein heavy chain domain 1 (DNHD1) were 
among the top down-regulated proteins in PL compared to FF.  
Protein predominance in the HE2 sample was higher after FF HE2/FF LE2 
comparison than the PL HE2/PL LE2 (respectively 2.08-6.21 and 2.00-3.71 fold change). 
Comparison of FF HE2 to FF LE2 identified keratin type II cytoskeletal 7 (KRT7), serum 
albumin (ALB), and cytokine receptor-like factor 3 (CRLF3) as the top three up-
regulated proteins and hemoglobin subunit alpha (HBA), hemoglobin subunit beta 
(HBB), and ubiquitin protein ligase E3 component n-recognin 4 (UBR4) as the top three 
down-regulated proteins in the  FF HE2. Suppressor of G2 allele of SKP1 
homolog(SUGT1), C8G protein (C8G), and SRGN were the top three up-regulated 
proteins and DDB1 and CUL4 associated factor 5 (DCAF5),  transmembrane protein 186
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Figure 3.2. General information on 231 proteins identified by the itraq-based scx nano-LC-MS/MS 
ESI PQD method with high confidence. (A) Number of unique peptides of the identified proteins; (B) 
Distribution of protein sequence coverage; (C) Distribution of protein pI values. (D) Distribution of protein 
molecular weights. 
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 (TMEM186), and HP the top three down-regulated proteins in PL HE2 compared to  PL 
LE2. Seven proteins were commonly found from PL HE2/ PL LE2 and FF HE2/FF LE2 
analyses: SUGT1, engulfment and cell motility 1 (ELMO1) and family with sequence 
similarity 81 member A (FAM81A) had opposite expressions in either fluid; KRT7 was 
up-regulated and immunoglobulin lambda-like polypeptide 1 (LOC100297192), HP and 
TMEM186 were down-regulated in the HE2 samples compared to the respective LE2 
samples of either fluid type.  
3.5.3 Functions of Identified Proteins 
To determine the functions of all proteins showing expression changes, the up- 
and down-regulated proteins derived from all paired analyses were compiled (103 in 
total) and functional analysis performed using PANTHER classification system. The up- 
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Figure 3.3. The number of up- and down regulated proteins (y-axis) after 
comparisons between any two samples (x-axis). The number of proteins in each 
category is shown on the bar.  PL HE2: Plasma high E2; PL LE2: Plasma low E2; FF 
HE2: Follicular fluid high E2; FF LE2: Follicular fluid low E2.   
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and down-regulated proteins were categorized into 4 MF, 11 BP, and 7 CC (Figure 3.5). 
The major MF were binding (52%) and catalytic activity (40.0%). The BP categorized 
were  cellular component organization or biogenesis (6.8%), cellular process (33.3%), 
localization (6.8%), biological regulation (6.8%), response to stimulus (5.1%), 
developmental process (6.8%), multicellular organismal process (6.0%), biological 
adhesion (4.3%), locomotion (0.9%), metabolic process (20.5%), and immune system 
process (2.6%).  The CC analysis revealed majority of the up- and down-regulated 
proteins were localized in the cell (31.8%), the extracellular region (22.7%), and 
organelle (21.2%). Panther classification for all identified proteins is shown in Appendix 
3. 
 
 
 
 
 
 
 
 
 
 
 
A B 
 
Figure 3.4. Overlap of number of up-regulated (a) and down- regulated (b) proteins in 
Pl and FF after paired analyses. PL HE2: Plasma high E2; PL LE2: Plasma low E2; FF 
HE2: Follicular fluid high E2; FF LE2: Follicular fluid low E2. Details of proteins 
from each paired analysis are shown in Table 3.1. 
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 3.5.4 Enriched Pathways 
DAVID was used to determine the pathways associated with the up- and down-
regulated proteins in PL and FF. The databases within the DAVID platform searched 
were KEGG and Reactome 128 databases. Results from KEGG showed the complement 
and coagulation cascades were enriched (p = 3.5 x 10-14); Figure 3.6.  The search in 
Reactome supported these enriched pathways by identifying platelet degranulation (p 
=8.2 x 10-9), intrinsic pathway of fibrin clot formation (p = 1.4 x 10-5), common pathway 
of fibrin clot formation (p = 2.4 x 10-4), scavenging of heme from plasma (p = 6.0 x 10-3), 
and terminal pathway of complement (p = 5.7 x 10-2) as the main pathways. 
3.6 DISCUSSION 
Proteomic workflows utilizing iTRAQ labeling allows for the simultaneous high- 
throughput identification and quantification of proteins. In this study, 4plex iTRAQ 
reagents were used to label PL and FF samples containing high or low concentrations of 
E2 (HE2 or LE2).  Ovaries of all cows were examined by transrectal ultrasonography and 
FF was subsequently aspirated from the DF. Blood was collected at slaughter. To reduce 
the masking effect of HAPs and matrix effect due to sample complexity, the samples 
were first subjected to an immunodepletion method which dramatically depleted targeted 
HAPs ALB, IgG, IgA, and alpha-1-antitrypsin. Subsequent steps in the workflow for the 
analysis included reduction, alkylation, and digestion of the plasma and FF proteins prior 
to labelling with the iTRAQ reagents. The iTRAQ-labeled peptides from each of the four 
samples were mixed at an equal mass ratio. The samples were then analyzed with off-line 
SCX and nanoLC-ESI-LTQ (PQD) method. Our approach enabled us to quantitatively 
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Table 3.1 Identified Up- and Down- regulated proteins in plasma and follicular fluid containing high or low pre-ovulatory E2   
Protein Description 
Uniprot 
Accession 
Gene ID 
 
PL HE2/ 
PL LE2 
 
FF HE2/ 
FF LE2 
PL LE2/ 
FF LE2 
   PL HE2/ 
FF HE2 
   
iTRAQ Ratio 
(A) Up-regulated proteins 
     
2-acylglycerol O-acyltransferase 3 (Fragment) E1BN30 LOC618076 
  
5.370 3.971 
Alpha-2-macroglobulin Q7SIH1 A2M 
  
6.965 7.617 
Ankyrin repeat and KH domain containing 1 G3MZJ0 ANKHD1 
  
5.482 7.516 
AP complex subunit beta F6PZ41 AP4B1 
   
2.144 
Apolipoprotein B E1BNR0 APOB 
 
2.340 11.669 7.312 
Apolipoprotein R G3N0S9 LOC515150 
  
5.234 4.912 
ApoN protein Q2KIH2 ApoN 
   
2.809 
Asparagine-linked glycosylation 5, dolichyl-
phosphate beta-glucosyltransferase homolog (S. 
cerevisiae) 
Q2KIM7 ALG5 
  
2.103 3.265 
ATP binding cassette subfamily B member 9 E1BKR0 ABCB9 
 
2.075 7.448 3.384 
B double prime 1, subunit of RNA polymerase III 
transcription initiation factor IIIB 
F1MEB1 BDP1 
  
5.131 2.928 
C8G protein A8YXZ2 C8G 3.000 
   
CAD protein F1MVC0 CAD 2.359 
   
CCDC80 protein A5PKA3 CCDC80 2.007 
 
6.742 
 
Cell adhesion molecule 1 Q2TBL2 CADM1 
  
2.680 2.187 
Coagulation factor V F1N0I3 F5 
  
2.323 
 
Coagulation factor XII F1MTT3 F12  2.418   
Coagulation factor XIII A chain F1MW44 F13A1 
  
3.170 2.328 
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Table 1. Continued  
Protein Description 
Uniprot 
Accession 
Gene ID 
 
PL HE2/ 
PL LE2 
 
FF HE2/ 
FF LE2 
PL LE2/ 
FF LE2 
   PL HE2/ 
FF HE2 
   
iTRAQ Ratio 
Cohesin subunit SA-3 E1B9B0 STAG3   3.175 5.194 
Complement C1s subcomponent Q0VCX1 C1S   3.884 6.060 
Conglutinin P23805 CGN1   3.279 3.521 
Cumulus cell-specific fibronectin 1 transcript variant B8Y9T0 FN1   2.620 2.334 
Cytochrome P450 20A1 Q5E980 CYP20A1  2.484 8.593 4.068 
Cytohesin 1 (Fragment) F1MCV3 CYTH1   5.453 15.900 
Cytokine receptor like factor 3 E1BCF2 CRLF3  3.048   
Delta-like protein E1BDN7 JAG1    13.738 
Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase subunit 1 
F1MJ36 LOC539818    2.280 
Dpy-19 like 4 (Fragment) F1MJJ1 DPY19L4   16.517 12.811 
DUOXA1 protein A6H723 DUOXA1  2.751 5.914  
Dynein heavy chain domain 1 F1MEF7 DNHD1  2.972   
E3 ubiquitin-protein ligase CHIP F1MUH4 STUB1   2.322 2.360 
Engulfment and cell motility 1 F1MQH0 ELMO1 2.133   2.514 
EPS8 like 1 E1BKS0 EPS8L1   2.727 2.352 
Family with sequence similarity 81 member A F1N4N5 FAM81A  2.279 2.035  
Fas activated serine/threonine kinase F1N4L0 FASTK   2.724  
FGG protein Q3SZZ9 FGG   6.258 4.117 
Fibrinogen alpha chain A5PJE3 FGA   9.225 5.720 
Fibrinogen beta chain F1MAV0 FGB   7.909 4.895 
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Table 1. Continued 
Protein Description 
Uniprot 
Accession 
Gene ID 
 
PL HE2/ 
PL LE2 
 
FF HE2/ 
FF LE2 
PL LE2/ 
FF LE2 
   PL HE2/ 
FF HE2 
   
iTRAQ Ratio 
Fibulin-1 F1MYN5 FBLN1   2.488 2.276 
Gametocyte-specific factor 1-like Q3T026 GTSF1L   8.291 10.840 
HEAT repeat containing 5B E1BB26 HEATR5B    3.123 
HECT domain E3 ubiquitin protein ligase 2 F1N7A0 HECTD2   2.196 2.908 
Homeobox D3 E1B856 HOXD3 
  
2.453 
 
Keratin, type II cytoskeletal 7 Q29S21 KRT7 2.271 6.209 
  
KRAS proto-oncogene, GTPase E1BMX0 KRAS    2.192 
Kruppel like factor 17 (Fragment) G3N1K6 KLF17    2.915 
Lumican Q05443 LUM  2.904   
Lysine methyltransferase 2C (Fragment) F1MYZ3 KMT2C   3.774 3.229 
NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex assembly factor 4 
A4FUH5 NDUFAF4   5.033 4.573 
NADH dehydrogenase [ubiquinone] 1 beta 
subcomplex subunit 11, mitochondrial 
Q8HXG5 NDUFB11   27.247 23.059 
NIMA (Never in mitosis gene a)-related kinase 2 Q2KIQ0 NEK2  2.215   
Ornithine decarboxylase 1 E1BG69 ODC1   4.726 4.681 
Pantothenate kinase 3 Q08DA5 PANK3   5.058 4.976 
Phosphoglycolate phosphatase Q2T9S4 PGP    2.091 
Protocadherin Fat 2 precursor (Fragment) F1MPF3 -  2.807   
Regulating synaptic membrane exocytosis 2  
(Fragment) 
E1B7V2 RIMS2  2.480 2.125  
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Table 1. Continued 
Protein Description 
Uniprot 
Accession 
Gene ID 
 
PL HE2/ 
PL LE2 
 
FF HE2/ 
FF LE2 
PL LE2/ 
FF LE2 
   PL HE2/ 
FF HE2 
   
iTRAQ Ratio 
Serglycin (Fragment) G5E5K5 SRGN 2.929    
Serum albumin P02769 ALB  5.960   
SH3 domain and tetratricopeptide repeats 1 G3MZW4 SH3TC1   2.137  
Sodium/glucose cotransporter 1-like (Fragment) G3MXJ0 LOC531152    3.779 
Sphingomyelin phosphodiesterase 5 (Fragment) F1N6X9 SMPD5   2.017  
Suppressor of G2 allele of SKP1 homolog Q2KIK0 SUGT1 3.741    
Synaptonemal complex protein 1 E1BLN1 SYCP1   5.469 5.407 
Synaptotagmin 12 E1BEH9 SYT12   4.194  
Titin F1N757 TTN 
   
2.320 
Trans-2-enoyl-CoA reductase, mitochondrial Q7YS70 MECR 
  
10.791 4.597 
Transcription factor 7-like 2 G3N0T7 - 
  
2.519 
 
Transcription initiation factor TFIID subunit 
(Fragment) 
F1MF62 TAF1 
  
3.579 2.963 
Transthyretin O46375 TTR 
 
2.403 3.208 
 
Uncharacterized protein E1BPG1 - 
   
2.677 
Uncharacterized protein F1MI18 - 
  
2.848 2.311 
Uncharacterized protein (Fragment) G3X6V5 - 
  
5.022 12.917 
Vacuolar protein sorting-associated protein 28 
homolog 
E1BIB3 VPS28 
  
6.898 8.348 
Von Willebrand factor A domain containing 5B1 E1BB39 VWA5B1 
  
2.316 2.377 
Zinc finger SWIM-type containing 3 (Fragment) F1MTI1 ZSWIM3 
  
3.527 2.750 
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Table 1. Continued 
Protein Description 
Uniprot 
Accession 
Gene ID 
 
PL HE2/ 
PL LE2 
 
FF HE2/ 
FF LE2 
PL LE2/ 
FF LE2 
   PL HE2/ 
FF HE2 
   
iTRAQ Ratio 
Zona pellucida binding protein 2 Q0VCG8 ZPBP2   5.962 5.099 
 
(B ) Down-regulated proteins 
      
Alpha-1-antiproteinase P34955 SERPINA1   0.392 0.201 
C8G protein A8YXZ2 C8G   0.289  
CAD protein F1MVC0 CAD   0.332  
Chromosome 14 open reading frame 166 ortholog Q3T0S7 RTRAF    0.467 
Complement component C6 F1MM86 C6    0.496 
Cytohesin 1 (Fragment) F1MCV3 CYTH1  0.341   
DDB1 and CUL4 associated factor 5 F1N0J7 DCAF5 0.043    
Dynein axonemal heavy chain 11 F1N724 DNAH11 0.263 
  
0.492 
Dynein heavy chain domain 1 F1MEF7 DNHD1   0.493 0.036 
Endophilin-A2 Q2KJA1 SH3GL1   0.384 0.478 
Engulfment and cell motility 1 F1MQH0 ELMO1  0.372 0.453  
Factor XIIa inhibitor precursor E1BMJ0 SERPING1   0.434 0.472 
Family with sequence similarity 81 member A F1N4N5 FAM81A 0.283   0.245 
Fas activated serine/threonine kinase F1N4L0 FASTK 0.396    
Filamin B E1BKX7 FLNB   0.471  
Gasdermin B F1MCQ4 GSDMB   0.479 0.439 
Haptoglobin G3X6K8 HP 0.211 0.351   
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Table 1. Continued 
Protein Description 
Uniprot 
Accession 
Gene ID 
 
PL HE2/ 
PL LE2 
 
FF HE2/ 
FF LE2 
PL LE2/ 
FF LE2 
   PL HE2/ 
FF HE2 
   
iTRAQ Ratio 
HECT, UBA and WWE domain containing 1, E3 
ubiquitin protein ligase 
E1BNY9 HUWE1    0.305 
Hemoglobin subunit alpha P01966 HBA  0.115 0.200  
Hemoglobin subunit beta P02070 HBB  0.177 0.261  
Immunoglobulin lambda-like polypeptide 1 F1MLW7 LOC100297
192 
0.242 0.433  0.499 
Immunoglobulin lambda-like polypeptide 1 
(Fragment) 
G3N2D7 LOC100297
192 
0.401    
Inhibin alpha chain P07994 INHA   0.079 0.062 
Keratin, type II cytoskeletal 7 Q29S21 KRT7    0.491 
Leucine rich repeat kinase 2 E1BPU0 LRRK2    0.422 
Lumican Q05443 LUM    0.469 
NIMA (Never in mitosis gene a)-related kinase 2 Q2KIQ0 NEK2    0.453 
Plasma serine protease inhibitor Q9N2I2 SERPINA5   0.353  
Protocadherin Fat 2 precursor (Fragment) F1MPF3 - 
   
0.360 
PTPRR protein A5PKF8 PTPRR   0.102  
Serglycin (Fragment) G5E5K5 SRGN   0.036 0.177 
Serpin family E member 2 F1MZX2 SERPINE2    0.140 
Serpin peptidase inhibitor, clade A (alpha-1 
antiproteinase, antitrypsin), member 3 
G8JKW7 SERPINA3 0.446   0.422 
Serum albumin P02769 ALB   0.302 0.073 
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Table 1. Continued 
Protein Description 
Uniprot 
Accession 
Gene ID 
 
PL HE2/ 
PL LE2 
 
FF HE2/ 
FF LE2 
PL LE2/ 
FF LE2 
   PL HE2/ 
FF HE2 
   
iTRAQ Ratio 
SPHK1 interactor, AKAP domain containing 
(Fragment) 
F1MZL5 SPHKAP    0.475 
Suppressor of G2 allele of SKP1 Q2KIK0 SUGT1  0.476 0.200  
TBC1 domain family member 4 E1BPA1 TBC1D4   0.315 0.334 
Transmembrane protein 186 Q5EA03 TMEM186 0.193 0.435  0.394 
Transthyretin O46375 TTR    0.257 
Ubiquitin protein ligase E3 component n-recognin 4 G3N0A8 UBR4  0.328   
Versican core protein F1N6I7 VCAN   0.129 0.331 
Vitamin D-binding protein F1N5M2 GC  0.393 0.330  
Zinc finger protein 618 E1BJV7 ZNF618   0.309 0.201 
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 measure and compare the proteomes in PL and FF containing high- and low-circulating 
levels of E2 during the pre-ovulatory period. Quantitative measurement of protein 
changes can confirm and/or provide better understanding of the protein’s functions. 
E2 is critical to the development and maturation of ovarian follicles115, 117. 
Concentration of E2 in PL and/or FF has been positively correlated to increased oocyte 
Figure 3.5. Panther analysis of up- and down-regulated proteins identified in bovine 
plasma (Pl) and follicular fluid (FF) containing low and high pre-ovulatory E2. The 
up- and down- regulated proteins were compiled from PL HE2/PL LE2, FF HE2/FF LE2, PL 
LE2/FF LE2 and PL HE2/FF HE2 analyses.  Proteins were classified according to (A) 
Molecular function (B), Cellular localization, and (C) Biological processes. 
90 
 
quality, fertilization and subsequent embryo quality129,  increased follicle size118, and 
improved pregnancy success130. Considering the vital role of proteins in cell function and 
regulation, this study thus examined the associations between E2 and protein expressions 
in FF and PL, because of the significant similarities between PL and FF proteins which 
results from the number of PL proteins capable of crossing the blood-follicular barrier 
during folliculogenesis131, 132.  
A total of 103 proteins significantly changed expression in the presence of E2 as 
defined by fold change. To determine a more direct influence of concentration of E2 on 
PL or FF proteome, high and low E2 in PL or FF were compared. The number and degree 
of fold change of proteins from the comparison between high and low E2 in FF was 
higher than the corresponding PL comparison.  This suggests pre-ovulatory circulating 
concentration of E2 has a greater impact on FF proteome than on PL proteome. This is 
not surprising as E2 is produced by the GCs of ovarian follicles116, 133 and FF is the 
immediate environment of the developing follicle and oocyte. The only predominant 
protein in PL HE2 which was also predominant in the FF HE2 when compared to the 
respective LE2 samples was KRT7 (keratin, type II cytoskeletal 7), a member of the 
keratin gene family. E2 seems to have a higher influence on KRT7 expression in FF than 
in PL evidenced by the higher fold change in FF (6.21 vs 2.27). The greater effect of E2 
on KRT7 in FF is further supported when PL and FF were compared. There was no 
observable fold change in KRT7 from PL LE2 and FF LE2 comparison but KRT7 was 
down-regulated in PL HE2 compared to FF HE2. The function of KRT7 is reported to be 
building structure integrity within complexes. Keratin genes are usually expressed in 
pairs consisting of one type I and one type II as both are necessary to for an intermediate 
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filament134, 135.  The presented data supports KRT7 involvement in developing follicles 
and possibly eliciting similar structural functions modulated by E2 in FF.  
Successful folliculogenesis requires adequate regulation of cellular apoptosis.  
ELMO1 promotes cellular apoptosis136. Specifically, ELMO1 is involved in cytoskeletal 
rearrangements required for phagocytosis of apoptotic cells and cell motility137. Very few 
apoptotic cells were found in primordial, primary, secondary and vital tertiary follicles. In 
contrast, apoptosis in atretic tertiary follicles was much more frequent138. Our observation 
of down-regulation of ELMO1 in FF HE2 compared to FF LE2 is therefore in support of 
decreased apoptosis in the pre-ovulatory follicle. The suppression of ELMO1 in the 
presence of E2 at the pre-ovulatory stage seems more localized in FF since it was more 
predominant in PL HE2 when compared to PL LE2.  
Proteins were more predominant in PL compared to FF which supports the 
hypothesis that several FF proteins originate from PL113. It should be noted that proteins 
down-regulated in PL compared to FF indicate their predominance in FF and possibly a 
more localized role in FF. A greater number of proteins showed expression change in the 
comparisons between PL and FF than between high and low E2 PL or FF comparisons.  
This is likely due to the inherent differences between PL and FF. The majority (50 out of 
72 or 78) of these proteins was common to the different comparisons between PL and FF 
and maintained their expressions (i.e. being up- or down-regulated) regardless of the E2 
level. Although the expressions for these common proteins did not change, individual 
iTRAQ ratios were generally lower for up-regulated proteins and higher for down-
regulated proteins after PL HE2 and FF HE2 paired comparison than PL LE2 and FF LE2 
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paired comparison. This further suggests a greater stimulating effect of high E2 on FF 
proteins such that the concentration difference of these proteins in PL and FF is lower 
resulting in lower up-regulated iTRAQ ratios and higher down-regulated iTRAQ ratios 
for the HE2 pair. Twenty-six out of 39 up-regulated proteins and 5 out of 11 down-
regulated proteins which were common to the different PL and FF paired comparisons 
showed this trend.  Common up-regulated proteins showing this trend included FGA, 
FGB, FGG, cumulus cell-specific fibronectin 1 transcript variant (FN1), apolipoprotein B 
(APOB), A2M, complement C1s subcomponent (C1S), and fibulin-1 (FBLN1). Common 
down-regulated proteins with this trend were F13A1, VCAN, endophilin-A2 (SH3GL1), 
SRGN, and TBC1 domain family member 4 (TBC1D4). 
PANTHER analysis revealed the up- and down-regulated proteins had 
multifunctional roles but cellular process and metabolic process were the major functions. 
Developing ovarian follicles undergo a series of coordinated cellular processes that 
induce morphological and functional changes within the follicle, leading to cell 
differentiation and oocyte development139. Further analysis in PANTHER showed the 
proteins under cellular function were involved in cell communication (52.4 %), cellular 
component movement (23.8%), cell growth (4.8%), cell cycle (14.3%), and chromosome 
segregation (4.8%). Coordinated communications between the granulosa, cumulus and 
thecal cells, and as well as the oocytes are critical for successful folliculogenesis and the 
development of an oocyte capable for ovulation and fertilization140. Of these 
communication between the oocyte and GCs is considered the most significant for 
growth regulation and maturation of the oocyte and follicular luteinization. The proteins 
linked to cell communication included INHA, FN1, FGG, FGB, lumican (LUM), 
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synaptotagmin-12 (SYT12), regulating synaptic membrane exocytosis 2 (RIMS2), and 
KRAS proto-oncogene, GTPase (KRAS). These proteins play vital roles in follicle 
growth and maturation. 
Folliculogenesis is highly regulated by gonadotropins and sex hormones. The 
secretions of these hormones are in turn regulated by a number of proteins. INHA is one 
such protein involved in the regulation of FSH secretion. Specifically, INHA selectively 
inhibits FSH secretion from the pituitary in a negative-feedback mechanism141. The 
decline in FSH continues to a level that is only able to be utilized by the largest follicle 
thereby enhancing its growth to become the DF. The inability of smaller follicles to 
utilize the low levels of FSH results in regression of their growth to become subordinate 
follicles142, 143.  INHA was found highly down-regulated in PL compared to FF with 
lower expression in the high E2 pair (PL HE2/FF HE2; iTRAQ ratio 0.062) than the low 
E2 pair (PL LE2/FF LE2; iTRAQ ratio 0.079). The high INHA concentration in FF from 
DF and with high E2 is consistent to the vital roles of INHA and E2 in the decline of FSH 
observed during follicular deviation142, 143. Apart from its role in regulating FSH 
secretion, INHA is also a critical regulator of different cellular processes including 
differentiation, cell migration, proliferation, and apoptosis144. 
SYT12 is another protein involved in regulation of hormonal secretion during 
follicular growth. It belongs to synaptotagmin family that serve as Ca2+ sensors for Ca2+ 
triggered release of hormones, including FSH from the pituitary gland145. RIMS2 is also 
involved in synaptic membrane exocytosis that results in the release of neurotransmitters. 
It functions by binding to pre-synaptic proteins including synaptotagmin 1 (SYT1), an 
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isoform of SYT12146, 147. SYT12 and RIMS2 were up-regulated in PL LE2 compared to 
FF LE2. RIMS2 was also up-regulated in FF HE2 compared to FF LE2. The expression 
changes in both proteins indicate their   involvement in follicle development.   
The proteins FN1, FGB, FGG, and apolipoprotein R were up-regulated in PL compared 
to FF but iTRAQ ratios indicate concentration increases in these proteins in FF with high 
E2 compared to low E2, signifying an influence of  E2 on these proteins. These proteins 
promote cellular processes by binding to a variety of cells and molecules. Indeed all five 
proteins were classified under biological adhesion by PANTHER. Cell adhesion leads to 
alterations in cell shape and motility that are required for different cellular functions 
during folliculogenesis and the development of a competent oocyte148, 149. Cell shape was 
reported to regulate cell proliferation in mouse GCs150 and steroidogenesis in rat GCs151. 
FN1 and fibrinogen have been reported to increase proliferation in a number of cells. 
Specifically, FN1 has been reported to stimulate proliferation of ovarian GCs152. Fibrin 
matrix composed of fibrinogen and thrombin has also been reported in the survival and 
proliferation of ovarian cells153 and promoted growth in primordial-primary follicles and 
secondary follicles. The growth to secondary follicles was greater compared to 
primordial-primary follicle growth154. Successful ovulation and capture of the oocyte by 
the oviduct and subsequent transport through the oviduct necessitates formation and 
expansion of the cumulus cell-oocyte (COC) matrix155. Stabilization and expansion of the 
COC matrix involves binding of several proteins including FN1, VCAN, and laminin 156.
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Figure 3.6.  Up-regulated (red) and down-regulated (pink) proteins involved in the complement and coagulation 
cascades identified in this study. Up- and down-regulated in plasma (PL) compared to follicular fluid (FF): Alpha-2-
macroglobulin (A2M), coagulation factor V (F5), coagulation factor XIII A chain (F13), complement C1s (C1S), 
complement C6 (C6), alpha-1-antiproteinase  (A1AT or SERPINA1), plasma serine protease inhibitor (PCI or 
SERPINA5), factor XIIa inhibitor precursor (C1INH or SERPING1), complement C8 gamma chain (C8G; this was also 
up-regulated in PL HE2 compared to PL LE2), and fibrinogen (fibrinogen alpha chain (FGA), fibrinogen beta chain 
(FGB), and fibrinogen gamma chain (FGG)). Fibrinogen is a ligand of complement receptor types 3 and 4 (CR3 and CR4; 
orange). Up-regulated in FF HE2 compared to FF LE2: Coagulation factor XII (F12).  
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Follicle development involves independent movements of cells and cellular 
components to sites of action and to enable interaction with other relevant molecules.  
Proteins with this function were categorized under cellular component movement, a sub-
set of cellular process. The proteins were AKAP domain containing SPHKAP 
(SPHKAP), dynein axonemal heavy chain 11 (DNAH11), DNHD1, ELMO1, and LUM. 
LUM is a widely distributed protein involved in different biological functions. 
Accordingly, LUM was categorized in 7 out of the 12 BP hererin: cellular process, 
biological regulation, cellular component organization or biogenesis, developmental 
process, locomotion, multicellular organismal process, and response to stimulus. LUM 
was up-regulated in FF HE2 compared to FF LE2, indicating a positive association with 
E2 in FF. This positive association is further supported by the PL and FF comparisons 
where LUM was down-regulated in PL HE2 compared to FF HE2 but showed no 
significant expression change from the low E2 comparison.  
Metabolic process was the second most associated BP. Primary metabolic process 
formed 46.7% of the metabolic processes which in turn was comprised of protein 
metabolism (48%) and nucleobase-containing compound metabolic process (28%). 
Protein metabolism is integral to the growth and maturation of follicles, occurring in cells 
including granulosa, cumulus, and thecal cells and the developing oocyte157. Protein 
synthesis competence, patterns, and rate in somatic cells and oocytes can be used as a 
measure of maturation of the follicles158, 159.  Proteins associated with protein metabolism 
in the current study were A2M, dpy-19 like 4 (DPY19L4), vacuolar protein sorting-
associated protein 28 homolog (VPS28), HP, E3 ubiquitin protein ligase HUWE1 
(HUWE1),  F13A1, Asparagine-linked glycosylation 5 (ALG5),  dolichyl-
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diphosphooligosaccharide-protein glycosyltransferase subunit 1 ( RPN1),  INHA, 
phosphoglycolate phosphatase (PGP), and transcription initiation factor TFIID subunit 
(TAF1).  
The protein A2M was predominant in PL compared to FF irrespective of high or 
low E2 levels. The lower concentration in FF than in PL is consistent to previous 
report160. However, concentration of A2M increases with follicle growth, promoted by its 
secretion by GCs and thecal cells160. A2M is involved in metabolic processes as well as 
regulating E2 production and follicular development via binding to a wide range of  
reproductive related targets  including inhibin, activin, transforming growth factor β and 
α (TGFβ, TGFα), and insulin-like growth factors to regulate their functions161-163. 
Another important metabolic protein is ALG5, which is involved in the formation of the 
COC matrix. The predominant component of the COC matrix is glycosaminoglycan 
hyaluronan (HA)140. Glycosylation of amino acids is therefore an important metabolic 
process in follicle maturation. ALG5 participates in the synthesis of oligosaccharides for 
asparagine-linked glycosylation. Concentration of ALG5 increased in FF and decreased 
in PL with high E2 than with low E2 but the expression changes were not significant 
(iTRAQ ratios 1.519 and 0.836 respectively). However, ALG5 significantly increased in 
PL when compared to FF (iTRAQ ratios 2.103-3.265). This observation shows a 
modulation of ALG5 by E2 in follicle growth. 
The immune system in the reproductive tract plays a critical role in 
simultaneously providing a protective microenvironment to support successful 
reproduction processes and conferring protection against potential pathogens. In fact, 
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folliculogenesis and ovulation are viewed as a hormone-induced inflammatory process164. 
Sex hormones, E2 and progesterone, significantly regulate the reproductive immune 
system cells, tissues, and molecules165.  This is supported by the results of this study by 
expression changes of immune-related proteins in the presence of high and low E2. 
Proteins relating to the immune system were categorized under response to stimulus- 
A2M, INHA, ankyrin repeat and KH domain containing 1 (ANKHD1), SPHK1 
interactor, AKAP domain containing (SPHKAP), LUM, and  Gasdermin-B (GSDMB);  
and immune system process- ANKHD1, immunoglobulin lambda-like polypeptide 1 
(LOC100297192) and apolipoprotein R (LOC515150).  
Follicuclogenesis is a developmental process that results in growth of primordial 
follicles into primary, secondary, and tertiary follicles. The proteins JAG1, VCAN, 
INHA, FBLN1, LUM, GSDMB, protocadherin Fat 2 precursor (FAT2), and titin (TTN) 
functions were classified under developmental process by PANTHER. Cell proliferation 
is key to the increase in size and transformation of follicles from one stage to the other. 
INHA and LUM promote cell proliferation. VCAN is a component of the extracellular 
matrix (ECM) of a variety of tissues. It forms large complexes with HA166 and in the 
ovary, binding to the HA of the COC matrix results in stabilization and expansion of the 
COC matrix156. VCAN also promotes cross-linking of the COC matrix by binding to 
several proteins including FBLN1 and FBLN2167. VCAN was up-regulated in FF 
compared to PL in the presence of low or high E2. 
A number of proteins were categorized under biological regulation. These 
proteins were identified mainly predominant in PL compared to FF. An example of such 
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proteins is ornithine decarboxylase (ODC1). ODC1 is the initial and rate-limiting step in 
the biosynthesis of polyamines required for growth, differentiation, and transformation of 
cells168. Inhibition of ODC1 with α-difluoromethylornithine (DFMO) was demonstrated 
to inhibit ovarian growth, the formation of graafian follicles, and the secretion of 
progesterone and E2 in immature mice. Administering of DFMO to adult cycling females 
on evening/night of proestrus markedly decreased plasma progesterone levels at diestrus 
which was linked to down-regulation of cytochrome cholesterol side-chain cleavage 
enzyme, steroidogenic factor 1,  and steroidogenic acute regulatory protein in the ovary 
and to a reduced vascularization of the corpora lutea169. Other proteins in the biological 
regulation category were SUGT1, SPHKAP, RIMS2, SYT12, LUM, CGN1, and 
epidermal growth factor receptor kinase substrate 8-like protein 1 (EPS8L1).  
Folliculogenesis involves proteins that transport and/or maintain substances 
including cells, cell components, metabolites, and proteins in specific locations of action. 
Proteins involved in this process were categorized under localization. Such proteins 
included GC and ALB. GC is the main protein involved in the transport of 25-
hydroxyvitamin D (25(OH)D), the precursor of the active form of vitamin D, and the 
recognized optimal indicator of vitamin D status. Vitamin D level is therefore 
predominantly contributed by GC level170, 171. Based on the free hormone hypothesis that 
protein-bound hormones are not biologically available and that unbound hormones are 
biologically active, down-regulation of GC as found in this study can indicate more 
bioavailable 25(OH)D170. Apart from its well-known role in bone morphology, vitamin D 
is increasing being viewed as vital for regulation of reproduction physiology. It has been 
positively associated with pregnancy, embryo implantation rate and IVF outcomes172 and 
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to reproductive steroid hormones173, 174. Our data asserts to a regulation of vitamin D by 
E2. 
ALB is a major component of PL and FF. Due to its abundance it was prior 
depleted to enable detection of lower abundant proteins. ALB transports a wide variety of 
substances including proteins, steroids, drugs, fatty acids, metabolites, hormones, and 
cations, facilitated by its multiple binding sites and longer circulatory half-life. ALB’s 
strong attraction to cations, its low molecular weight and its abundance enable it to play a 
central role in maintaining colloidal osmotic pressure (COP) that regulates the 
distribution of extracellular fluids between the vascular and extravascular 
compartments175, 176. STRING analysis of the up- and down-regulated proteins showed 
ALB had the highest interactions with other proteins (Figure 3.7) supporting ALB 
versatile role.  Identified proteins in this study that bind to ALB include GC, F13, HBA, 
C1S, apolipoprotein C-III (APOC3), and kininogen-2 (KNG2)177. 
Pathway analysis showed the complement and coagulation cascades were the 
predominant pathways, consistent with previous studies on FF40, 178. The stage of follicle 
development seems to regulate the proteins involved in coagulation pathway. Proteins 
involved in coagulation were found down-regulated in the pre-deviation, early deviation 
and pre-ovulatory stages and up-regulated in later deviation to post deviation stages40. 
Here, the coagulation and complement pathway involved 13 proteins showing different 
levels of expression changes, supporting a dependence on individual protein roles in the 
pathway. The predominance of the complement and coagulation cascades supports the 
view that the follicle development and ovulation are hemorrhagic and inflammatory- 
induced events.  
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Figure  3.7. Network of identified up- and down-regulated proteins in bovine PL 
and FF containing low and high concentration of estradiol during the pre-ovulatory 
stage. A total of 89 proteins are connected with 52 paired interactions annotated by 
STRING database. The highest number of interaction is seen with ALB, signifying the 
versatility of its function. There are no interaction among majority of the proteins which 
can suggest the independence and critical role each play in follicle growth and maturation. 
The relationships among proteins were derived from evidence from known interactions 
(from curated databases and experimentally determined), from predicted interaction (gene 
fusions, gene neighborhood and gene co-occurrence) and from other sources (textmining, 
co-expression and protein homology). These are shown in the legend with different colors. 
Details of the proteins are shown in Table 3.1. 
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The complement cascade and coagulation cascade are closely related and each 
activates the other in a reciprocal way.  For instance, activated platelets can activate the 
classical and alternative complement pathways. Thrombin, coagulation factors FIXa, 
FXa, FXIa, and plasmin can activate C3 and C5. F12a can activate C1qrs complex to 
activate the classical complement pathway. Conversely, mannan-binding lectin 
associated serine protease 2 (MASP-2) and the final stage complement complex C5b–9 
are able to generate thrombin through direct cleavage of prothrombin. Thrombin is a vital 
coagulation component that converts fibrinogen to fibrin. C5a promotes procoagulant 
activity by several actions on cells including inducing mast cell and basophil to switch 
from profibrinolytic to prothrombotic activities through the upregulation of the 
coagulation component plasminogen activator inhibitor-1 (PAI-1)179.  
F12 is the first component of the coagulation pathway and its activation triggers 
the intrinsic pathway of the coagulation system179. F12 was up-regulated in FF HE2 
compared to FF LE2, indicating a greater influence of E2 on F12 in FF. Five other 
proteins were down-regulated in PL compared to FF namely A1AT, PCI, C1INH, C6, 
and C8G. A1AT expression in FF HE2 was about double that in FF LE2 when compared 
to the corresponding PL samples. A1AT, C1INH, and PCI are protease inhibitors 
belonging to the SERPIN superfamily. The SERPINs regulate a wide range of proteins 
including those involved in the coagulation, fibrinolysis, and complement pathways180, 
181. Proteins in the coagulation and fibrinolytic system inhibited by A1AT include 
neutrophil elastase, activated protein C (APC), cathepsin G, thrombin, plasmin, 
coagulation factor X (F10), and coagulation factor XI (F11)182-186. PCI inhibits the down-
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regulation of coagulation system by inhibiting the activation of protein C by thrombin in 
the presence of thrombomodulin and by inhibiting APC186. APC down-regulates the 
coagulation system by degrading the coagulation factors Va and VIIIa by limited 
proteolysis and by eliciting anti-inflammatory response and cytoprotective signaling in 
endothelial cells by activating protease-activated receptor 1 (PAR-1)186. PCI also down-
regulates coagulation by inhibiting proteolytic cleavage of fibrinogen by thrombin in the 
presence of heparin187. 
 C1INH is a vital regulator of complement cascade and functions by inactivating 
C1r and C1s, components of C1q, and mannan-binding lectin associated serine proteases 
MASP-1 and MASP-2188. C1q is the first component in the classical pathway and MASP-
1 and MASP-2 are first components in the lectin pathway. C1INH is also a major 
regulator of the coagulation cascade. It inhibits inflammation by blocking the activities of 
activated F12 and plasma kallikrein, two proteins that participate in the production of 
bradykinin which promotes inflammation by increasing vascular permeability188, 189. C6 
and C8G are part of the later stage of complement activation and function as membrane 
attack proteins. They interact to form membrane attack complexes that are able to 
associate with the lipid bilayer of target molecules, leading to eventual disruption of the 
lipid bilayer188. The up-regulation of the six proteins in FF indicates their vital roles in 
regulation of coagulation and complement cascades during bovine follicular 
development.  
Other identified proteins in the coagulation and complement system were A2M, 
F5, F13, C1S, FGA, FGB, and FGG (up-regulated in PL compared to FF) and C8G (up-
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regulated in PL HE2 compared to PL LE2). The functions and associations of these 
proteins in the coagulation and complement pathway are shown in Figure 5. The up-
regulation of C8G in PL containing high E2 than low E2 suggests greater influence of E2 
on this protein in PL.  
3.7 CONCLUSION 
In conclusion, iTRAQ proteomic enabled probing of protein changes in PL and 
FF containing high and low concentrations of E2 during the pre-ovulatory period. E2 
influence the expression changes of several proteins in PL and FF. Protein expression 
changes is greater with high E2 in FF than in PL when compared to their respective low 
E2. But protein expression change with high and low E2 is similar when PL and FF are 
compared and this is possibly due to the inherent difference in protein concentrations in 
PL and FF. The expression changes of several of the proteins are associated to their 
function in follicle growth and maturation. The coagulation and complement cascades are 
enriched during bovine follicle development and support the view that folliculogenesis 
and ovulation are hemorrhagic events. 
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CHAPTER 4 
ATHEROSCLEROSIS DEVELOPMENT IN THREE REGIONS OF THE 
AORTIC ROOTS OF APOLIPOPROTEIN E KNOCKOUT (APOE-/-) MICE 
 4.1 ABSTRACT 
The aortic root is a predilection site for atherosclerosis development in mice. We report a 
investigation of atherosclerotic progression in three specific regions of the aortic roots, 
namely the ascending aorta region (AAR), region showing the orifices of the coronary 
arteries marking the start of the ascending arch (OCAR) and aortic sinus region (ASR) in 
a large population of ApoE-/- male and female mice at different ages.  In this study, 67 
ApoE-/- and 27 wild-type C57BL/6J mice (controls) were fed with a high fat diet (HFD) 
until age 8, 12, 18, or 24 weeks. Through systematic classification and quantification of 
lesions in each region and statistical data analysis, we found that the complexity and total 
atherosclerotic lesion areas in ApoE-/- mice was location and age dependent. It was 
slowest in the AAR with lesions progressing from dominant type I at 8 weeks, type II at 
12 weeks, types III at 18 and types III and IV at 24 weeks of age. Lesion development 
was comparable in the OCAR and ASR regions; types II and III lesions dominated in 
mice at 8 and 12 weeks of age, respectively, while types IV and types IV and V 
dominated at 18 and 24 weeks of age, respectively. Average percentage of atherosclerotic 
lesions typically increased from the AAR to the OCAR to the ASR at a specific age, and 
from 8 to 24 weeks of ApoE-/- mice at each region, correlating with the histological data.  
Aatherosclerosis development was found to be slightly faster in female than male ApoE-/- 
mice.  As expected, no lesions were observed in wild-type mice. These findings would be 
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beneficial in experimental design and targeting of lesion types in aortic roots of the 
popular ApoE-/- murine atherosclerosis model.  
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 4.2 BACKGROUND AND MOTIVATION 
The aortic root is a predilection site for lesion development67 in mice and is often 
investigated to determine the overall extent of atherosclerosis71 in mice. The aortic root 
has three identifiable regions: the ascending aorta region (AAR), the region showing  the 
orifices of the coronary arteries marking the start of the ascending arch (OCAR), and the 
aortic sinus region (ASR) characterized by the appearance of the aortic cusps190. The 
apolipoprotein E knock-out (ApoE-/-) mouse model65, 66 is efficient for demonstrating the 
progressive atherosclerotic events and lesion-morphological features found in humans191.  
ApoE-/- mice spontaneously develop atherosclerotic lesions when fed a normal mouse 
chow diet. These conditions are accelerated with a high saturated fat and cholesterol 
diet65.  The C57BL/6 mouse strain is more susceptible in developing atherosclerosis70 and 
is therefore often the background for ApoE-/- mice71. In this study, 67 ApoE-/- female and 
male mice on C57BL/6 background were fed a HFD for different periods of time 
corresponding to four age groups: 8, 12, 18 and 24 weeks. Serial cross-sectioning 
method190 with subsequent staining and calculation of lesion areas with image analysis 
software were then used to carefully identify, and quantify atherosclerotic lesions.  
 4.3 OBJECTIVES 
Although different atherosclerosis studies have examined the aortic root, none 
have characterized and quantified the three regions simultaneously in a large population. 
Our primary objective is to meet this limitation. Data from a large population size will be 
beneficial in experimental design of atherosclerotic studies with this mouse model. Other 
objectives are to identify atherosclerosis progression trends in the regions and to 
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investigate gender-specific differences in the disease development. This study provides 
photomicrographs of the different types of atherosclerotic lesions which could be 
beneficial, when used in conjunction with related images derived from nuclear and non-
nuclear imaging techniques55 for disease diagnosis and target interventions. Future work 
is to perform proteomic analysis on blood samples from mice in this study to identify 
potential phosphoprotein biomarkers of atherosclerosis. 
 4.4 MATERIALS AND METHODS 
4.4.1 Mice Housing 
ApoE-/- on C57BL/6 background and wild-type C57BL/6 mice were bought at 
three weeks of age from Jackson Laboratory (Maine). Both ApoE-/- and wild-type 
C57BL/6 mice were fed standard chow diet (contained 20% protein by weight, 4.5% fat 
by weight, 0.02% cholesterol by weight, no sodium cholate and casein) for one week 
upon arrival and then transferred onto a high fat diet (HFD) until they reached 8, 12, 18, 
or 24 weeks of age. These feeding periods have been shown to induce different degrees 
of atherosclerotic lesions in ApoE-/- mice67. The HFD (Harlan Laboratories, Madison, 
WI) contained 21% fat by weight, 0.15% cholesterol and 19.5% by weight casein without 
sodium cholate. There were 36 male ApoE-/- mice, with nine mice in each of the four 
groups. Female ApoE-/- mice totaled 32 with six mice in the 8 week group, eight mice in 
the 12 week group, nine mice in the 18 week group and nine mice in the 24 week group. 
One mouse from the 24 weeks female group died after the feeding period and was 
excluded from further analysis. For wild-type C57BL/6 male mice, there were four in the 
8-week group and three in each of the 12, 18 and 24 week groups (13 in total). There 
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were 14 female wild-type mice in total with three mice each in the 8- and 12-week groups 
and four mice in each of the 18 and 24 week groups. Mice were given diet and tap water 
ad libitum. The mice were housed in pathogen free 12 h dark cycles. All research 
protocols in this mouse study were approved by Institutional Animal Care and Use 
Committee (IACUC) in South Dakota State University.    
4.4.2 Histological Analysis of Aortic Roots 
All mice were sacrificed at the end of their designed feeding period and then 
dissected and sectioned according to the method previously described190. During 
dissection, the heart was separated from the aorta and placed in phosphate-buffered saline 
solution. At the time of sectioning, the lower ventricular portion of the heart was cut 
away such that the remaining upper cardiac portion was about 30% of the total heart 
tissue size. The upper cardiac portion was placed in a tissue mold and then completely 
covered with optimal cutting temperature (OCT) compound. Each OCT-embedded tissue 
was manipulated to ensure that it was placed center and perpendicular to the tissue mold 
and free of any bubbles. The mold was then quickly frozen on dry ice and sectioned 
immediately or wrapped in parafilm and frozen at -20oC for later sectioning.  
Tissues were sectioned with the upper ventricular portion facing outwards in the 
tissue mold. During sectioning, the frozen tissue was mounted on a cryostat (Leica 
CM3050 S) and cross-sectioned at 8 µm intervals until all three regions of the aortic root 
(i.e. AAR, OCAR, AAR, ASR) are collected, identified by the region spanning the 
appearance of the aortic cusps to the region of the disappearance of the circular shape of 
the ascending aorta. About 140 sections per mouse were collected spanning the three 
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regions. Frozen sections were collected in sequence on histological slides (8 to10 tissue 
sections per slide) and frozen at -80 °C until ready for staining.  
4.4.3 Oil Red Staining and Imaging 
Oil red O is commonly used to assist in quantification of atherosclerotic lesions in 
mice. Oil red O stains neutral lipids, enabling determination of lesions areas with image 
analysis softwares190. Oil red O stock solution was prepared by dissolving 0.5 g Oil red O 
(CI 26125; Sigma Aldrich, Saint Louis, MO, USA) in isopropanol (Fisher Scientific, 
Hampton, NH, USA) using a gentle heat of a water bath. Oil red O working solution was 
prepared by diluting 30 mL of stock solution with 20 mL of distilled water and filtering. 
Working solution was prepared fresh for use at each staining time. For Oil red O staining, 
frozen sections were first dried under room temperature for about 15 minutes to reduce 
tissue loss resulting from a weak bond with the histological slide. Tissue sections were 
fixed in formalin (paraformaldehyde in PBS; 4% w/v, pH = 6.9) and then washed under 
running tab water for about 10 minutes and rinsed with 60% isopropanol. Tissues were 
then stained with freshly prepared Oil red O working solution, rinsed with 60% 
isopropanol and then counter stained with Harris hematoxylin solution (Sigma Aldrich, 
St. Louis, MO, USA). Stained tissues were cover slipped with glycerin jelly mounting 
medium (Electron Microscopy Sciences, Hatfield, PA) and imaged immediately or 
refrigerated overnight or stored at -20 oC until ready for imaging. All tissue sections 
collected from each ApoE-/- mouse were stained. For C57BL/6 controls, alternating 
histological slides from the serial cross-sectioning were selected for staining. Images of 
Oil Red O stained aortic root tissues on histological slides were captured at 35 
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magnification using a Leica EZ4HD light microscope (0.057 nA ) equipped with Leica 
Acquiring Service, V.4.0 software. 200 (0.4 nA) and 600 (oil immersion nA 1.4-0.6) 
magnifications were obtained using Leica DM14000B inverted  light microscope 
connected to a Cool Snap Pro color video camera (Media Cybernetics) equipped with 
QCapture-Pro 5.1 software. Other magnifications (50 µm) were obtained with Olympus 
AX70 Upright Compound Microscope equipped with Olympus DP70 Digital Camera. 
4.4.4  Classification of Lesions 
Lesions were classified based on their size and morphology as previously 
described58-60 for atherosclerotic lesions. Lesion classification was done by individuals 
not involved in mice experimental design and feeding to prevent classification errors and 
bias. Lesion types observed in this study are shown in Figures 4.2 to 4.4. Type I lesions 
were characterized by the presence of scattered macrophages containing lipid droplets 
(foam cells) (Figure 4.2). Multilayer macrophage foam cells and lipid-laden smooth 
muscle cells were characterized as type II lesions (fatty streaks) (Figure 4.2, Panel C and 
D). Lesions that had pools of extracellular lipids in addition to features of type II lesions 
but lack the lipid rich core (necrotic core) were labeled type III (intermediate) lesions 
(Figure 4.3). The necrotic core is a key feature of types IV and V lesions. Type V lesion 
(Figure 4.4, Panels C and D) was differentiated from type IV (Figure 4.4, Panel A and B) 
by the additional presence of a substantial amount of spindle-shaped fibrous tissues 
mixed with the necrotic core lipids (sometimes occurred as multilayers of fibrous tissues 
in the lipid core) and/or a fibrous cap covering the top of the lipid core. 
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Figure 4.1. Workflow of the experimental design for the characterization and 
quantification of atherosclerotic lesions from aortic root regions of ApoE-/- mice.  
 
Type VI lesion, the complicated lesion, is characterized by the presence of fissure, 
hematoma, and thrombus, sometimes in addition to features of type IV or V. Type VI 
lesion was not observed in aortic roots from mice in this study. The overall disease state 
in a region was defined by the highest lesion type observed in tissues from that region.  
4.4.5 Quantification of Lesions 
Lesion areas and aortic luminal boundaries were manually measured using ImageJ 
analysis software developed by NIH. Lesion-area calculation with imageJ was achieved 
by tracing along a lesion outer boundary.  Measurement of lesion areas was carried out on 
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alternating tissue sections on all histological slides collected from the serial cross-
sectioning of an ApoE-/- mouse. About 70 tissue sections per mouse were quantified. A 
total of 15 mice, seven male and eight female ApoE-/- mice, were excluded from the 
quantification due to tissue loss from at least one of the regions during sectioning and/or 
staining. Thus a total of 29 male and 23 female ApoE-/- mice were quantified. To 
determine the percent of lesions in each stained tissue, the sum of all lesion areas 
(obtained from ImageJ analysis) in the tissue was expressed as the percent of the area 
corresponding to aortic luminal boundary. Average percent lesion for an aortic root 
region per mouse was calculated by taking the average of all the percent lesions 
calculated for tissues from that region. The average percent for a region per mouse was 
used to calculate the average percent of a region for a group, standard deviations and 
perform one-way analysis of variance (ANOVA).  
ANOVA performed included comparisons between the aortic root regions from 
mice within a group, the aortic root regions between the different groups and the aortic 
root regions between genders. The comparisons were made to determine whether the 
differences in lesion development were purely random or significant. Significant 
difference was established at p<0.05.  
4.5  RESULTS 
4.5.1 Atherosclerotic Lesions Progression and Characteristics in ApoE-/- Mice 
Atherosclerosis lesions were observed in all three regions of the aortic root of 
ApoE-/- mice but as expected, not in C57BL/6 control mice fed with the same HFD for the 
same time periods. Lesion size, distribution, and complexity increased from the AAR to 
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the OCAR and to the ASR. The size and severity of lesions also increased in all three 
regions with increasing age of mice (Figure 4.6). Lesion types I to V were observed and 
the progression occurred faster in female than in male mice. Type I lesions were 
dominant in the AAR while type II lesions were dominant in the OCAR and the ASR in 8 
week ApoE-/- male and female mice. By 12 weeks of age, type II lesions were dominant in 
the AAR. The dominant lesion was type III which were in some cases undergoing 
progression to type IV in the OCAR and ASR regions for both genders.  At 18 weeks, 
lesion progression in the AAR was dominantly type III in females and type II in males. 
Both genders showed mainly type IV lesions in the other two regions. The 24-week 
group developed dominant type IV lesions and type III lesions in AAR of females and 
males respectively. Types IV and V lesions were dominant in the other two regions.  The 
degree of fibrous tissues, identified at 200 and 630 magnification as spindle- shaped 
fibrous tissues in lesions were higher in 24 weeks mice than in 18 weeks mice.  In both 
the 18- and 24-week groups, fibrous tissues were higher in the ASR compared to the 
OCAR. However, fibrous tissues were not quantified.  Although advanced lesions (types 
IV to V) were dominant feature in older mice (18 to 24 weeks), early lesions (types I to 
III) were also observed, often at the shoulder regions of advanced lesions.  
The overall disease state in a region was defined by the highest lesion type 
observed in tissues from that region. The disease state in the AAR was type I at 8 weeks, 
types II at 12 weeks, type III at 18 weeks, and type V at 24 weeks. The disease state in 
the OCAR and ASR regions were type II at 8 weeks, type III (in some cases undergoing 
progression to type IV) at 12 weeks, and type V at 18 and 24 weeks. 
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 Figure 4.2. Photomicrographs of type I and type II lesions in tissue from the region 
showing the orifice of the coronary artery (OCAR) and from the arotic sinus region 
(ASR) respectively in 8 weeks female ApoE-/- mice fed a HFD. Insert in panel A and C 
(original magnification x35) are areas shown in Panel B and D (original magnification 
x630). Type I lesion consists of scattered macrophage foam cells (arrows). Type II 
consists of multilayer of foam cells and lipid-laden smooth muscle cells. Type I and II 
lesions are clinically benign. Tissues were embedded in formalin and then stained with 
oil red O to detect neutral lipids. Hematoxylin was used as the counter-stain. 
 
4.5.2 Magnitude of Atherosclerotic Lesions in ApoE-/- Mice  
Average percent lesion values (Table 4.1) for the ApoE-/- mice correlated well with 
histological observation of oil red-stained tissue sections from the regions of the different 
age groups. Average percent lesion values increased from the AAR to the OCAR to the 
ASR. This trend (Table 4.1, Figure 4.7) was observed in all age groups except in 24- 
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Figure 4.3. Photomicrograph of type III (intermediate) lesion from the region showing 
the orifice of the coronary arteries (OCAR) from 12 week male ApoE-/- mouse. Insert on 
panels A (original magnifications, x35) is area shown on panel B (original magnification, 
x200). Type III is an intermediate between the advanced types of lesions that can cause 
symptoms of atherosclerosis and the clinically benign lesions of type I and II. Type III is 
distinguished from the advanced types by the lack of the presence of necrotic lipid cores. 
Mouse was fed with high-fat diet. Tissue was stained with oil red O to visualize neutral 
lipids and counter-stained with hematoxylin. 
 
week female mice, whose average percent lesion value was slightly higher for the OCAR 
(47.96 ± 5.75) than the ASR (44.51 ± 6.07) but not statistically significant based on result 
(p = 0.263) from ANOVA analysis. Results from comparison between aortic root regions 
from mice within an age group showed that the average percent lesion value increased 
significantly (p<0.05; Table 2) from OCAR to ASR in 8 weeks mice. Comparison was 
not made between AAR and OCAR or AAR and ASR due to limited data obtained for the 
AAR in this age group. In the 12-week group, the percent lesion difference was 
significant between any two of the three regions. Among 18- and 24-week mice groups, 
lesion percentage differences were significant between any two regions except between 
the OCAR and the ASR of the 18/24- week male mice and of the 24-week female mice. 
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Average percent lesion values for the three regions also increased in an age-
dependent manner as showed in Figure 4.6. Average percentage lesions increased faster 
in older mice (18-week to 24-weeks) than younger mice (8 to 12 weeks) in the AAR. By 
contrast, it increased slower in older mice in the OCAR and the ASR. The similar 
changing trend observed in the OCAR and the ASR suggests that atherosclerotic 
development became more similar in these two regions as mice grew. 
To determine the significant level of lesion increase between the ages for each 
region, an ANOVA statistical analysis was performed. P-values obtained after 
comparison between the different ages for each region of the aortic root are listed in 
Table 4.3. In the AAR, a significant change (p< 0.05) of average percentage of 
atherosclerotic lesions was only observed from 18 to 24 weeks. In the OCAR and ASR, 
significant changes were observed from 8 to 12 to 18 weeks for both female and male 
ApoE-/- mice.  Only female mice showed significantly lesion increase in OCAR from 
week 18 to 24. No significant changes were observed in the ASR from week 18 to 24 for 
both genders. 
As observed in the histological data, the percent values were generally higher in 
females than in males (Table 4.1). However, ANOVA comparisons between males and 
females for the regions and different ages only found significant differences in the OCAR 
of 12-week (p = 0.0005) and 24-week (p=0.0049) male and female mice.  
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Figure 4.4. Photomicrographs of types IV and V lesions from the aortic sinus region 
(ASR) from 18 weeks respectively male and female ApoE-/- mice. Insert on panels A and 
C (original magnifications, x35) are areas shown on panel B and D (50 µm). The necrotic 
lipid core (LC) is a distinguishable feature of advanced lesions (types IV and V). A 
fibrous cap (arrows) covers the LC. A distinguishing feature of type IV form type V is 
substantial amount of fibrous tissues in type V. Both types of lesions can cause 
complications of atherosclerosis. Mice were fed with a high fat diet. Tissues were stained 
with oil red O to visualize neutral lipids and counter-stained with hematoxylin. 
 
  4.6 DISCUSSION 
4.6.1 Atherosclerosis in Aortic Root Regions of ApoE-/- Mice 
The atherogenic process is progressive in nature68.  In this study, increases in lesion  
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Figure 4.5. Atherosclerosis in three regions of ApoE-/- mice at ages (from left to right) 8, 
12, 18 and 24 weeks. A. AAR. B. OCAR. C. ASR. Lesion distribution and complexity 
increase from the AAR to the OCAR to the ASR. Lesions also increased with age of 
mice. Mice were fed a high fat diet. Tissues were embedded in formalin and stained with 
oil red O and hematoxylin. Original magnification, x35. 
 
Table 4.1. Average % lesions in three regions of the aortic root of ApoE−/− mice. 
* Total number quantified. This is less than the total number of mice in each age category used in 
the overall study.  
 
Age of Mice (Weeks) AAR OCAR ASR 
 
Average %Lesion ± SD (*# of mice quantified) 
 
Males  
8 0.90 (1) 1.02 ± 0.78 (3) 3.65 ± 0.77 (5) 
12 2.70 ± 1.47 (5) 6.78 ± 2.90 (7) 14.61 ± 6.99 (7) 
18 4.22 ± 2.84 (5) 33.83 ± 9.75 (7) 37.67 ± 7.66 (8) 
24 21.16 ± 7.65 (6) 37.88 ± 6.33 (8) 41.30 ± 7.04 (9) 
         
Females       
8 0.45 ± 0.12 (2)  0.78 ± 0.16 (3) 4.57 ± 0.36 (3) 
12 1.80 ± 1.70 (3)  16.14 ± 2.60 (4) 22.30 ± 2.72 (4) 
18 8.97 ± 2.54 (4) 35.20 ± 6.39 (8) 43.29 ± 7.39 (7) 
24 30.20 ± 1.85 (3) 47.96± 5.75 (8) 44.51± 6.07 (8) 
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Table 4.2. p-values obtained from comparison between aortic root regions from mice 
within an age group. 
Age of Mice (Weeks) *AAR vs. OCAR  *AAR vs. ASR OCAR vs. ASR 
Males    
8 N/A N/A 3.47E-03 
12 1.66E-02 4.10E-03 1.81E-02 
18 6.77E-05 1.60E-06 4.08E-01 
24 7.50E-04 1.57E-04 3.11E-01 
    
Females    
8 N/A N/A 7.74E-05 
12 2.33E-03 6.98E-04 1.70E-02 
18 1.54E-05 1.01E-05 4.05E-02 
24 6.47E-04 3.63E-03 2.63E-01 
*Comparisons was not done between AAR and OCAR and AAR and ASR of 8 weeks ApoE-/- 
mice due to limited quantification data for the AAR. 
 
severity and percentage from 8 weeks to 24 weeks in different ApoE-/- mice demonstrated 
this progressiveness. ApoE-/- mice on C57BL/6 background provided an effective model 
for studying disease progression in the aortic root. The aortic root is commonly examined 
in murine-atherosclerotic studies due to its predisposition to develop atherosclerosis.  
Majority of studies in the mouse aortic root have been focused on the ASR68 because 
complicated lesions develops in this region72, 192 and the appearance of the aortic cusps of 
the ASR allows for easy comparison between different mice.  Accordingly, lesion types 
and progression in the ASR has been broadly characterized whiles similar descriptions 
for the AAR and OCAR are rare. This study presents simultaneous characterization and 
quantification of all three regions of the aortic root in a large population of ApoE-/- mice 
on C57BL/6 background. 
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Table 4.3. p-values obtained after comparison between the different ages for each region 
of the aortic root. 
*Comparison was not done between 8 and 12 weeks ApoE-/- mice for AAR due to limited 
quantification data for the AAR. 
 
Lesion distribution, size, and complexity increased from the AAR to the OCAR to the 
ASR. Differences in the extent of atherosclerotic lesions in these three regions of the 
aortic root are linked to hemodynamic factors in each region. The AAR is circular and 
straight, which enables uniform laminar blood flow and the generation of high shear 
stress on the region’s endothelium lining. Straight arterial segments with high shear stress 
have been correlated to minimal/no development of atherosclerotic lesions. Conversely, 
areas where shear stress is low, such as the inner curve of the aortic arch, or where flow is 
oscillatory, such as near bifurcations, have turbulent blood flow and are associated with 
increased or extensive development of atherosclerotic lesions193, 194.  Low and/or 
oscillatory shear stress (OSS) increases atherosclerosis risk by primarily inducing 
dysfunction of the local endothelium57, 195. Endothelial dysfunction is an established 
condition that triggers initial atherosclerosis events including increasing the expression of 
cellular adhesion molecules ICAMs (e.g. ICAM-1), vascular cell adhesion molecules 
(VCAMs) (e.g. VCAM-1), chemokines, and platelets55-57. Progression of atherosclerotic 
Age of Mice (Weeks) *AAR OCAR ASR 
Males    
8 to 12 N/A 1.11E-02 6.32E-03 
12 to 18 3.19E-01 1.36E-05 4.06E-05 
18 to 24 1.19E-03 3.51E-01 3.25E-01 
    
Females    
8 to 12 N/A 1.73E-04 1.10E-04 
12 to 18 2.46E-02 2.19E-04 4.50E-04 
18 to 24 6.67E-05 8.94E-04 9.87E-01 
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lesions can then rapidly occur when risk factors such as hyperlipidemia, diabetes, and 
hypertension are present195. The high susceptibility of mouse ASR to develop lesions is a 
result of OSS196 caused by the aortic cusps. The extent of lesion formation in the OCAR 
is also associated with OSS and/or low shear stress in this region, predisposed by the 
branching of the coronary arteries. Also, closer proximity to the ASR potentially 
encourages easy spreading of the disease to this region. The generally higher lesion 
prevalence in the ASR compared to OCAR suggests higher OSS in the ASR. 
The morphology of atherosclerotic lesions is an indication of the severity of the 
disease. Accordingly, lesion types in a region corresponded to the severity of the disease 
in that region. The observation of complex lesions in the ASR in this study supports the 
common use of this region for probing advanced types of lesions  However, the AAR can 
be of use if early forms of lesion are the target of interest, such as in drug intervention 
studies aimed at preventing advancement of early atherosclerotic lesions. This would be 
particularly useful as the early types of lesion in OCAR and ASR in the ApoE-/- mice fed 
HFD rapidly progresses to advanced forms which could make early lesions difficult to 
target or enough time for expected effect of a target drug. In using the AAR for 
comparative studies, the, circular shape of this region could be a guide for accurate 
identification. The statistical differences or similarities in the average percent lesion 
values between regions and ages as shown above can provide a guide for designing future 
atherosclerotic studies.  
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Figure 4.6. Average percent lesions in three regions (i.e., AAR, OCAR and ASR) of the 
aortic root of 8- to 24-week male (a) and female (b) ApoE-/- mice.  
 
4.6.2 Lesion Progression with Age of ApoE-/- Mice 
The progression of lesion severity in the three aortic root regions from 8 to 24 
weeks observed in our study confirms age as a risk factor of atherosclerosis197. The risk 
with age is validated by the types of lesions formed at different ages in a specific region.  
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8-week ApoE-/- mice developed type I or II lesions (known to be clinically benign). By 
contrast, clinical important types IV and V lesions (necrotic core lesions) developed in 
older mice. 
4.6.3 Influence of Gender on Lesion Formation in Aortic Root Regions 
Histological data from this study revealed that lesion development were generally 
faster in female than in males ApoE-/- mice. However, statistical significant difference in 
average percentage of lesions between genders was only observed in the OCAR of 12- 
and 24-week mice. Higher disease proliferation in female mice is consistent with 
previous report198. However, the opposite is observed in humans. Premenopausal women 
are viewed to have lower risk of atherosclerosis and related heart diseases than age 
matched males, but the risk become similar in postmenopausal women and men of 
comparable age199. The decreased risk with younger women has been linked to protective 
effects of estrogen which decrease in women with age. The cardioprotective mechanisms 
of estrogen include decreased low-density lipoprotein (LDL), increased high-density 
lipoprotein (HDL), and release of vasodilators such as nitric oxide (NO) and prostacyclin 
(PGI2) from vessel walls, which results in inhibition of vascular constriction and 
lowering of blood pressure, as well as decreased platelet aggregation199. Similar disease 
proliferation in both genders with increased age was observed in mice from this study 
demonstrated by comparable lesions (in size and type) in higher prevalent regions. 
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 4.7 CONCLUSIONS 
This study showed a simultaneous comparison of atherosclerosis progression in 
three regions of the aortic root of ApoE-/- mice fed HFD. The ASR is a predilection site 
for lesion development in mice. Lesions in this region progress rapidly to advanced types 
of lesions by 18 weeks of age, which implies that this region is better suited for the study 
of advanced types of atherosclerotic lesions using the ApoE-/- mouse model. By contrast, 
the slowest lesion formation is in the AAR, with lesions progressing to the advanced 
forms in this region only in the 24-week mice. Therefore, AAR is suitable for the study of 
drug targeted at early types of lesions. Lesion types in the OCAR are mainly of types I 
and III in younger mice (8 and 12 weeks) and types IV-V in older mice (18 and 24 
weeks). This region is thus best suited for investigating all lesion types guided by the 
presented age limits for various lesion developments. The progressiveness and age 
dependency of the atherogenic process is also confirmed in this study. The data presented 
serve well as a guide in designing future murine atherosclerotic studies. 
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CHAPTER FIVE 
5.0  SUMMARY AND FUTURE WORK 
5.1 Summary 
The objectives of this work were (i) develop an immunodepletion method for 
bovine fluids, (ii) to analyze changes in proteins in FF and plasma (PL) from cattle with 
high E2 (HE2) or low E2 (LE2) during the pre-ovulatory period, and (iii) characterize 
and quantify atherosclerotic lesion development in three regions of the aortic root of 
ApoE-/- mice.  
A proteomic-shotgun (bottom down) approach was selected to achieve our second 
objective. This approach is suitable for analyzing complex matrices. An important and 
often required step in the shotgun approach is to employ a protein fractionation step. The 
protein fractionation method of choice was immunodepletion due to the high selectivity, 
sensitivity, and reproducibility reported for this method. However, because 
immunodepletion methods for bovine fluids are currently very limited, development of an 
immunodepletion method became necessary and this formed our first objective. 
Therefore an immmunodepletion method utilizing MARS Hu6-HC was developed for 
bovine PL, FF, epididymis sperm types, and ejaculated sperm types. High depletion rates 
for targeted HAPs albumin, IgG, IgA, and alpha-1-antitrypsin (or alpha-1-antiproteinase) 
was achieved. The depletion rates confirmed by sandwich ELISA for albumin, IgG, and 
IgA ranged from 98.7 to 99.9% in all the bovine samples investigated. A similar 
depletion rate was expected for alpha-1-anti-trypsin based on dramatic depletion of its gel 
band. The observed high depletion rates were primarily attributed to the high structural 
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similarity of these proteins between human and bovine. There was also dramatic 
depletion of binder of sperm proteins (BSP) - PDC-109, BSP-A3, and BSP-30kDa, which 
are HAPs in seminal plasma component of ejaculated sperm, forming 40-57% of the total 
protein component. The depletion of the BSP proteins was therefore considered 
beneficial if both bound and depleted fractions are analyzed. 
Protein quantification in proteomics enables detection of expression changes 
between treatments. iTRAQ reagents were successfully used for the quantification. 4-plex 
iTRAQ reagents were used to individually label PL HE2, PL LE2, FF HE2, and FF LE2 
and subsequent nanoLC-ESI-LTQ (PQD) analysis identified a total of 231 proteins with 
high confidence (FDR ≤0.05). 103 of the identified proteins showed expression changes 
(up-regulated or down-regulated) after comparisons between samples. Important 
information was drawn from our proteomic approach: higher number of proteins showed 
expression change between different fluid types (i.e. PL and FF) than between HE2 and 
LE2 of a fluid; E2 has a greater effect on FF proteins than PL proteins; the up- and down-
regulated proteins were mainly localized in the cell, the extracellular region and organelle 
and were mainly associated to cellular process and metabolic process. Binding and 
catalytic activity were the most associated molecular processes; E2 is critical to the 
development and maturation of ovarian follicles. Several of the proteins showing 
expression changes play important roles in folliculogenesis and are modulated by E2; and 
complement and coagulation pathways were the main pathways associated with the 
proteins, supporting the view that folliculogenesis and ovulation are hemorrhagic events. 
This work therefore demonstrates the ability of proteomic to provide insights into 
reproduction in bovine. The presented data specifically provides the basis for further 
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investigation of specific processes involved in E2 regulation of reproductive associated 
proteins.  
Atherosclerosis is the underlining cause for heart attack and stroke, the two 
leading cause of cardiovascular death worldwide. The ApoE-/- -mouse model is popular 
for atherosclerosis research. This work characterized and quantified atherosclerosis 
development in three regions of the aortic root of ApoE-/- mice. The examined three 
regions of the aortic root were ascending aorta region (AAR), region showing the orifices 
of the coronary arteries marking the start of the ascending arch (OCAR), and aortic sinus 
region (ASR). Lesion development in the three regions was location and age dependent.  
It was slowest in the AAR and formed types I-III lesions in this region from 8-18 weeks 
of age and type IV at 24 weeks of age. Lesion development was faster in OCAR and ASR 
and developed to types IV and V by 18 weeks. Average percent lesion values increased 
from the AAR to the OCAR to the ASR, correlating to the histological data. These 
findings would be beneficial in experimental design and targeting certain lesion types in 
aortic roots of the popular ApoE-/- murine atherosclerosis model. 
5.2 Future Work 
5.2.1  Identification of phosphoproteins biomarker candidates for atherosclerosis 
Protein phosphorylation entails the reversible incorporation of phosphate group to 
amino acid side chains of proteins and it is the most studied post-translational 
modification (PTM). Phosphoproteins are important biomarker targets for atherosclerosis 
because of the crucial regulatory role of protein phosphorylation in most cellular 
processes. Cellular processes such as metabolism, contraction and relaxation of muscles, 
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transcription and genetic information, hormonal and nerve signaling, proliferation, 
apoptosis, differentiation, cell growth, aging, and inflammation are directly or indirectly 
regulated by protein phosphorylation200, 201. Because casual factors for atherosclerosis 
development are widely recognized to be multiple, it is expected that alteration in 
associated phosphorylation/dephosphorylation regulatory processes could create disease 
conditions with the associated phosphoproteins being up- or down-regulated. For 
example, the most studied potential phosphoprotein biomarker is VSMC heat shock 
protein 27 (HSP27)81, 202. HSP27 expression is reported to increase in normal appearing 
vessels adjacent to atherosclerotic lesion whereas levels in the atherosclerotic lesion itself 
are significantly decreased. Both lesion and adjacent artery show decreased HSP27 
phosphorylation compared with reference vessel81, 203.  
The future work would be to use proteomic approach to identify and quantify the 
expression levels of phosphoproteins in the plasma samples from the ApoE-/- and control 
mice of all the ages from this study. Comparison between the plasma proteome of the 
ApoE-/- and control mice, and between the different ages groups could provide more 
insights into the differentially expressed phosphoproteins in the development of 
atherosclerosis. Possible biomarker candidates could then be sought for and further 
investigated.   
The experimental approach could employ  proteomic bottom-up methods which 
could include enrichment of phosphoproteins in the plasma sample, trypsin digestion of 
proteins into peptides, iTRAQ labeling of peptides, SCX separation of peptides, and 
analysis of samples using nanoLC-MS/MS with subsequent protein identification and 
quantification with the SEQUEST and Proteome Discoverer softwares. Enrichment of 
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phosphoproteins is particularly important for three main reasons: 1. Phosphoproteins are 
PTMs and therefore are low abundance in nature. 2. Phosphorylation is a transient 
modification, so the target protein could present in both the native and phosphorylated 
form and 3. Phosphopeptides ionize poorly in MS strategies particularly in the presence 
of non-phosphorylated molecules resulting in lower signal intensities204. Phosphoproteins 
enrichment can be achieved using metal oxide affinity chromatography (MOAC), 
immobilized metal affinity chromatography (IMAC), and titanium dioxide (TiO2)204, 205. 
Because the ApoE-/- group developed atherosclerosis as shown in this dissertation, 
it is expected the phosphoproteome in this group to differ, with phosphoproteins levels 
either up- or down-regulated compared to the control group. Our study shows that ApoE-/- 
mice fed with a HFD developed atherosclerosis as early as 8 weeks, with lesions mainly 
in the early-staged form. By 24 weeks, the disease had reached its advanced stage as 
visualized by the presence of features like the necrotic lipid core (LC) and greater degree 
of fibrous tissues. Therefore, identified phosphoprotein candidates showing expression 
changes in plasma samples from younger ApoE-/- mice (8 or 12 weeks) would be better 
markers for early stages of the disease whereas those from older ApoE-/- mice (18 and 24 
weeks) would be better biomarkers for advanced stage of the disease. Accordingly, 
special attention would be given to such proteins. Also, protein candidates that would be 
consistently present throughout all the stages of the disease would be sought for as these 
would be more robust in predicting risk of the disease.  
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5.2.2 Profiling and iTRAQ quantification of Epididymis and Ejaculated Sperm 
Proteins 
A focus of this dissertation was to profile proteins relevant to productivity of the 
cow, specifically at the folliculogenesis stage. Future work will be to profile sperm 
proteins relevant to bull productivity. During ejaculation, stored sperms from the cauda 
epididymis transit through the vas deferens and secretions from the accessory sex glands 
(prostate gland, cowper’s gland, and seminal vesicles) called seminal plasma is added and 
is released together with sperm as semen. With the contact with the seminal fluid, sperm 
undergoes series of biochemical and structural changes associated with sperm 
capacitation. Capacitation is required to make sperm competent to fertilize an oocyte206. 
Therefore, the protein composition of epididymis and ejaculated sperms are different. 
The future work would use proteomic shotgun approach to investigate these differences. 
Proteins of the sperm membranes and in the fluids surrounding either sperm type (herein 
labeled as ejaculated sperm proteins, ejaculated semen plasma, epididymis sperm 
proteins, and epididymis semen proteins) would be quantitatively measured using iTRAQ 
reagents. The immunodepletion method discussed in this work showed high depletion 
rates for abundant proteins in either sperm type and would be incorporated in the 
analysis. 
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APPENDICES 
Appendix 1. Details on 231 proteins identified in bovine PL and FF with high and low 
E2 during the pre-ovulatory stage. 
Description (* indicates protein was 
up- or down-regulated in at least 
one sample) 
Accession Coverage # Peptides # unique 
peptides 
Score 
  *2-acylglycerol O-acyltransferase 3 
(Fragment)  
E1BN30 2.62 1 1 20.86 
Acidic mammalian chitinase Q95M17 3.18 1 1 34.89 
Actin, cytoplasmic 1  F1MRD0 4.80 1 1 33.01 
Afamin G3MYZ3 3.15 2 2 81.25 
A-kinase anchoring protein 9 
(Fragment)  
F1MXF5 0.86 2 1 428.46 
Aldehyde oxidase 4  E1BL62 1.57 1 1 105.29 
Alpha-1-acid glycoprotein  Q3SZR3 52.48 12 12 1535.16 
*Alpha-1-antiproteinase  P34955 15.14 5 5 529.12 
Alpha-1B-glycoprotein  Q2KJF1 38.37 10 9 1035.57 
Alpha-2-antiplasmin  P28800 16.06 4 3 259.00 
Alpha-2-HS-glycoprotein P12763 25.35 6 6 1390.94 
*Alpha-2-macroglobulin  Q7SIH1 45.43 48 47 7776.09 
Alpha-amylase F1MJQ3 4.50 2 2 15.59 
Angiotensinogen  Q3SZH5 11.79 3 2 91.25 
*Ankyrin repeat and KH domain 
containing 1 
G3MZJ0 0.67 1 1 118.87 
Antithrombin-III  F1MSZ6 43.44 14 13 1121.12 
*AP complex subunit beta F6PZ41 3.11 1 1 56.29 
AP-2 complex subunit beta  G3X7G4 2.84 1 1 779.71 
Apolipoprotein A-I  P15497 63.77 26 26 4696.98 
Apolipoprotein A-II  P81644 27.00 4 4 339.84 
Apolipoprotein A-IV  F1N3Q7 46.58 16 15 655.00 
*Apolipoprotein B E1BNR0 0.68 2 2 140.79 
Apolipoprotein C-III  P19035 16.67 1 1 24.41 
*Apolipoprotein R G3N0S9 8.54 1 1 19.91 
*ApoN protein  Q2KIH2 16.54 4 4 110.40 
*Asparagine-linked glycosylation 5, 
dolichyl-phosphate beta-
glucosyltransferase homolog (S. 
cerevisiae)  
Q2KIM7 10.49 2 2 28.98 
*ATP binding cassette subfamily B 
member 9 
E1BKR0 0.96 1 1 61.08 
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*B double prime 1, subunit of RNA 
polymerase III transcription initiation 
factor IIIB 
F1MEB1 0.68 1 1 129.29 
BCL2 interacting protein 2 F1N6R4 4.46 1 1 53.24 
Beta-2-glycoprotein 1  P17690 13.91 4 4 205.18 
Beta-2-microglobulin  P01888 10.17 1 1 15.16 
C3 and PZP like, alpha-2-
macroglobulin domain containing 8 
E1BAA2 0.61 1 1 200.14 
C4b-binding protein alpha chain  Q28065 4.59 2 2 50.60 
*C8G protein  A8YXZ2 8.86 1 1 10.66 
*CAD protein F1MVC0 0.90 1 1 119.60 
Caspase recruitment domain family 
member 10 
F1MW90 1.36 1 1 72.61 
*CCDC80 protein A5PKA3 2.41 1 1 80.34 
*Cell adhesion molecule 1  Q2TBL2 4.56 1 1 599.16 
Ceruloplasmin F1N076 29.40 22 22 1539.90 
Chaperone activity of bc1 complex-
like, mitochondrial  
Q29RI0 2.01 1 1 84.33 
*Chromosome 14 open reading frame 
166 ortholog  
Q3T0S7 5.31 1 1 175.46 
Chromosome 20 open reading frame 
96 (Fragment)  
F1N466 5.59 1 1 276.11 
Clusterin  P17697 5.24 2 2 116.19 
CMP-N-acetylneuraminate-poly-
alpha-2,8-sialyltransferase  
F1MVI9 2.23 1 1 71.46 
Coagulation factor IX  F1MBC5 2.78 1 1 36.96 
*Coagulation factor V F1N0I3 1.83 2 2 37.79 
*Coagulation factor XII  F1MTT3 2.78 1 1 14.55 
*Coagulation factor XIII A chain  F1MW44 3.96 2 1 89.51 
*Cohesin subunit SA-3 E1B9B0 3.43 2 1 363.69 
*Complement C1s subcomponent Q0VCX1 6.39 2 1 27.90 
Complement C3  Q2UVX4 50.09 65 1 11912.41 
Complement C3  G3X7A5 49.91 65 1 11675.41 
 complement C3 (Fragment)  E1B805 3.82 4 4 165.08 
Complement C5a anaphylatoxin  F1MY85 11.87 15 13 633.38 
Complement C8 alpha chain F1MX87 11.04 4 3 92.83 
Complement C8 beta chain F1N102 12.37 4 3 123.27 
complement component 4A E1BH06 26.88 32 16 1940.14 
*Complement component C6  F1MM86 12.88 7 7 256.29 
Complement component C7  Q29RQ1 4.15 3 3 50.20 
Complement component C9  Q3MHN2 25.36 11 9 700.87 
Complement factor B  P81187 32.06 17 17 2031.94 
Complement factor H  Q28085 11.73 10 9 766.87 
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Complement factor I F1N4M7 12.30 6 6 300.36 
*Conglutinin  P23805 11.59 4 4 99.90 
Corticosteroid-binding globulin  E1BF81 13.37 3 2 86.85 
C-reactive protein  C4T8B4 4.46 1 1 62.37 
C-type lectin domain family 1 member 
A  
Q0VCS6 3.96 1 1 85.12 
*Cumulus cell-specific fibronectin 1 
transcript variant  
B8Y9T0 2.73 4 4 139.98 
*Cytochrome P450 20A1  Q5E980 2.81 1 1 47.83 
*Cytohesin 1 (Fragment) F1MCV3 3.49 1 1 79.67 
*Cytokine receptor like factor 3 E1BCF2 3.19 1 1 33.06 
*DDB1 and CUL4 associated factor 5 F1N0J7 1.83 1 1 125.40 
DEAH-box helicase 16 E1BF68 2.30 1 1 99.02 
*Delta-like protein  E1BDN7 1.40 1 1 71.56 
*Dolichyl-diphosphooligosaccharide--
protein glycosyltransferase subunit 1 
F1MJ36 2.80 1 1 380.50 
*Dpy-19 like 4 (Fragment)  F1MJJ1 2.77 1 1 74.83 
*DUOXA1 protein  A6H723 4.45 1 1 81.06 
*Dynein axonemal heavy chain 11 F1N724 0.22 1 1 198.47 
*Dynein heavy chain domain 1 F1MEF7 0.78 1 1 68.05 
Dystonin F1MPT5 0.15 1 1 569.35 
*E3 ubiquitin-protein ligase CHIP F1MUH4 7.95 1 1 21.38 
*Endophilin-A2  Q2KJA1 7.07 1 1 78.25 
*Engulfment and cell motility 1 F1MQH0 3.30 1 1 115.02 
*Epidermal growth factor receptor 
kinase substrate 8-like protein 1 
E1BKS0 2.00 1 1 31.95 
*Factor XIIa inhibitor precursor E1BMJ0 18.80 7 6 341.85 
*Family with sequence similarity 81 
member A 
F1N4N5 4.38 1 1 32.29 
*Fas activated serine/threonine kinase F1N4L0 7.14 1 1 45.88 
Fetuin-B  Q58D62 6.20 3 3 90.71 
*FGG protein  Q3SZZ9 48.05 16 15 2805.06 
*Fibrinogen alpha chain  A5PJE3 38.70 22 22 4967.64 
*Fibrinogen beta chain  F1MAV0 58.79 31 30 3584.70 
*Fibulin-1 F1MYN5 3.26 1 1 100.67 
*Filamin B E1BKX7 0.91 1 1 188.29 
Fragile X mental retardation 
syndrome-related protein 2 
E1B9L5 4.02 1 1 121.87 
G1/S-specific cyclin-D1  Q2KI22 5.42 1 1 157.65 
*Gametocyte-specific factor 1-like Q3T026 12.43 1 1 49.67 
*Gasdermin B F1MCQ4 1.99 1 1 9.35 
Gelsolin F1MJH1 12.18 6 5 252.10 
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Glutathione peroxidase  G3X8D7 7.59 1 1 13.51 
Glutathione S-transferase  E1BKD8 10.00 1 1 25.42 
*Haptoglobin  G3X6K8 12.47 4 4 123.61 
HAUS augmin like complex subunit 3 F1MNN1 1.16 1 1 34.23 
*HEAT repeat containing 5B E1BB26 1.45 1 1 345.14 
*HECT domain E3 ubiquitin protein 
ligase 2 
F1N7A0 3.48 1 1 47.44 
*HECT, UBA and WWE domain 
containing 1, E3 ubiquitin protein 
ligase 
E1BNY9 0.16 1 1 114.05 
*Hemoglobin subunit alpha  P01966 50.00 5 5 461.90 
*Hemoglobin subunit beta  P02070 70.34 10 10 1298.93 
Hemopexin Q3SZV7 48.15 16 16 2252.77 
 Hepatocyte growth factor activator 
preproprotein (Fragment)  
E1BCW0 10.77 2 2 46.89 
Histidine-rich glycoprotein  F1MKS5 18.28 9 5 530.26 
Histidine-rich glycoprotein 
(Fragments)  
P33433 14.65 5 1 282.49 
*Homeobox D3 E1B856 4.38 1 1 297.84 
*Immunoglobulin lambda-like 
polypeptide 1 
F1MLW7 22.65 4 2 313.19 
*Immunoglobulin lambda-like 
polypeptide 1 (Fragment)  
G3N2D7 12.93 1 1 28.07 
Importin 8 E1B8Q9 0.87 1 1 48.73 
*Inhibin alpha chain  P07994 10.28 2 1 44.05 
 Insulin like growth factor binding 
protein acid labile subunit(IGFALS) 
(Fragment)  
F1MJZ4 9.18 3 3 115.59 
Inter-alpha-trypsin inhibitor heavy 
chain H1 
F1MMP5 22.30 16 15 1046.27 
Inter-alpha-trypsin inhibitor heavy 
chain H2  
F1MNW4 18.50 11 10 531.07 
Inter-alpha-trypsin inhibitor heavy 
chain H3  
P56652 1.12 1 1 99.98 
Inter-alpha-trypsin inhibitor heavy 
chain H4  
F1MMD7 28.28 21 20 1460.66 
*Keratin, type II cytoskeletal 7 Q29S21 4.94 2 2 178.36 
Kinesin family member 13B E1BGB0 0.59 1 1 50.27 
Kininogen-1  P01044 13.85 7 4 339.99 
Kininogen-2 P01045 9.69 5 2 314.99 
*KRAS proto-oncogene, GTPase E1BMX0 6.38 1 1 115.89 
*Kruppel like factor 17 (Fragment)  G3N1K6 5.88 1 1 124.69 
Leucine rich repeat containing 4C F1MXH5 3.44 1 1 111.10 
*Leucine rich repeat kinase 2 E1BPU0 0.36 1 1 147.56 
Leucine-rich alpha-2-glycoprotein 1 Q2KIF2 23.41 6 5 697.42 
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Leucine-rich single-pass membrane 
protein 1  
A5PK14 9.38 1 1 137.68 
L-lactate dehydrogenase B chain  Q5E9B1 5.09 1 1 7.76 
*Lumican  Q05443 9.36 2 1 104.51 
*Lysine methyltransferase 2C 
(Fragment)  
F1MYZ3 0.19 1 1 57.82 
Maltase-glucoamylase G3MY87 1.31 2 2 46.70 
Mitogen-activated protein kinase 
kinase kinase 5 
F1MXH6 0.73 1 1 55.14 
*NADH dehydrogenase [ubiquinone] 
1 alpha subcomplex assembly factor 4  
A4FUH5 9.71 1 1 61.89 
*NADH dehydrogenase [ubiquinone] 
1 beta subcomplex subunit 11, 
mitochondrial  
Q8HXG5 14.94 1 1 21.41 
NADPH-dependent diflavin 
oxidoreductase 1  
Q1JPJ0 3.02 1 1 49.02 
*NIMA (Never in mitosis gene a)-
related kinase 2  
Q2KIQ0 5.22 1 1 17.48 
Nuclear factor interleukin-3-regulated 
protein  
Q08D88 2.81 1 1 87.28 
Olfactory receptor  E1BDG1 4.13 1 1 2.87 
*Ornithine decarboxylase 1 E1BG69 2.49 1 1 68.78 
Pantetheinase  Q58CQ9 6.47 2 2 52.55 
*Pantothenate kinase 3  Q08DA5 2.43 1 1 71.93 
Paraoxonase 1  Q2KIW1 17.18 4 4 109.17 
 Peptidoglycan recognition protein 2 
(Fragment)  
E1BH94 5.76 3 3 68.02 
Phosphatidylinositol-3,4,5-
trisphosphate dependent Rac exchange 
factor 2 
E1BDL7 1.18 1 1 74.79 
*Phosphoglycolate phosphatase  Q2T9S4 6.54 1 1 232.07 
Pigment epithelium-derived factor  Q95121 31.01 8 7 399.24 
*Plasma serine protease inhibitor  Q9N2I2 9.16 2 2 82.95 
Plasminogen  P06868 22.29 15 14 1272.51 
Primary amine oxidase, liver isozyme  Q29437 25.07 12 11 1069.72 
Progesterone immunomodulatory 
binding factor 1 
E1BCF0 0.92 1 1 51.54 
Protein AMBP  F1MMK9 17.05 4 4 255.61 
Protein HP-20  Q2KIT0 28.80 3 3 762.34 
Protein HP-25 homolog 1  Q2KIX7 22.17 3 3 177.58 
Protein HP-25 homolog 2  Q2KIU3 40.00 5 5 1012.44 
Protein phosphatase 1 regulatory 
subunit 37  
A7Z026 1.72 1 1 38.25 
Prothrombin P00735 40.48 18 17 779.65 
*Protocadherin Fat 2 precursor 
(Fragment)  
F1MPF3 0.41 1 1 59.65 
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PSMD1 protein A7MBA2 1.05 1 1 149.30 
*PTPRR protein  A5PKF8 3.36 1 1 21.91 
Pyridine nucleotide-disulfide 
oxidoreductase domain-containing 
protein 1  
A7YVH9 5.78 1 1 104.19 
*Regulating synaptic membrane 
exocytosis 2  (Fragment) 
E1B7V2 1.56 1 1 62.25 
Regulating synaptic membrane 
exocytosis 3 
E1BAB7 3.90 1 1 63.55 
RELT, TNF receptor F1N3F7 3.20 1 1 125.55 
Retinoic acid induced 1 E1B9X1 1.01 1 1 52.94 
Retinol-binding protein 4  P18902 17.49 3 3 158.77 
Ribosomal protein S6 kinase C1 E1BB43 1.70 1 1 122.46 
*Serglycin (Fragment)  G5E5K5 5.33 1 1 28.09 
Serine peptidase inhibitor, Kazal type 
5 
F1MJH0 1.10 1 1 141.20 
Serotransferrin  Q29443 67.90 48 3 10359.71 
Serotransferrin  G3X6N3 69.03 49 2 10020.55 
Serpin A3-2  A2I7M9 30.66 11 4 2476.77 
Serpin A3-4  A2I7N0 27.01 9 2 1486.42 
Serpin A3-7  A2I7N3 14.39 9 9 1090.11 
Serpin A3-8  A6QPQ2 21.77 8 6 516.68 
*Serpin family E member 2 F1MZX2 6.55 2 2 42.36 
*Serpin peptidase inhibitor, clade A 
(alpha-1 antiproteinase, antitrypsin), 
member 3 
G8JKW7 25.24 8 2 1430.95 
Serpin peptidase inhibitor, clade A 
(Alpha-1 antiproteinase, antitrypsin), 
member 7  
Q3SYR0 13.14 4 4 130.93 
SERPINA10 protein  A5PJ69 7.96 3 3 81.88 
SERPIND1 protein A6QPP2 19.15 7 6 323.80 
*Serum albumin  P02769 35.91 18 18 1669.86 
*SH3 domain and tetratricopeptide 
repeats 1 
G3MZW4 0.83 1 1 80.24 
SHBG protein  A5PKC2 8.73 2 1 33.21 
 *Sodium/glucose cotransporter 1-like 
(Fragment)  
G3MXJ0 2.43 1 1 32.29 
Solute carrier family 12 member 7 
(Fragment)  
F1N140 1.65 1 1 25.10 
 *Sphingomyelin phosphodiesterase 5 
(Fragment)  
F1N6X9 3.30 1 1 19.12 
 *SPHK1 interactor, AKAP domain 
containing (Fragment)  
F1MZL5 0.68 1 1 25.46 
Superoxide dismutase [Cu-Zn]  A3KLR9 16.60 3 3 25.75 
*Suppressor of G2 allele of SKP1  Q2KIK0 5.62 1 1 66.16 
*Synaptonemal complex protein 1 E1BLN1 1.90 1 1 41.64 
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*Synaptotagmin 12 E1BEH9 2.85 1 1 103.23 
*TBC1 domain family member 4 E1BPA1 2.00 1 1 172.77 
Tetranectin  Q2KIS7 18.32 3 3 156.53 
*Titin F1N757 0.13 2 2 1674.93 
*Trans-2-enoyl-CoA reductase, 
mitochondrial  
Q7YS70 6.17 1 1 75.63 
Transcription elongation factor A N-
terminal and central domain-
containing protein 2  
A5PKE4 3.85 1 1 20.37 
*Transcription factor 7-like 2 G3N0T7 6.53 1 1 116.94 
*Transcription initiation factor TFIID 
subunit (Fragment)  
F1MF62 0.48 1 1 268.01 
*Transmembrane protein 186  Q5EA03 7.55 1 1 289.96 
*Transthyretin  O46375 41.50 5 4 295.47 
Tubulin beta-6 chain (Fragment) G3X7R8 5.08 1 1 76.34 
Tyrosine-protein kinase  F1MCX4 0.93 1 1 45.94 
Ubiquitin carboxyl-terminal hydrolase 
2  
Q2KHV7 2.15 1 1 158.76 
*Ubiquitin protein ligase E3 
component n-recognin 4 
G3N0A8 0.40 1 1 118.70 
*Uncharacterized protein E1BPG1 2.67 1 1 47.01 
*Uncharacterized protein  F1MI18 13.33 16 15 404.88 
Uncharacterized protein  E1BH27 1.44 1 1 144.13 
Uncharacterized protein (Fragment)  F1MVK1 15.95 20 5 1479.93 
*Uncharacterized protein (Fragment)  G3X6V5 1.12 1 1 242.91 
Uncharacterized protein (Fragment)  G3N2S5 2.56 1 1 112.08 
Uncharacterized protein (Fragment)  G3N1I8 13.01 1 1 11.29 
Uncharacterized protein (Fragment); 
(Ig-like protein) 
G5E513 3.06 1 1 40.37 
Uncharacterized protein (Ig-like 
protein) 
F1MH40 6.67 1 1 127.21 
Uncharacterized protein (Ig-like 
protein) 
F1MLW8 14.16 3 1 123.85 
Utrophin F1MRT9 0.29 1 1 192.91 
*Vacuolar protein sorting-associated 
protein 28 homolog  
E1BIB3 8.60 1 1 90.26 
*Versican core protein F1N6I7 5.95 2 2 91.74 
*Vitamin D-binding protein Q3MHN5 30.17 11 1 1602.50 
*Vitamin D-binding protein  F1N5M2 32.07 11 1 1628.97 
Vitronectin Q3ZBS7 7.77 3 3 333.47 
Von Willebrand factor A domain 
containing 3B 
E1BB22 0.82 1 1 75.31 
*Von Willebrand factor A domain 
containing 5B1 
E1BB39 2.12 1 1 86.25 
Xin actin binding repeat containing 2 E1BL04 0.34 1 1 326.21 
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Zinc-alpha-2-glycoprotein  Q3ZCH5 24.41 5 3 109.60 
Zinc finger CCHC domain-containing 
protein 7 
Q2KIN0 1.65 1 1 260.09 
*Zinc finger protein 618 E1BJV7 2.71 1 1 73.67 
 *Zinc finger SWIM-type containing 3 
(Fragment)  
F1MTI1 2.03 1 1 108.62 
*Zona pellucida binding protein 2 Q0VCG8 12.50 1 1 81.07 
 
Appendix 2. Functions and cellular localization of 231 proteins identified in bovine PL 
and FF with high and low E2 during the pre-ovulatory stage. 
Description (* indicates 
protein was up- or 
down-regulated in at 
least one sample) 
Biological Process Molecular 
Function 
Cellular Component 
  *2-acylglycerol O-
acyltransferase 3 
(Fragment)  
metabolic process catalytic activity   
Acidic mammalian 
chitinase 
metabolic process catalytic activity   
Actin, cytoplasmic 1  cellular component 
organization or biogenesis; 
cellular process; 
localization   
structural 
molecule activity 
cell part; 
organelle 
Afamin localization      
A-kinase anchoring 
protein 9 (Fragment)  
      
Aldehyde oxidase 4  cellular process; 
metabolic process 
binding; 
catalytic activity  
cell part 
Alpha-1-acid 
glycoprotein  
      
*Alpha-1-antiproteinase      extracellular region 
Alpha-1B-glycoprotein  cellular process; 
response to stimulus  
receptor activity   
Alpha-2-antiplasmin      extracellular region 
Alpha-2-HS-glycoprotein biological regulation catalytic activity   
*Alpha-2-macroglobulin  cellular process; 
metabolic process; 
response to stimulus 
binding; 
catalytic activity 
  
Alpha-amylase       
Angiotensinogen      extracellular region 
*Ankyrin repeat and KH 
domain containing 1 
immune system process; 
response to stimulus 
  cell part 
Antithrombin-III      extracellular region 
*AP complex subunit 
beta 
localization      
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AP-2 complex subunit 
beta  
localization      
Apolipoprotein A-I  biological regulation; 
cellular component 
organization or biogenesis; 
cellular process; 
developmental process; 
localization; 
metabolic process; 
multicellular organismal 
process; 
response to stimulus  
binding; 
catalytic activity; 
transporter 
activity  
extracellular region; 
macromolecular 
complex 
Apolipoprotein A-II  biological regulation; 
cellular component 
organization or biogenesis; 
metabolic process; 
multicellular organismal 
process 
binding; 
catalytic activity; 
transporter 
activity 
extracellular region; 
macromolecular 
complex 
Apolipoprotein A-IV  biological regulation; 
cellular component 
organization or biogenesis; 
cellular process; 
developmental process; 
localization; 
metabolic process; 
multicellular organismal 
process; 
response to stimulus   
binding; 
catalytic activity; 
transporter 
activity  
extracellular region; 
macromolecular 
complex 
*Apolipoprotein B       
Apolipoprotein C-III        
*Apolipoprotein R biological adhesion; 
cellular process; 
immune system process  
    
*ApoN protein        
*Asparagine-linked 
glycosylation 5, dolichyl-
phosphate beta-
glucosyltransferase 
homolog (S. cerevisiae)  
cellular process; 
metabolic process  
    
*ATP binding cassette 
subfamily B member 9 
cellular process; 
metabolic process 
catalytic activity; 
transporter 
activity 
membrane 
*B double prime 1, 
subunit of RNA 
polymerase III 
transcription initiation 
factor IIIB 
cellular component 
organization or biogenesis; 
cellular process; 
metabolic process 
binding  cell part; 
macromolecular 
complex; 
organelle 
BCL2 interacting protein 
2 
cellular process; 
developmental process; 
metabolic process  
catalytic activity cell part 
Beta-2-glycoprotein 1  biological adhesion; 
cellular process; 
immune system process  
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Beta-2-microglobulin  response to stimulus   macromolecular 
complex 
C3 and PZP like, alpha-2-
macroglobulin domain 
containing 8 
cellular process; 
metabolic process; 
response to stimulus  
binding; 
catalytic activity 
  
C4b-binding protein 
alpha chain  
biological adhesion; 
cellular process; 
immune system process  
    
*C8G protein        
*CAD protein cellular process; 
metabolic process  
catalytic activity cell part 
Caspase recruitment 
domain family member 
10 
cellular process      
*CCDC80 protein       
*Cell adhesion molecule 
1  
      
Ceruloplasmin   catalytic activity macromolecular 
complex; 
membrane 
Chaperone activity of bc1 
complex-like, 
mitochondrial  
    cell part; 
membrane 
*Chromosome 14 open 
reading frame 166 
ortholog  
cellular process      
Chromosome 20 open 
reading frame 96 
(Fragment)  
      
Clusterin    binding  cell part; 
extracellular region; 
organelle 
CMP-N-
acetylneuraminate-poly-
alpha-2,8-
sialyltransferase  
      
Coagulation factor IX      extracellular region 
*Coagulation factor V       
*Coagulation factor XII  metabolic process catalytic activity extracellular region 
*Coagulation factor XIII 
A chain  
metabolic process catalytic activity   
*Cohesin subunit SA-3 cellular process  binding    
*Complement C1s 
subcomponent 
  catalytic activity extracellular region 
Complement C3  cellular process; 
metabolic process; 
response to stimulus  
binding; 
catalytic activity 
  
Complement C3  cellular process; 
metabolic process; 
response to stimulus 
binding; 
catalytic activity  
  
 complement C3 
(Fragment)  
cellular process; 
metabolic process; 
binding; 
catalytic activity  
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response to stimulus 
Complement C5a 
anaphylatoxin  
cellular process; 
metabolic process; 
response to stimulus 
binding; 
catalytic activity 
  
Complement C8 alpha 
chain 
      
Complement C8 beta 
chain 
      
complement component 
4A 
cellular process; 
metabolic process; 
response to stimulus 
binding; 
catalytic activity 
  
*Complement component 
C6  
      
Complement component 
C7  
      
Complement component 
C9  
      
Complement factor B        
Complement factor H        
Complement factor I       
*Conglutinin  biological regulation; 
cellular component 
organization or biogenesis; 
cellular process; 
localization; 
multicellular organismal 
process   
binding  cell part; 
extracellular region; 
organelle 
Corticosteroid-binding 
globulin  
    extracellular region 
C-reactive protein        
C-type lectin domain 
family 1 member A  
      
*Cumulus cell-specific 
fibronectin 1 transcript 
variant  
biological adhesion; 
cellular process  
binding  extracellular region 
*Cytochrome P450 20A1        
*Cytohesin 1 (Fragment)       
*Cytokine receptor like 
factor 3 
  binding  cell part; 
organelle 
*DDB1 and CUL4 
associated factor 5 
cellular process; 
metabolic process  
binding; 
catalytic activity 
  
DEAH-box helicase 16 cellular process; 
metabolic process  
catalytic activity cell part; 
macromolecular 
complex; 
organelle 
*Delta-like protein  developmental process      
*Dolichyl-
diphosphooligosaccharid
e--protein 
glycosyltransferase 
subunit 1 
cellular process; 
metabolic process  
catalytic activity cell part; 
macromolecular 
complex; 
membrane; 
organelle 
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*Dpy-19 like 4 
(Fragment)  
cellular process; 
metabolic process  
catalytic activity cell part; 
membrane; 
organelle 
*DUOXA1 protein        
*Dynein axonemal heavy 
chain 11 
cellular process  binding; 
catalytic activity 
cell part; 
macromolecular 
complex; 
organelle 
*Dynein heavy chain 
domain 1 
cellular process  binding; 
catalytic activity 
cell part; 
macromolecular 
complex; 
organelle 
Dystonin cellular process  binding; 
structural 
molecule activity  
cell part 
*E3 ubiquitin-protein 
ligase CHIP 
      
*Endophilin-A2        
*Engulfment and cell 
motility 1 
cellular process  binding    
*Epidermal growth factor 
receptor kinase substrate 
8-like protein 1 
biological regulation; 
cellular component 
organization or biogenesis; 
cellular process  
  Cell part; membrane; 
organelle 
*Factor XIIa inhibitor 
precursor 
    extracellular region 
*Family with sequence 
similarity 81 member A 
      
*Fas activated 
serine/threonine kinase 
cellular process      
Fetuin-B  biological regulation catalytic activity   
*FGG protein  biological adhesion binding  extracellular region 
*Fibrinogen alpha chain        
*Fibrinogen beta chain  biological adhesion; 
cellular process  
binding  extracellular region 
*Fibulin-1 cellular process; 
developmental process  
binding; 
structural 
molecule activity 
extracellular region; 
extracellular matrix 
*Filamin B       
Fragile X mental 
retardation syndrome-
related protein 2 
cellular component 
organization or biogenesis; 
cellular process; 
developmental process; 
localization; 
metabolic process; 
multicellular organismal 
process  
binding; 
translation 
regulator activity  
cell part; 
macromolecular 
complex; 
organelle; 
synapse  
G1/S-specific cyclin-D1  biological regulation; 
cellular component 
organization or biogenesis; 
cellular process; 
metabolic process  
binding; 
catalytic activity  
cell part; 
macromolecular 
complex; 
organelle 
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*Gametocyte-specific 
factor 1-like 
      
*Gasdermin B cellular process; 
developmental process; 
response to stimulus   
binding    
Gelsolin cellular component 
organization or biogenesis; 
cellular process 
binding; 
structural 
molecule activity  
cell part; 
organelle 
Glutathione peroxidase  immune system process; 
metabolic process; 
response to stimulus 
antioxidant 
activity; 
catalytic activity 
  
Glutathione S-transferase        
*Haptoglobin  metabolic process catalytic activity extracellular region 
HAUS augmin like 
complex subunit 3 
cellular component 
organization or biogenesis; 
cellular process  
  cell part; 
organelle 
*HEAT repeat containing 
5B 
      
*HECT domain E3 
ubiquitin protein ligase 2 
      
*HECT, UBA and WWE 
domain containing 1, E3 
ubiquitin protein ligase 
cellular process; 
metabolic process 
  cell part 
*Hemoglobin subunit 
alpha  
      
*Hemoglobin subunit 
beta  
      
Hemopexin     extracellular matrix 
 Hepatocyte growth 
factor activator 
preproprotein (Fragment)  
metabolic process catalytic activity extracellular region 
Histidine-rich 
glycoprotein  
biological regulation catalytic activity   
Histidine-rich 
glycoprotein (Fragments)  
biological regulation catalytic activity   
*Homeobox D3       
*Immunoglobulin 
lambda-like polypeptide 
1 
immune system process     
*Immunoglobulin 
lambda-like polypeptide 
1 (Fragment)  
immune system process     
Importin 8 biological regulation; 
cellular process; 
localization; 
response to stimulus   
transporter 
activity 
cell part; 
organelle 
*Inhibin alpha chain  cellular process; 
developmental process; 
metabolic process; 
response to stimulus   
binding  extracellular region 
 Insulin like growth 
factor binding protein 
biological regulation; binding    
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acid labile 
subunit(IGFALS) 
(Fragment)  
cellular component 
organization or biogenesis; 
cellular process; 
developmental process; 
locomotion; 
multicellular organismal 
process; 
response to stimulus   
Inter-alpha-trypsin 
inhibitor heavy chain H1 
metabolic process binding; 
catalytic activity  
  
Inter-alpha-trypsin 
inhibitor heavy chain H2  
metabolic process binding; 
catalytic activity 
  
Inter-alpha-trypsin 
inhibitor heavy chain H3  
metabolic process binding; 
catalytic activity  
  
Inter-alpha-trypsin 
inhibitor heavy chain H4  
metabolic process binding; 
catalytic activity 
  
*Keratin, type II 
cytoskeletal 7 
      
Kinesin family member 
13B 
cellular process; 
metabolic process  
binding; 
catalytic activity  
cell part; 
organelle 
Kininogen-1  biological regulation catalytic activity   
Kininogen-2 biological regulation catalytic activity   
*KRAS proto-oncogene, 
GTPase 
biological adhesion; 
cellular process; 
localization; 
multicellular organismal 
process  
binding; 
catalytic activity 
  
*Kruppel like factor 17 
(Fragment)  
cellular process; 
metabolic process 
binding  cell part; 
organelle 
Leucine rich repeat 
containing 4C 
      
*Leucine rich repeat 
kinase 2 
      
Leucine-rich alpha-2-
glycoprotein 1 
      
Leucine-rich single-pass 
membrane protein 1  
      
L-lactate dehydrogenase 
B chain  
metabolic process catalytic activity   
*Lumican  biological regulation; 
cellular component 
organization or biogenesis; 
cellular process; 
developmental process; 
locomotion; 
multicellular organismal 
process; 
response to stimulus     
binding    
*Lysine 
methyltransferase 2C 
(Fragment)  
      
Maltase-glucoamylase metabolic process catalytic activity   
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Mitogen-activated protein 
kinase kinase kinase 5 
biological regulation; 
cellular process; 
metabolic process; 
response to stimulus  
catalytic activity; 
signal transducer 
activity 
  
*NADH dehydrogenase 
[ubiquinone] 1 alpha 
subcomplex assembly 
factor 4  
      
*NADH dehydrogenase 
[ubiquinone] 1 beta 
subcomplex subunit 11, 
mitochondrial  
  catalytic activity   
NADPH-dependent 
diflavin oxidoreductase 1  
  binding; 
catalytic activity 
cell part 
*NIMA (Never in mitosis 
gene a)-related kinase 2  
      
Nuclear factor 
interleukin-3-regulated 
protein  
cellular process; 
metabolic process; 
rhythmic process  
binding  cell part; 
organelle 
Olfactory receptor        
*Ornithine decarboxylase 
1 
biological regulation; 
cellular process; 
metabolic process  
catalytic activity cell part 
Pantetheinase  cellular process; 
metabolic process  
catalytic activity   
*Pantothenate kinase 3        
Paraoxonase 1    catalytic activity   
 Peptidoglycan 
recognition protein 2 
(Fragment)  
      
Phosphatidylinositol-
3,4,5-trisphosphate 
dependent Rac exchange 
factor 2 
cellular process; 
metabolic process; 
response to stimulus  
binding; 
catalytic activity 
membrane 
*Phosphoglycolate 
phosphatase  
cellular process; 
metabolic process  
catalytic activity cell part 
Pigment epithelium-
derived factor  
    extracellular region 
*Plasma serine protease 
inhibitor  
    extracellular region 
Plasminogen    catalytic activity   
Primary amine oxidase, 
liver isozyme  
      
Progesterone 
immunomodulatory 
binding factor 1 
      
Protein AMBP        
Protein HP-20        
Protein HP-25 homolog 1        
Protein HP-25 homolog 2        
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Protein phosphatase 1 
regulatory subunit 37  
immune system process; 
metabolic process; 
response to stimulus 
binding    
Prothrombin metabolic process; 
response to stimulus 
catalytic activity   
*Protocadherin Fat 2 
precursor (Fragment)  
developmental process      
PSMD1 protein cellular process; 
metabolic process  
catalytic activity cell part; 
macromolecular 
complex; 
organelle 
*PTPRR protein        
Pyridine nucleotide-
disulfide oxidoreductase 
domain-containing 
protein 1  
  catalytic activity   
*Regulating synaptic 
membrane exocytosis 2  
(Fragment) 
biological regulation; 
cellular process; 
multicellular organismal 
process  
binding  cell part; 
organelle; 
synapse  
Regulating synaptic 
membrane exocytosis 3 
biological regulation; 
cellular process; 
multicellular organismal 
process  
binding  cell part; 
organelle; 
synapse  
RELT, TNF receptor       
Retinoic acid induced 1 cellular process; 
metabolic process 
binding  cell part; 
organelle 
Retinol-binding protein 4  localization      
Ribosomal protein S6 
kinase C1 
biological regulation; 
cellular process; 
metabolic process; 
response to stimulus  
catalytic activity   
*Serglycin (Fragment)        
Serine peptidase 
inhibitor, Kazal type 5 
  binding    
Serotransferrin    binding  cell part; 
macromolecular 
complex; 
membrane; 
organelle 
Serotransferrin    binding  cell part; 
macromolecular 
complex; 
membrane; 
organelle 
Serpin A3-2      extracellular region 
Serpin A3-4      extracellular region 
Serpin A3-7      extracellular region 
Serpin A3-8      extracellular region 
*Serpin family E member 
2 
    extracellular region 
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*Serpin peptidase 
inhibitor, clade A (alpha-
1 antiproteinase, 
antitrypsin), member 3 
    extracellular region 
Serpin peptidase 
inhibitor, clade A (Alpha-
1 antiproteinase, 
antitrypsin), member 7  
    extracellular region 
SERPINA10 protein      extracellular region 
SERPIND1 protein     extracellular region 
*Serum albumin  localization      
*SH3 domain and 
tetratricopeptide repeats 1 
      
SHBG protein        
 *Sodium/glucose 
cotransporter 1-like 
(Fragment)  
cellular process; 
localization  
transporter 
activity 
  
Solute carrier family 12 
member 7 (Fragment)  
biological regulation; 
cellular process; 
localization; 
multicellular organismal 
process   
transporter 
activity 
  
 *Sphingomyelin 
phosphodiesterase 5 
(Fragment)  
      
 *SPHK1 interactor, 
AKAP domain 
containing (Fragment)  
biological regulation; 
cellular process; 
response to stimulus  
binding  cell part 
Superoxide dismutase 
[Cu-Zn]  
cellular process; 
response to stimulus  
antioxidant 
activity; 
binding; 
catalytic activity 
cell part; 
extracellular region 
*Suppressor of G2 allele 
of SKP1  
biological regulation; 
metabolic process 
    
*Synaptonemal complex 
protein 1 
      
*Synaptotagmin 12 biological regulation; 
cellular component 
organization or biogenesis; 
cellular process; 
multicellular organismal 
process  
binding  membrane 
*TBC1 domain family 
member 4 
cellular component 
organization or biogenesis; 
cellular process; 
localization; 
metabolic process  
binding; 
catalytic activity 
cell part 
Tetranectin  multicellular organismal 
process 
  extracellular region 
*Titin cellular component 
organization or biogenesis; 
cellular process; 
binding; 
structural 
molecule activity  
cell part; 
macromolecular 
complex; 
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developmental process; 
multicellular organismal 
process  
organelle 
*Trans-2-enoyl-CoA 
reductase, mitochondrial  
cellular process; 
metabolic process  
catalytic activity cell part; 
organelle 
Transcription elongation 
factor A N-terminal and 
central domain-
containing protein 2  
metabolic process binding    
*Transcription factor 7-
like 2 
      
*Transcription initiation 
factor TFIID subunit 
(Fragment)  
cellular component 
organization or biogenesis; 
cellular process; 
metabolic process  
binding; 
catalytic activity 
cell part; 
macromolecular 
complex; 
organelle 
*Transmembrane protein 
186  
      
*Transthyretin  cellular process; 
metabolic process 
    
Tubulin beta-6 chain 
(Fragment) 
cellular component 
organization or biogenesis; 
cellular process  
binding; 
structural 
molecule activity  
cell part; 
organelle 
Tyrosine-protein kinase        
Ubiquitin carboxyl-
terminal hydrolase 2  
      
*Ubiquitin protein ligase 
E3 component n-recognin 
4 
      
*Uncharacterized protein       
*Uncharacterized protein        
Uncharacterized protein  cellular process; 
metabolic process  
catalytic activity   
Uncharacterized protein 
(Fragment)  
cellular process; 
metabolic process; 
response to stimulus  
binding; 
catalytic activity 
  
*Uncharacterized protein 
(Fragment)  
      
Uncharacterized protein 
(Fragment)  
      
Uncharacterized protein 
(Fragment)  
      
Uncharacterized protein 
(Fragment); (Ig-like 
protein) 
biological regulation; 
cellular component 
organization or biogenesis; 
cellular process; 
immune system process; 
localization; 
metabolic process; 
multicellular organismal 
process; 
response to stimulus  
binding  extracellular region; 
macromolecular 
complex; 
membrane 
Uncharacterized protein 
(Ig-like protein) 
immune system process     
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Uncharacterized protein 
(Ig-like protein) 
immune system process     
Utrophin cellular component 
organization or biogenesis 
    
*Vacuolar protein 
sorting-associated protein 
28 homolog  
cellular process; 
localization; 
metabolic process   
binding  cell part; 
macromolecular 
complex; 
membrane; 
organelle 
*Versican core protein developmental process; 
multicellular organismal 
process   
  extracellular region; 
extracellular matrix 
*Vitamin D-binding 
protein 
localization      
*Vitamin D-binding 
protein  
localization      
Vitronectin cellular process      
Von Willebrand factor A 
domain containing 3B 
      
*Von Willebrand factor 
A domain containing 5B1 
      
Xin actin binding repeat 
containing 2 
cellular process  structural 
molecule activity 
cell part 
Zinc-alpha-2-
glycoprotein  
    extracellular region 
Zinc finger CCHC 
domain-containing 
protein 7 
      
*Zinc finger protein 618 metabolic process binding    
 *Zinc finger SWIM-type 
containing 3 (Fragment)  
      
*Zona pellucida binding 
protein 2 
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Appendix 3 
 
(A) Molecular Function translation regulator
activity (0.7%)
binding (42.7%)
receptor activity
0.7%)
structural molecule
activity (4.9%)
signal transducer
activity (0.7%)
catalytic activity
(44.1%)
antioxidant activity
(1.4%)
transporter activity
(4.9%)
(B) Cellular Component
synapse (2.0%)
membrane (8.1%)
macromolecular
complex (12.8%)
extracellular matrix
(2.0%)
cell part (29.7%)
organelle (20.3%)
cellular component organization or biogenesis
cellular process
localization
biological regulation
response to stimulus
developmental process
rhythmic process
multicellular organismal process
biological adhesion
locomotion
metabolic process
immune system process
7.1%
28.2%
6.8%
8.9%
9.6%
4.6%
0.4%
5.7%
2.5%
0.7%
21.8%
3.6%
(C) Biological Process
 PANTHER analysis of all  identified proteins (231 in total) in bovine plasma (PL) and 
follicular fluid (FF) containing low and high pre-ovulatory E2. Proteins were classified 
according to (A) Molecular Function (B), Cellular Component, and (C) Biological Processes. 
The percentages in the different categories are comparable to that from the analysis of only 
proteins showing expression changes. 
